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I 
ABSTRACT 
 
The limited access to the brain of a large number of therapeutic actives due to the presence of 
the blood-brain barrier (BBB) has led to intensive research toward the development of 
nanotechnology-based approaches. Polysaccharides such as chitosan, guar gum, pectin and 
pullulan have been selected as starting materials for this study due to their biocompatibility, 
biodegradability, good drug carrier properties, and ease of chemical modification with short 
chain alkylglycerol-like moieties (expected to enhance drug permeability through the BBB).  
 
A series of butylglyceryl-modified polysaccharides were prepared and characterised using 
chromatographic, spectroscopic and thermal analysis techniques prior to formulation into 
nanoparticles (NPs) by means of a selection of methods that include reverse emulsification, 
nanoprecipitation, and ionotropic gelation. Dynamic Light Scattering, Nanoparticle Tracking 
Analysis, Electrophoretic Mobility Measurements and Electron Microscopy were employed 
to characterise all NPs (overall size range 120–200 nm, and zeta potential values ranging 
from -27 to +39 mV). Modified pullulan (PUL-OX4) and guar gum (GG-OX4) NPs were 
found to be most stable at physiological pH (7.4), in contrast to chitosan (CS-OX4) NPs that 
demonstrated an increase in size as a result of aggregation.  
 
PUL-OX4 NPs (< 145 nm) had the highest Angiotensin II model peptide loading (8.46 %), 
while GG-OX4 NPs showed the highest loading degree with Doxorubicin (19.11 %) and 
Rhodamine B (3.78 %). Drug release studies demonstrated that PUL-OX4 NPs released 
fastest all the model actives tested, while GG-OX4 NPs were able to retain them for the 
longest period of time. The in vitro interactions of NPs with mouse brain endothelial cells 
(bEnd3) were investigated using a Transwell permeability model, with results suggesting an 
increased model membrane permeability in the presence of the modified polysaccharide 
nanoparticles.   
 
The cytotoxicity of these NPs at physiologically-relevant concentrations was studied using 
MTT assays; all NPs were non-toxic at concentration below 2 mg/mL, however a decrease in 
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cell viability was noticed at higher concentrations. PUL-OX4 nanoparticles were found to be 
the least toxic, having the lowest LC50 value (9.48 mg/mL; for comparison, CS-OX4 has 7.30 
mg/mL). Haemolysis study demonstrated that at concentration below 12 mg/mL, all the NPs 
studied did not induce a haemolysis effect significantly when compared to PBS control, 
however an increase in the effect was observed at higher concentration. PUL-OX4 
nanoparticles exhibited the highest LC30 value of 19.87 mg/mL while the lowest value was 
exhibited by CS-OX4 nanoparticles (13.95 mg/mL). Confocal microscopy and flow 
cytometry investigations confirmed that all modified polysaccharide NPs were successfully 
taken up by bEnd3 cells, becoming localised in the cytoplasm.  
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1 
LITERATURE REVIEW 
 
1.1. Drug delivery to the brain 
Research on the epidemiology of brain disorders illustrates the vast burden imposed by brain 
diseases with regard to human suffering and cost. Brain conditions such as unipolar 
depressive disorders have been the single biggest cause of life lost in the high income 
countries, and the third biggest in the world.1-3 Contributing to around 35 % of the total 
disease burden in Europe, the treatment cost has increased significantly from € 386 billion in 
2004 to € 798 billion in 2010.4 As a result of enormous demand for effective therapeutics, the 
development of CNS drugs is estimated to grow by more than five times and perhaps soon 
equal the level of the cardiovascular drug market.5, 6 
 
Recent progress in the treatment of brain disorders has been so far seriously hindered by the 
fact that most drugs are unable to enter the brain.7-12 Novel developments have been gaining 
wide interest due to the challenges imposed by the blood-brain barrier (BBB), which restricts 
the access of many potentially useful neuro-pharmaceuticals. While the use of invasive 
methods appears effective, the benefits usually come at the cost of very harmful side effects. 
Current research concentrates therefore on non-invasive strategies, with the use of colloidal 
drug carriers as a very promising approach for systemic drug delivery to the brain.13, 14 In 
designing ideal therapeutic systems for delivering drugs across the BBB, fundamentals about 
brain disorders and the function of the blood-brain barrier are essential.  
 
1.1.1. Brain disorders 
The brain is unique in the sense that it possesses the ability to adapt and is capable of self-
repair.15 However, despite possessing these characteristics, it is still at risk of damages that 
can lead to changes and disruption to the normal brain functions. Brain disorders that include 
any conditions or damages affecting the brain (such as Alzheimer’s, dementia, epilepsy, 
anxiety disorders or Parkinson that occur when the brain is harmed by disease, injury, or 
inappropriate health conditions) account for approximately 35 % of the total burden of all 
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diseases in Europe.1-3 When the brain is damaged, a number of things may be affected 
including memory, sensation, or even someone’s personality. Brain disorders can be 
categorised into several main types 16-19 : 
 
 Neurodegenerative 
- Alzheimer’s is a progressive dementia that usually affects older population and 
may cause confusion, change of personality and physical capabilities. 
- Parkinson’s disease normally affects about 1 in 100 people aged above 60, with 
symptoms of resting tremor, slow movement, postural instability and stiffness. 
- Huntington’s is a fatal and genetically determined neurodegenerative disease, with 
symptoms of depression, mood swings and difficult to make decision or 
concentrate on intellectual tasks. 
 Cerebrovascular 
- A stroke is the most prevalent cerebrovascular illness, where one part of the brain 
is damaged due to lack of blood flow as a consequence of either blockages in the 
blood vessels that feed the brain or a burst blood vessels in the brain. 
- Aneurysms are unusual weak spots in the blood vessel wall of an artery that feed 
the brain. The rupture of aneurysm leads to a burst blood vessel, releasing blood 
into the space between the brain and the tissues covering the brain; this leads to a 
phenomenon called subarachnoid haemorrhage.  
 Inflammatory or infectious 
- Multiple sclerosis can damage tissue neurons and nerves, thus affecting how brain 
communicates with body. 
- Encephalitis is a brain inflammatory disease caused by viral infection that may 
induce swelling and dysfunction of the brain.  
- Reye’s syndrome normally occurs among children either 3 to 5 days after a 
primary viral infection such as flu or varicella disease. 
 Brain tumours 
- Brain tumours are abnormal growths within the central nervous system that may 
or may not be malignant. It is considered as serious due to the pressure they can 
cause in the brain as they grow.  
- Brain tumours can be classified into primary (originating in brain tissue) or 
secondary (arising from cancer cells that have spread to the brain from other parts 
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of the body, usually the lungs or breast). Secondary brain tumours are always 
considered as malignant. 
 Mental health disorders 
- Schizophrenia is a mental disturbance with symptoms of derangement of speech, 
behaviour and normal thoughts that may be caused by either genetic, 
environmental factors or a combination of both. 
- Bipolar disorder is characterised by extreme swings in someone’s mood, energy 
and functionality. This manic-depressive illness may be accompanied by 
psychotic symptoms that regularly reflect the extreme behaviour of a person. 
 
In 2010 it was estimated that the total cost of brain diseases in Europe was around €798 
billion, with an average cost per person ranging between €285 for headache and €30000 for 
neuromuscular disorders (variable depending on the disorder).4 Brain disorders appear to be 
an emerging public health problem for developed and developing countries where those 
affected often require intensive care and lifelong treatment. In 2010, the global burden of 
brain disorders was estimated to represent 10.4 % of disability-adjusted life years (DALY), 
increased from 7.3 % in 1990, which has exceeded other chronic conditions including cancer 
and cardiovascular diseases.20 Based on the Comprehensive Medicinal Chemistry (CMC) 
database, only 5 % of almost 7000 small-molecule drugs are essentially active in the CNS, as 
more than 98 % of small molecule drugs and almost all large molecule actives cannot reach 
the brain.6, 21  
 
1.1.2. The blood-brain barrier 
The blood-brain barrier is a tightly regulated interface in the CNS that separates the brain 
from the internal body environment. The BBB provides both anatomical and physiological 
protection for the CNS, in which allows essential metabolites including oxygen and glucose 
to get into the brain but blocks out unwanted and neurotoxic metabolites. However, as an 
effective barrier to protect the brain from foreign substances, it also often prevents CNS-
active therapeutics.22  Details about the structural components of the BBB, its functions, and 
the transport mechanisms across the BBB will be presented in the following sections.  
 
1.1.2.1. Structural components and functions of the blood-brain barrier 
The brain is the most complex organ in human body, where it acts as a control centre that 
regulates the functioning of the whole organism (including growth, reproduction, ability to 
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talk, breathe etc.).23 Being the most complex organ, the brain is composed of nearly 1 x 1011 
neurons (impulse-conducting cells) and approximately 1 x 1012 astrocytes (supporting 
cells).24 Each neuron can have around 1000–10000 synapses (connections between individual 
neurons), where the electrical impulse changes to chemical signals; the total number of 
synapses is around 1 x 1014 to 5 x 1014 in adults.25, 26 
 
Ehrlich was the first one who suggested the presence of a barrier between the brain and 
bloodstream, which was later confirmed by Lewandowski in 1900, when he found no bile 
acids or ferrocyanide in the brain after intravenous administration.19 In 1909, a study 
performed by Goldman employing Trypan blue revealed the dye exclusion from the brain 
following intravenous injection.27, 28 Findings from electron microscopy studies using 
horseradish peroxidase and ferritin showed that the BBB is located at the endothelial cells of 
the blood capillaries in the brain.29-31 
 
The BBB (Figure 1.1) is formed by vascular endothelial cells, tightly regulated by pericytes, 
fixed in the vascular basement membrane, perivascular microglial cells, astrocytes and 
neurons, in which on the whole forming the neurovascular unit (NVU).32, 33 Forming a 
continuous layer covering the surface of capillaries, endothelial cells is inter-connected by 
tight junctions in which inhibits passage of the majority of substances. The main functions of 
the BBB are listed below34, 35: 
 Shielding the brain from unwanted and foreign substances such as toxins, bacteria, 
virions present in the blood that may harm the brain. 
 Maintaining homeostatic balance of nutrients in the brain. 
 Preventing hormones and neurotransmitters in the body from getting into the brain. 
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Figure 1.1. Blood-brain barrier neurovascular unit: the capillary endothelial cells are 
surrounded by basal lamina and astrocyte perivascular end feet. Reproduced from 36. 
 
The brain endothelial cells differ significantly from non-brain endothelial cells because of 
their high number of mitochondrial content to provide the metabolic work capacity for 
maintaining the ionic gradient across the BBB,37 low level of pinocytic activity, and lack of 
fenestrations correlating with the presence of tight junctions (TJ). The endothelial cells of 
brain capillaries are covered with a thick layer of basement membrane and, in contrast to the 
non-cerebral capillaries, normally do not contain microvesicles for vesicular transport 
(Figure 1.2).38, 39  
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Figure 1.2. Schematic drawing of cerebral (a) and non-cerebral (b) capillaries. Reproduced 
from 39. 
 
As opposed to peripheral capillaries that allow exchange of substances across cells, the BBB 
restricts the transport of many substances into the brain due to the presence of specific tight 
junctions and metabolic barriers. This is attributed to the structural differences between 
peripheral capillaries and the brain capillaries endothelium that is associated with the tight 
junctions.40-42  
 
1.1.2.2. Transport across the blood-brain barrier 
Essential molecules are needed for the brain to perform its functions and maintain brain 
integrity.43 The transport of molecules across the BBB can follow a passive or active, energy-
dependent manner. In order to design strategies for transporting molecules across the BBB, 
possible passage pathways need to be considered (Figure 1.3). Paracellular (severely 
restricted for diffusion of small hydrophilic solutes) and transcelullar transport pathways are 
possible and the likely mechanisms need to be considered.11 Drugs with appropriate 
lipophilicity and charge (also with low hydrogen bonding ability), and having sizes less than 
500 Da may be transported transcellularly to reach the brain.12, 44 However, if the drugs are 
too lipid soluble, they can be secluded by the capillary bed and not reach the cells behind the 
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BBB due to the property of the membrane that requires the drugs to partition into the aqueous 
environment of the brain’s interstitial fluid to give an effect.45  
 
Compounds that are not able to diffuse across the BBB need active carriers or receptor-
mediated or vesicular mechanism to pass through the BBB. The presence of various 
specialised transporters such as glucose transporter (GLUT1) may also be useful in designing 
solutions for overcoming the BBB.10 Other small hydrophilic molecules such as amino acids 
may also use transporters (via carrier mediated transport) expressed at the luminal (blood) 
and basolateral (brain) side of the endothelial cells. Larger and/or hydrophilic molecules 
including hormones, insulin, transferrin and lipoproteins utilise specific receptors (via 
receptor mediated transcytosis) that are widely expressed on the luminal side of the 
endothelial cells. These molecules are recognised by specific receptors which results in 
specific transport into the brain. Therefore, some drugs can be modified to exploit the 
presence of BBB nutrient transport systems or by conjugation to ligands that will recognise 
receptors expressed at the BBB. 
 
 
Figure 1.3. Schematic representation of transport mechanisms across the BBB. Reproduced 
from 12. 
 
Mechanisms of transport pathways across the BBB are represented in Figure 1.3. The BBB is 
composed of a polarised layer of endothelial cells that are connected by tight junctions. 
Various transport mechanism can be identified12, 41 : 
a) Small hydrophobic molecules such as alcohol and steroid hormones follow diffusion 
pathway, driven by a concentration gradient.46 Drugs such as caffeine, nicotine, 
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heroine and all small neurotherapeutics can enter the brain lipid-mediated diffusion, 
however too high in lipophilicity may increase uptake by peripheral tissue, as well as 
seclusion in the brain microvasculature, in which may lead to decreased drug delivery 
to the brain.45 
b) Small hydrophilic molecules are transported via paracellular pathway, however they 
are restricted by tight junctions from entering the brain freely. Drugs candidates 
developed for treating CNS diseases are often hydrophilic, therefore resulting in low 
BBB penetration.47 
c) Carrier-mediated pathway for endogenous substances such as glucose, amino acids, 
nucleosides. The presence of glucose transporter, GLUT1, has been exploited for the 
transport of glycosylated enkephalin analogues across the BBB.48 Several drugs that 
have structures that mimic the endogenous amino acids such as L-dopa, α-
methyldopa, α-methyltrypsin, bacrofen, gabapentin can be transported via amino acid 
transporter (LAT1).7 Peptides such as enkephalin, arginine-vasopressin, Peptide-T 
and thyrotropin-releasing hormone can be transported via the peptide transport 
system, PTS-1 to -5 to cross the BBB.49, 50 
d) Specific proteins such as insulin, leptin, transferrin and interleukins which are used 
for signalling, as well as nutrients such as iron and LDL are transported via receptor-
mediated transcytosis. Human serum albumin (HSA) nanoparticles have been coated 
with transferrin or transferrin antibodies in order to enhance the transport of 
loperamide to the brain.51 Low-density lipoprotein (LDL) receptors have been 
exploited to transport polybutyl-cyanoacrylate (PBCA) loaded with anti-cancer agents 
by coating the particles with apolipoprotein E and B.52 
e) Adsorptive transcytosis is useful to transport positively charged particles (that can 
interact in a non-specific manner with the negative charge membranes of endothelial 
cells). Cationic proteins and peptides bind to the luminal plasma membrane (regulated 
by electrostatic interactions with anionic sites of the membrane) and trigger the 
pathway. Protein transduction domains (PTDs) such as TAT,53 Syn-B54 and 
penetratin55  have been conjugated to drugs or nanoparticles to introduce positively 
charged surface and enabling them to be transported via this pathway. 
 
Proton pump efflux transporters such as P-glycoprotein  are  are expressed at the BBB and 
can result in efflux of molecules out of the brain, preventing a large number of small, lipid 
soluble molecules from accumulating within the brain parenchyma and thus limiting  overall 
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uptake by the BBB.56, 57 Another transporter such as peptide transporter, PTS-6, prevents the 
accumulation in the brain of 27 amino acid form of pituitary adenylate cyclase activating 
polypeptide (PACAP27).58 
 
1.1.3. Strategies to overcome the blood-brain barrier 
A number of potential strategies have been explored to overcome the BBB-imposed 
limitations to the entry of drugs into the CNS, which mainly can be categorised into invasive 
and non-invasive. Invasive approaches include intracerebral implants, intraventricular / 
intrathecal / interstitial delivery, blood-brain barrier modulating agents, and biological tissue 
delivery, meanwhile, for non-invasive, the use of chemical and biological approaches, as well 
as colloidal drug carriers/nanothechnologies are considered.13, 14  
 
1.1.3.1. Invasive techniques 
Invasive methods are neurosurgical-based which often performed by administering the drug 
by intracerebral or intracerebroventricular delivery.59 Even though this techniques are the 
most aggressive to deliver drugs to the brain, however they have been developed and widely 
used in several ways, including direct application of implants,60, 61 focused ultrasound,62, 63 
application of alkylglycerols,64, 65 and hyperosmotic disruption using polyol solutions.63, 66, 67 
The use of these techniques is sometimes required to deliver an adequate concentration of 
drugs to the brain and avoid serious toxic side effects caused in other tissues when 
administered intravenously or orally.  
 
Intracerebral implants 
Therapeutic agents can be delivered to the brain intracerebrally using implants following 
diffusion process. As this happens at a slow rate, the approach is only applicable for local 
delivery as it is hard to get an adequate drug distribution in the entire brain.68 In this 
approach, the employment of biodegradable polymeric matrix (as a reservoir) that contains 
therapeutic agents has been used. It possessed some advantages such as localised delivery, 
sustained drug release and adjustable release properties. However, it has poor drug 
penetration and the drug dosage is limited by the implant size.14 In 1996, FDA approved the 
use of this technique to treat recurrent high-grade gliomas using BCNU (bis-
chloroethylnitrosourea)(carmustine)-contained in a polyanhydride polymer wafer. This 
device was designed to release carmustine gradually over 2 to 3 weeks following implant 
onto the surface of the tumor resection cavity.69  
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Strasser et al. investigated the intracranial distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea 
(BCNU) in the rabbit brain after interstitial delivery by biodegradable polymer implants, 
where it was found that the drug diffused and accumulated within the region 1 to 2 mm from 
the surface of the polymer.70 The limited diffusion of BCNU after intracranial implantation 
has also been shown by Fung et al. where the concentration of the drug in rat brain decreased 
90 % at a distance of 0.5 mm from the polymeric implant.71 Some other chemotherapy agents 
have also been employed for this approach such as paclitaxel (for intralesional injection)72 
and mitoxantrone (for intracranial implantation).73 
 
Intraventricular / intrathecal / interstitial delivery 
Similar to intracerebral delivery that employs direct administration of drugs to the brain, 
therapeutic drugs can also be directly delivered to intraventricular, intracavitary, or interstitial 
system of the brain, therefore circumventing the BBB. These techniques have the potential to 
treat primary brain tumors as they provide direct delivery to targeted area, however it still 
exhibits some drawbacks including infection to CNS and inadequate drug distribution.14 
Methotrexate and morphine are among the drugs with promising outcome that have 
undergone various clinical trials.74, 75 
 
Blood-brain barrier modulating agents 
The function of BBB can be modulated naturally, leading to an increase in brain 
permeability, such as the opening of BBB’s tight junctions during inflammation.9, 76 Some 
molecules have been investigated their effect in modulating the integrity of the blood-brain 
barrier such as sodium caprate,77 bradykinin78, 79 and alkylglycerols.80 Certain inflammatory 
mediators such as histamine that help to increase permeability in peripheral capillary also 
work on brain endothelial cells. The histamine released from nerve terminals triggers the 
opening of the tight junctions to allow the entry of growth factors and antibodies into the 
brain.41, 81, 82  
 
A bradykinin agonist, called labradimil was developed to increase the permeability of the 
BBB. Labradimil is a 9-amino-acid-peptide designed for the bradykinin B2 receptor, with 
plasma half-life longer than bradykinin. Intravenous administration of labradimil onto rat 
models demonstrated an increase in the BBB permeability and a 2-fold greater uptake of 
chemotherapeutics agents such as carboplatin into the brain. Preliminary clinical trials of 
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labradimil in patients with gliomas illustrated evidence that it can permeabilise the BBB and 
the administration of this substance with carboplatin exhibited statistically enhanced survival 
when compared when patients received the drug alone.83-86 
 
Studies have shown that alkylglycerols could enhance the brain uptake of co-distributed 
drugs following intra-carotidal administration.64, 65, 80, 87-89 Mono- and di-alkylglycerols have 
been found to open the BBB temporarily following intra-carotidal administration. The 
concentration of methotrexate in the brain was found to be higher 2 to 230 fold when 
compared to control. The effect however was positive only in the case of intracarotidal 
administration of alkylglycerols, since no positive results was shown by intravenous 
administration. The effect of alkylglycerols on the BBB was explained as the outcome of 
their interaction with the membrane of the endothelial cells, in which lipid bilayer structure 
was disorganised and fluidified to facilitate trans-endothelial incorporation and diffusion of 
the drug molecules.64 The BBB opening induced by alkylglycerols was reported to be more 
rapid and localised to the injection site, with no in vitro and long term in vivo toxicity or 
neuropathological changes.80 
 
Biological tissue delivery 
This strategy employs the implantation of a specific tissue that can naturally release a desired 
active into the brain.14  This is among the simplest ways to deliver drugs to the interstitial 
area and has been used for the treatment of Parkinson’s disease in animal models 90, 91; foetal 
nerve-grafts were used as therapeutic tools to treat rodents and monkeys. The review 
discussed the possible advantages, risks and limitations associated with this technique for the 
potential application in humans. It was found that, due to lack of innervations of 
neovascularisation, often the transplanted tissue failed to survive.14 Efforts to improve the 
survival of foreign tissue grafts have been done such as by using co-culture principle.92, 93  
 
Piccini et al. monitored the release of dopamine in vivo from embryonic nigral transplants in 
the striatum of a Parkinson’s disease’s patient. The patient who was grafted with human 
embryonic mesencephalic tissue in the right forebrain 10 years earlier showed positive results 
during the observation, in which level of dopamine was found at normal level. 
Immunosuppressive treatment was stopped at 64 months and there were no signs of rejection 
shown.94 Clinical trial and one year observation was performed on 2 immunosuppressed 
patients with Parkinson’s disease who were implanted into the putamen with ventral 
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mesencephalic tissue from aborted human foetuses. Based on the observation, there were no 
postoperative complications and both patients showed a significant improvement of 
parkinsonian symptoms as early as 6 to 12 weeks after grafting and reached the maximum 
stability after 4 to 5 months; the patients remained stable during the 1-year observation 
period. These results illustrated the potential of intrastriatal implantation of foetal dopamine-
rich mesencephalic tissue in treating patients with Parkinson’s disease.95 
 
1.1.3.2. Non-invasive techniques 
Non-invasive techniques include the use of chemical, biological, as well as colloidal drug 
carriers and are more desirable as they do not involve any surgery, therefore provide ease of 
drug administration compared to the invasive approaches. 
 
Chemical approaches 
Chemical approaches involve the use of prodrugs in order to enhance deficiency in 
physicochemical property, for instance solubility or membrane permeability.14 Prodrug is a 
biologically inactive substance where it will be metabolised (generally by an enzymatic 
cleavage) within the body to produce its active form for instance, esterification or amidation 
of hydroxyl-, amino acid-containing drugs may increase hydrophobicity and facilitate drug 
entrance to the brain.96, 97 Apart from increasing hydrophobicity, the prodrug approach can be 
also achieved by means of endogenous transporters, macromolecular delivery mechanisms, as 
well as gene-directed enzyme prodrug therapy.10 
 
The presence of the glucose transporter (such as GLUT1) on both the luminal and the 
abluminal membrane of the endothelial cells has been exploited for this purpose; as an 
example of carrier-mediated transport, glycosylation of 7-chlorokynurenic acid has increased 
the uptake in the brain.98 Several other drugs such as dopamine99 and chlorambucil100 have 
been used to investigate the ability of glycosyl derivatives to bind specifically to GLUT1 
glucose transporter. GLUT1 transporter has also been suggested for the transport of peptides, 
as reported by Polt et al., where glycosylated enkephalin analogues were transported across 
the BBB in the mouse brain.48 Another example of carrier-mediated transport is large neutral 
amino acid transporter (LAT1) which is expressed on the luminal and abluminal membranes 
of capillary endothelial cells. Previous studies have shown the potential in transporting amino 
acid mimicking drugs, such as gabapentin101 and melphalan.102  
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The exploitation of enzymatic processes or pH are often employed for this approach, however 
in pathological conditions the environment may have been altered, thus disturbing the 
process. Another related problem with prodrugs is that, the increased hydrophobicity not only 
enhances drug diffusion across the BBB, but also increases the uptake into other tissues, 
leading to an increase in tissue burden.103  
 
Drug conjugates 
This approach includes the drugs conjugation with biological substances such as antibodies, 
which are useful to target the antigen on the target tissues.14, 104 Some of the antibodies are 
able to go through receptor-mediated transcytosis across the mouse BBB e.g. antibodies to 
transferrin receptor such as the OX26,105-108 the 8D3 or the R17-217 MAb.109, 110 However, it 
is hard to find specific antigens that will provide a clear-cut targeting site for instance, in 
cancer, where specific antigens are found not only on the target tissues, but also everywhere 
in the body.111 Another example of this approach is the use of sugar or lectins that acts as 
targeting ligands that can be targeted to specific receptor on the cell surfaces.112, 113 
Glycoconjugates containing complex oligosaccharide structures can be selectively recognised 
by membrane lectins that are expressed on the surface of various cells.114, 115 
 
Colloidal drug carriers 
Colloidal drug carriers (Figure 1.4) have been studied intensively as one of the most 
promising non-invasive strategies for drug delivery to the brain. Nanoparticles (nanospheres 
and nanocapsules), solid lipid nanoparticles, liposomes, exosomes, micelles and dendrimers 
are common examples of colloidal drug carriers sized in the submicron range.14, 116-118 
Actives molecules can either be entrapped within the carrier, adsorbed on the surface or 
attached covalently.119 These carriers have the advantage of improving the therapeutic index 
of active molecules by modifying their distribution, therefore increasing their efficacy. This is 
because the drug distribution is also influenced by the carrier, rather than only depending 
merely on the physicochemical properties of the drug.120 Therefore these carriers need to be 
designed properly based on the target and the administration route. The ideal colloidal drug 
carriers must be non-toxic, non-immunogenic, biocompatible and have a prolonged 
circulation time in the blood.46, 121  
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Figure 1.4. Colloidal drug carriers used in drug delivery. Reproduced from 122. 
 
Colloidal drug carriers have to overcome however several hurdles for effective drug delivery 
after intravenous administration. The human body is equipped with a complex system that is 
responsible foreign matter exclusion. Clearance by mononuclear phagocyte system (MPS) 
from blood circulation prevents the carriers from reaching an adequate concentration and 
uniform delivery of therapeutic agents to intended tissue area. The MPS clearance is 
modulated by opsonisation, where particles will bind to plasma proteins, before taken up by 
phagocytic cells in the blood, liver, spleen and bone marrow.123-126 As for brain delivery, the 
main challenge is to overcome the presence of the blood-brain barrier that prevents almost all 
therapeutics from entering the brain, which has been the highlight in delivering drugs to the 
brain effectively.  
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Table 1.1. Types of materials used in the formulation of nanoparticles investigated for drug 
delivery and imaging applications. 
Materials Comments / applications Ref. 
Inorganics Silica Controlled release drug delivery and gene transfection carriers of mesoporous 
silica nanoparticles 
127 
Loaded silica NPs with fluorescent dye molecules for cancer imaging 128 
Silica-based nanoparticles for both imaging and therapy of tumor 129 
Iron oxide Drug delivery for MRI monitored magnetic targeting of brain tumors 130 
Conjugation of the nanoparticles with Annexin V for detection of apoptosis 131 
Conjugation with Herceptin for in vivo detection of cancer 132 
Conjugation with bombesin peptide for imaging of pancreatic cancer 133 
Quantum dots 
(QDs) 
siRNA delivery approach by co-transfection of siRNA and QDs with 
Lipofectamine 
134 
Functionalisation of QDs with nanogels of cholesterol-bearing pullulan (CHP) 
for live cell imaging 
135 
Conjugation of Tat peptide with QDs for molecular and cellular imaging 136 
Gold Functionalized gold nanoparticles with calixarene derivatives, crown ethers 
DNA and peptides for recognition of amino acids, quaternary ammonium ions 
and pyridinium 
137 
 
Investigation of targeted gold nanoparticles for molecular CT imaging of cancer 138 
A study on the potential of gold NPs for colourimetric biosensing assays 139 
Organics Polymers Synthetic 
 
Polymeric emulsion and crosslink-mediated synthesis of 
super-stable nanoparticles as sustained-release anti-
tuberculosis drug carriers 
140 
 
Polybutyl-cyanoacrylate (PBCA) NPs for delivery of 
functional proteins into neurons and neuronal cell lines. 
141 
Polysaccharides 
 
Chitosan NPs for targeted delivery of peptides 142 
Pectin nanoparticles for colon targeting of 5-Fluorouracil 143 
Guar gum nanoparticles as the potential carriers for 
tamoxifen citrate in the treatment of breast cancer 
144 
Carbon 
nanotubes 
Application of CNT as a template for presenting bioactive peptides to the 
immune system 
145 
 
Investigation of translocation of bioactive peptides to across cell membranes 146 
Imaging of systemic circulation and urinary excretion following intravenous 
administration 
147 
Functionalisation of nanotubes with IgG for breast cancer detection 148 
Solid lipid 
nanoparticles 
(SLN) 
Functionalisation of NPs with cRGDfK peptide for contrast-enhanced MRI and 
molecular imaging 
149 
Coating of silica NPs with bis-sorbylphosphatidylcholine for tracking in 
cultured endothelial cells 
150 
Lipid-based nanoparticles for biolabeling and cellular imaging 151 
 
The use of nanoparticles for drug delivery has been gaining wide interest and rapidly 
expanding. Examples of nanoparticles based on a variety of inorganic or organic materials as 
listed in Table 1.1. According to Mudshinge et al., nanoparticles are a type of colloidal drug 
carriers having the size ranging from 10 to 1000 nm. They can be classified into several types 
such as fullerenes, solid lipid nanoparticles (SLN), liposomes, nanostructured lipid carriers 
(NLC), nanoshells, quantum dots, superparamagnetic nanoparticles and also dendrimers.152 
Apart from their small size that can allow penetration into cells, the ease of surface 
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modification (suitable for multifunctional therapy) and the ability to escape from lysosome 
after endocytosis are among other advantages.123, 153, 154 .  
 
Table 1.2. Commercial nanoparticles approved by FDA for drug delivery and imaging 
applications.155 
Product name Technology Indication Approval 
Abelcet Liposomal amphotericin B Fungal infections 1995 
Abraxane Albumin-paclitaxel nanoparticles Metastatic breast cancer 2005 
Cimzia PEGylated fragment of an anti-TNF 
antibody 
Crohn’s disease and 
rheumatoid arthritis 
2008 
Copaxone Glutamine, Alanine, Tyrosine copolymer Multiple sclerosis 1996 
DaunoXome Liposomal daunorubicin HIV-associated Kaposi’s 
sarcoma 
1996 
Depocyt Liposomal cytosine arabinose Cancer 1999 
Doxil/Caelyx PEGylated liposomal doxorubicin Various cancer types 1995 
Emend Nanocrystal particles Chemotherapy related 
nausea and vomiting 
2003 
Gastromark Silicon-coated SPIONs MRI contrast agent 1996 
MultiHance Gadolinium-based nanoparticles MRI contrast agent 2004 
Pegasys PEG-interferon alpha Hepatitis B and C 2002 
Visudyne Liposomal verteporfin Age-related macular 
degeneration 
2000 
 
Examples of the first generation of nanomedicines available on the market such as Doxil® / 
Caelyx® and Abraxane®156-159 are presented in Table 1.2. They have passed the clinical trials 
and were approved by the U.S. Food and Drug Administration (FDA). Doxorubicin and 
paclitaxel are both effective anticancer drugs but they possess severe side effects when 
administered on their own. However, when these drugs are encapsulated in nanocarriers 
(doxorubicin in liposomes and paclitaxel in albumin nanoparticles), the systemic toxicity 
were found to be low, therefore enhanced the efficiency.160, 161  
 
1.2. Carbohydrate nanoparticles for drug delivery 
The use of polysaccharides for the formulation of nanoparticles possess several advantages; 
polysaccharides are highly stable, safe, non-toxic, biodegradable and most of them have 
hydrophilic moieties (Figure 1.5) such as hydroxyl, carboxyl and amino groups which allow 
formation of non-covalent bonds with biological tissue (such as epithelia and mucus 
membrane).162, 163  
 
Another advantage of using biodegradable materials such as polysaccharides for nanoparticle 
preparation is the ability to perform sustained drug release within the target site over a period 
of time.164 Polysaccharides can also be easily modified chemically and biochemically due to 
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the presence of various reactive groups in their structure to provide a better efficiency 
especially in targeting the drugs/nanoparticles to the desired action.165 In drug delivery, a 
targeted drug carrier system is needed and can be achieved by either passive or active 
targeting of drugs to the desired site of action.166 Passive targeting uses the differences in the 
anatomy of normal and damaged tissues to deliver drugs owing to the fact that the physiology 
of damaged tissues may be altered, hence enhancing the permeability. Meanwhile, active 
targeting exploits the conjugation of receptor specific ligands to promote site-specific 
targeting.167 
 
In recent years, carbohydrate nanoparticles (Table 1.3) have been investigated with a great 
potential for the development of drug delivery systems. Chitosan nanoparticles grafted with 
PEG was prepared using ionic gelation for nasal delivery; the nanoparticles that were loaded 
with insulin was found to increase the nasal absorption of the drug.168 Comparison between 
chitosan, trimethyl-chitosan (TMC) and carboxymethyl chitosan for tetanus toxoid antigen 
release was made by Sayin et al.; chitosan and TMC showed a better effect than 
carboxymethyl chitosan nanoparticles.169 Apart from tripolyphosphate (TPP), chitosan also 
has been cross-linked with cyclodextrin in the formation of nanoparticles. 
Chitosan/cyclodextrin nanoparticles have been investigated in the preparation of hepatitis B 
vaccine delivery systems.170 Chitosan also has been investigated in the formation of hybrid 
nanoparticles with metallic gold. Having associated with insulin with 53 % efficiency, these 
hybrid nanocarriers exhibited promising results in nasal delivery systems.171 
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Figure 1.5. Examples of polysaccharides considered for drug delivery applications. 
 
Thiolated pectin nanoparticles formulated via ionotropic gelation technique was reported by 
Sharma et al. for the delivery systems in ophthalmic application. Using timolol maleate as the 
model drug, the nanoparticles illustrated an enhanced ex vivo corneal permeation of the drug 
across goat cornea compared to the conventional solution.172 Yadav who prepared 
fluconazole-loaded nanoparticles from gum cordia polysaccharide (obtained from Cordia 
Obliqua fruit) investigated the effect of the nanoparticles on corneal permeation. The results 
were compared with the commercial aqueous fluconazole and the results indicated no 
significant difference between those two.173  
 
Pullulan 
Chitosan 
Pectin Carboxymethylcellulose 
Carrageenan 
Guar gum 
Alginate 
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Woitiski et al. reported the formulation of hydrogel nanocarriers from the polyelectrolyte 
complexation of alginate, dextran sulphate and poloxamer. The nanoparticles that were 
loaded with insulin (70–90 % entrapment efficiency) exhibited the size ranging from 200 to 
500 nm and investigated for oral delivery.174 Another investigation on oral delivery of insulin 
was performed using alginate/chitosan nanoparticle system, which was protected by forming 
complexes with cationic β-cyclodextrin polymer.175 The nanoparticles exhibited the size 
lower than 350 nm with insulin loading efficiency up to 87 %. The insulin was protected 
from extreme gastrointestinal conditions due to electrostatic interaction with cyclodextrins 
and retained in the core of the nanoparticles.  
 
Table 1.3. Drug delivery applications investigated with carbohydrate based nanoparticles. 
Site of action Comments/applications Ref. 
Skin Skin permeation of soluble proteins using chitosan-pluronic F-127 nanoparticles 176 
Investigation of warfarin-loaded β-cyclodextrin nanoparticles for transdermal 
delivery 
177 
The transport of chitosan nanoparticles loaded with clobetasol propionate across 
pig skin 
178 
Studies on in vitro skin permeation of monoolein nanoparticles entrapping 
hydroxypropyl-β-cyclodextrin 
179 
Development of a delivery system based on cyclodextrin complexation and loading 
into nanostructured lipid carriers (NLC) for ketoprofen topical delivery 
180 
Nasal Studies on the effect of PEG-grafted chitosan in enhancing insulin nasal absorption 168 
Studies on starch nanoparticles as a potential trans-nasal mucoadhesive carrier 181 
Insulin-loaded chitosan/alginate nanoparticles for transmucosal delivery 182 
Pullulan nanoparticles loaded with vaccine for nasal delivery  183 
Development of non-invasive vaccine delivery based on mono-N-carboxymethyl 
chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles 
169 
Ophthalmic Studies on ex vivo corneal permeation of timolol maleate-loaded thiolated pectin 
nanoparticles 
172 
Investigation of cholesterol hydrophobically modified chitosan for delivery of 
drugs to ocular surface 
184 
Studies on hyaluronic acid/chitosan nanocarriers for ocular gene therapy 185 
Studies on tropicamide-loaded tamarind seed xyloglucan nanocarriers for 
ophthalmic delivery 
186 
Development of betamethasone sodium phosphate-loaded nanocarriers for 
ophthalmic delivery 
187 
Intestine Insulin delivery using alginate/dextran sulphate/poloxamer nanoparticles 174 
Development of B12-coated dextran nanoparticles for oral delivery of insulin 188 
In vitro evaluation of thiolated chitosan nanoparticles for oral delivery application 189 
Development of β-cyclodextrin-insluin-encapsulated chitosan/alginate nanocarriers 
for oral delivery system 
190 
Oral delivery of mEpo gene to intestine in vivo by chitosan-DNA nanoparticles 191 
 
It has been reported in the literature that most nanoparticles used for brain delivery should 
ideally have the size below 100 nm.192-196 Gao and Jiang also investigated the delivery of 
methotrexate-loaded poly(butyl cyanoacrylate) nanoparticles coated with polysorbate 80, 
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which were administered in vivo into rats. Nanoparticles with size of 70, 170, 220 and 345 
nm were used, and the concentration of the drug in the brain was investigated; 70 nm sized 
nanoparticles exhibited the highest drug concentration (20 % increase in drug delivery) with 
no differences in methotrexate brain delivery shown between 170, 220 and 345 nm sized 
particles. These results  suggest that nanoparticles with less than 100 nm could overcome the 
BBB better than bigger nanoparticles and the insignificant particle size effect may be due to 
the mechanism nanoparticle uptake.197 
 
Jain et al. investigated the use of starch nanoparticles to deliver insulin in nasal application.181 
The nanoparticles were prepared using different cross-linking agents and techniques, with 
size ranging from 190 nm to almost 1 micron. Pullulan based nanoparticles have been 
investigated for the delivery in nasal application, particularly for vaccination. Other 
polysaccharides that exhibited good bio adhesion capacity such as cellulose, pectin, 
hyaluronan were also used for the development of nanoparticulate systems for peptide release 
to the nasal mucosa.183  
 
1.2.1. Polysaccharide nanoparticles for drug delivery to the brain 
A considerable research effort in the area of drug delivery to the brain using polysaccharide-
based nanomedicines has already provided several promising alternative for the treatment of 
brain diseases. Table 1.4 shows examples of several polysaccharide-based nanoparticles that 
have been investigated for imaging and transporting drugs to the brain.  
 
Polysaccharides that possess native charges may be useful in brain delivery as suggested by 
literature in which electrostatic interaction between positively charged polysaccharides and 
negatively charged brain endothelium may provide passage to the brain via adsorptive-
mediated transport (AMT).198 Brain endothelial cells contains glycocalyx groups on their 
luminal surface that contributes to a strong negative charge.199 Negatively charged particles 
including nanoparticles or FITC-dextran are able to cross the BBB, however in lower 
concentration than neutral or cationic ones.193, 200 Adsorptive-mediated transcytosis has been 
reported to transport cell penetrating peptides such as TAT-derived peptides201 and cationic 
protein such as albumin across the BBB.202, 203 Huang et al. reported the uptake of chitosan 
nanoparticles by A549 cells was triggered by electrostatic interactions between the 
nanoparticles and the cell membrane204 and Amidi et al. found that trimethyl chitosan 
chloride (TMC) nanoparticles could be transported across the nasal mucosa owing to 
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intracellular uptake by epithelial in in vivo studies.205 Based on this, nanoparticles formulated 
from cationic polysaccharides such as chitosan are believed to have the potential to trigger 
AMT by an electrostatic interaction between the positively charged moiety of the 
nanoparticles and a negatively charged plasma membrane surface on the brain capillary 
endothelium.  
 
Table 1.4. Polysaccharide-based or -coated nanoparticles for brain imaging and drug 
transport across the BBB. 
Polysaccharide Comments/applications Ref. 
Chitosan (CS) Surface modification of CS NPs with PEG to deliver peptide across 
the BBB 
206 
Chitosan (CS) Effect of alkylglyceryl-modified chitosan nanoparticles upon BBB 
integrity 
207 
Chitosan (CS) Investigation of CS NPs as a peptide nanocarrier to transfer across 
the BBB 
142 
Chitosan (CS) Peptide delivery to the brain by peptide nanofibers coated with 
glycol chitosan 
208 
Dextran Effect of alkylglyceryl-modified dextran that was covalently linked 
to PLA in enhancing permeability across the BBB 
209 
Maltodextrin Studies on the effect of surface charge and inner composition of 
NPs to pass through the BBB 
210 
Maltodextrin Studies on the influence of surface charge and lipid coating of NPs 
to cross BBB model 
193 
β-cyclodextrin Cross-linking of β-cyclodextrin and poly(β-aminoester) for the 
formation of nanoparticles across the BBB 
211 
β-cyclodextrin Formulation of quaternary ammonium β-cyclodextrin (QAβCD) 
nanoparticles as drug delivery carriers for doxorubicin across the  
BBB 
212 
Mannan In vitro and in vivo evaluation of mannan-coated nanoparticles for 
delivery of didanosine 
213 
Pullulan Cholesterol bearing pullulan nanoparticles for Alzheimer’s disease 
treatment 
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Caban et al. investigated the potential of chitosan nanoparticles loaded with either small 
peptides or large peptides to move across the blood-brain barrier. Nile red was loaded into the 
nanoparticles for imaging purpose and observation from intravital fluorescent microscopy 
indicated a rapid movement across the blood-brain barrier.142 A study on the potential of 
nanoparticles formulated from alginate polysaccharide has been demonstrated by Haque et al. 
for the treatment of depression via intranasal nose to brain delivery route. The nanoparticles 
were loaded with Venlafaxine (VLF) and the brain uptake was compared to VLF solution, in 
which greater concentration of VLF in the brain was found by administering VLF-loaded 
alginate nanoparticles.142  
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Jeong YI et al. formulated nanoparticles from a complexation between chitosan and dextran 
in order to study the potential of drug targeting via the transferrin (Tr-chitosan) receptor-
mediated transport. Chitosan that was previously conjugated with transferrin and 
doxorubicin-conjugated dextran (DEX-DOX) have been employed for this particular brain 
tumour drug delivery.215  
 
Further work on chitosan has been done by Yesim Aktas et al., who prepared chitosan 
nanospheres conjugated with poly(ethylene glycol). These nanospheres were conjugated with 
OX26 monoclonal antibody, whose affinity for the transferrin receptor may potentially 
activate receptor-mediated pathway across the BBB. The nanoparticles were fluorescently 
labelled and injected to mice in order to investigate their efficacy for brain translocation.216 
The use of maltodextrin polysaccharide for the formulation of nanoparticles has been 
described by Loiseau et al. and Youssef Jallouli et al. to investigate the effect of surface 
charge and inner composition of porous nanoparticles to cross the BBB in vitro.210, 217  
 
Another work on polysaccharide was demonstrated by Gil,218 who prepared novel 
polysaccharide-based nanogels containing poly(β-aminoester) and β-cyclodextrin that was 
reported to exhibit sustained release of doxorubicin for 40 days and insulin for 13 days, as 
well as enhancing insulin permeation across the blood-brain barrier by 20 %. These materials 
also can include both hydrophobic (in hydrophobic central cavity of β-cyclodextrin) and 
hydrophilic (on the outer surface of oligosaccharide) drugs. Cross-linking β-cyclodextrin and 
poly(β-aminoester) to produce nanoparticles was performed by other researchers, resulting in 
particles with 80 nm loaded with doxorubicin; in vitro results indicated that the particles did 
not affect the integrity of BBB model and the release of doxorubicin can be sustained for at 
least one month.211 
 
The surface charge of nanoparticles can have different effects on the integrity and 
permeability of the blood-brain barrier.219 High concentrations of anionic and cationic 
nanoparticles were found to be toxic for the BBB while neutral and low concentrations of 
anionic nanoparticles demonstrated no effect on BBB integrity. In terms of brain uptake, 
neutral and cationic nanoparticles possess were uptaken into the brain higher when compared 
to anionic particles. Therefore, the surface properties of nanoparticles must be considered for 
the efficiency of the drug carrier system.123 Surface modification can be demonstrated by 
polymer that has been coated with surfactant that allows the nanoparticles to mimic the 
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substances that would often enter the brain. For instance, polysorbate-coated nanoparticles 
are able to mimic low-density lipoproteins (LDL), facilitating them to across the capillary 
wall, hence enter the brain by means of LDL receptor.116, 220-222  
 
1.2.2. Nanoparticle formulation techniques 
Techniques to formulate nanoparticles vary depending on the nature of the selected 
polysaccharides which include self-aggregating, nanoprecipitation, solvent displacement, 
reverse emulsification, covalent crosslinking and ionic gelation. These drug carriers can be 
designed to have drugs entrapped inside the core of the particle, or distributed within the 
particle matrix, therefore protecting them from an environment that can degrade their 
activity.223 The interest application of nanoparticles also influences the preparation 
techniques as it will affect the properties of the nanoparticles, therefore ultimately deciding 
their fate. Therefore, it may be useful to identity the application of nanoparticles before 
deciding the formulation methods. There are other methods commonly used in formulating 
nanoparticles such as supercritical fluid technology, electrospraying, as well as 
polymerisation of monomers, which will be described below. 
 
1.2.2.1. Self-assembled nanoparticles 
Amphiphilic polysaccharides comprising hydrophilic and hydrophobic segments can form 
nanoparticles with a hydrophobic core and a hydrophilic outer surface owing to the intra-
and/or intermolecular interactions of hydrophobic parts in aqueous media.224, 225 This 
technique is suitable to entrap hydrophobic drugs, as well as some biomacromolecules such 
as proteins and genes for improving their stability and controlling their release.226, 227 
Chemical modifications such as acetylation228, 229 and alkylation230, 231 can be performed onto 
a number of hydrophilic polysaccharides in order to increase the hydrophobicity, therefore 
yielding amphiphilic polysaccharides.   
 
The morphology of these nanoparticles can be finely tuned by varying the molecular weight, 
also the type and the degree of substitution (DS).232-234 Na et al. formulated nanoparticles 
from hydrophobically modified pullulan (pullulan acetate) that were loaded with doxorubicin 
by a dialysis method, yielding particles with average size of 100 nm and loading degree of 8–
17 %.228 Yinsong et al. prepared nanoparticles by dispersing amphiphilic chitosan 
(cholesterol-modified O-carboxymethyl chitosan) in water to give particles with size ranging 
from 100 nm to 240 nm and negative zeta potentials.235 Another work employing amphiphilic 
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chitosan to formulate peptide loaded nanoparticles has been demonstrated by Lalatsa et al., 
where quaternary ammonium palmitoyl glycol chitosan (GCPQ) was dispersed in aqueous 
media and probe sonicated, yielding particles with size ranging from 70 to 600 nm.236 
 
1.2.2.2. Solvent displacement / nanoprecipitation 
Solvent displacement, also known as nanoprecipitation, involves the precipitation of a 
dissolved polymer after exposure to a non-solvent that is miscible with the solvent. 
Nanoparticles therefore are formed instantaneously during the fast diffusion of the polymer 
solution in the non-solvent. The process can take place either in the presence or absence of a 
surfactant.237 Organic solvents are normally used and low boiling point solvent is preferable 
as it will be easy to remove the solvent in the later process, however the use of other organic 
solvent is also possible. The solvent can be removed by techniques such as evaporation (for 
low-boiling point solvent) and dialysis (for high-boiling point solvent such as DMSO). The 
separation of nanoparticles can be achieved using centrifugation. The resulting nanoparticles 
can be affected by the choice of water-miscble solvents, in which the diffusion rate of the 
solvent into non-solvent is enough to initiate spontaneous precipitation.238  
 
 
Figure 1.6. Schematic representation of the solvent displacement (dialysis) method. 
 
In some cases, if the coalescence rate of formed particles is higher than the precipitation, the 
resulting particles may exhibit large size. Other than that, the concentration of polymer, the 
viscosity, the dielectric constant, the stirring speed, the dropping rate of the solvent, and the 
presence (or concentration) of a surfactant also play vital role in affecting the properties of 
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resulting nanoparticles 239, 240. This simple technique is normally used for encapsulating 
hydrophobic drugs and may not be an ideal option for hydrophilic drugs.241 
 
Poorly soluble anti-fungal drugs such as bifonazole and clotrimazole, were highly loaded 
(entrapment efficiency of 32–117 and 25–78 %, respectively) into amphiphilic h-
cyclodextrins nanoparticles (< 300 nm) that were prepared via this technique in order to 
facilitate parenteral administration.242 This method has been widely used to formulate other 
polysaccharide nanoparticles for materials such as dextran (particle size ranged from 86 to 
256 nm with entrapment efficiency of lidocaine between 11 and 29 %)243 and cellulose 
(particle size 177–1110 nm).244 
 
Apart from introducing solvent directly into non-solvent (used in nanoprecipitation), dialysis 
(Figure 1.6) can offer a slight different option for solvent displacement technique, where the 
semi permeable membrane of dialysis bag allows the solvent diffusion process to happen in a 
slower manner.  The mechanism is believed to be similar to nanoprecipitation though it is not 
fully elucidated.245 In dialysis, the solvent diffusion process may be done in a slower rate 
compared to nanoprecipitation method. Polymer is dissolved in a solvent and put inside a 
dialysis bag with a particular molecular weight cut-off (MWCO). Solvent inside the bag will 
diffuse out into the outside media (non-solvent) and the polymer will start to precipitate due 
to loss solubility, leading to the formation of nanoparticles.237 Similar to nanoprecipitation 
method, the solvent plays an important role in affecting the morphology and the size of the 
particles.237  
 
1.2.2.3. Emulsion 
In this technique, the nanoparticles can be obtained from the emulsion droplets where 
polysaccharide is dissolved in the water phase. Polysaccharides possess good solubility in 
water, hence making them suitable for this method.246 In general, aqueous polysaccharides 
solution will be emulsified into an oil/organic phase containing the appropriate surfactant, 
therefore ensuring the spherical shape and reduced size of the particles. The mechanism 
behind the formation of nanoparticles lies on two following steps; emulsification (size-
determining step) and evaporation.247 Emulsification step will produce emulsion droplet, 
leading to the formation of nanocapsules via the combination of polymer precipitation and 
interfacial phenomena during solvent diffusion.248 Eventually, the evaporation of volatile 
solvent will take place in the final process, producing nanoparticles that are suspended in 
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aqueous media. Many polysaccharides have been formulated using this technique such as 
chitosan (size of 30–100 nm with ascorbyl palmitate loading degree of 8–20 % and 365 nm to 
> 2 µm particle size with plai oil entrapment efficiency of 81–88 %)249, 250, alginate (size of 
6–400 nm)251 and dextran (size ranged from 267 nm to 2.76 µm with insulin encapsulation 
efficiency of 82.5 %).252 
 
1.2.2.4. Ionic gelation 
This method is based on the ability of polyelectrolytes (including polysaccharides) to 
crosslink by physical interactions in the presence of small size counter-ions.253, 254 A number 
of polymeric nanoparticles are prepared using this technique such as; chitosan with either 
tripolyphosphate (TPP) (size ranged from 200 to 633 nm),255, 256 dextran sulphate (size ranged 
from 600–800 nm with amphotericin entrapment efficiency of 65 % and 144–711 nm with 
BSA entrapment efficiency of 46–95 %),257, 258 or hyaluronic acid (size ranged from 165–213 
nm) 259, 260; and pectin with calcium chloride (size ranged from 100 to 150 nm)261 and 
magnesium chloride (size of 237 nm with timolol maleate entrapment efficiency of 94.6 
%).172 In the case of chitosan and TPP, the positively charged amino group of chitosan 
interacts with the negatively charged tripolyphosphate which results in the formation of 
hydrogels with size in the range of nanometer (Figure 1.7).262  
 
 
Figure 1.7. Typical crosslinking reaction between chitosan and sodium tripolyphosphate. 
Reproduced from 263. 
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1.2.2.5. Covalent crosslinking 
Cross-linking is based on the formation of chemical links between molecular chains to form a 
3-dimensional network of connected macromolecules. Cross-linking is necessary to prevent 
the dissolution of polysaccharides in water and the degree of cross-linking could affect the 
swelling properties of the cross-linked molecules. Cross-linked polysaccharides have been 
used for coating and/or encapsulation of therapeutic actives.264 Chemical cross-linking agents 
can be either homo- or hetero-bifunctional, aimed for the formation of inter- and intra-
molecular bonds. The most frequently used are the following glutaraldehyde and other 
dialdehydes, genipin and epichlorhydrine.163 Guar gum (size ranged from 200–300 nm with 
tamoxifen citrate drug loading > 15 %),144, 265, 266 pullulan (size of 40 nm with FITC-dextran 
entrapment efficiency of 90 %),267 and chitosan (size of around 100 nm with doxorubicin 
entrapment efficiency of 60–65 %)268, 269 are among the polysaccharides that have been 
formulated into nanoparticles using this method. 
1.2.2.6. Other techniques 
In polymerisation method, monomers are reacted to form nanoparticles in solution. Drugs can 
be introduced to the system by dissolving them in polymerisation medium or via adsorption 
onto nanoparticles after the polymerisation ends.270 Purification needs to be done in order to 
remove stabilising agents such as surfactants that are used during the formulation process, in 
which can be achieved by centrifugation of nanoparticles suspension. The formation of 
nanocapsule and the size are influenced by the concentration of surfactants and stabilising 
agents.237, 245, 271  
 
Supercritical fluid technologies provide alternatives to the classic nanoformulation methods 
owing to the properties of the supercritical fluid that is environmentally friendly and be able 
to produce biodegradable nanoparticles. CO2 is the most common supercritical fluid used in 
this method. Techniques to formulate nanoparticles using supercritical fluid can be either 
supercritical anti-solvent (SAS) or expansion of critical solution (RESS). In SAS, solvent that 
is miscible with supercritical fluid, such as methanol, is used to dissolve solutes that will be 
micronised. Since solutes are not soluble in supercritical fluid, therefore a spontaneous 
precipitation will take place, forming nanoparticles. In RESS, solutes will be dissolved in 
supercritical fluid under high pressure and sprayed through nozzle into a lower pressure area. 
Difference in pressure will therefore decrease the ability of the supercritical fluid to dissolve 
28 
 
the solutes, hence initiate the precipitation of small particles (in the form of nanoparticles).272-
274  
 
Another technique to formulate nanoparticles is by electrospraying (Figure 1.8), in which can 
be performed by applying a high voltage to a polymeric solution to force the polymer to come 
out from the syringe as droplets. Droplets produced by this technique are highly charged 
which can help to prevent from coagulation. The size of droplets can be in nano-size range 
depending on parameters such as applied voltage, flow rate, solvents and working 
distance.275, 276  
 
Figure 1.8. Schematic representation of an electrospraying setup. Reproduced from 277. 
 
1.2.3. Nanoparticle characterisation techniques 
Nanoparticle parameters that are commonly measured include average particle diameter, size 
distribution, zeta potential and morphology. Average particle diameter of nanoparticles is 
analysed using dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA).278, 
279 Scanning electron microscopy (SEM), transmission electron microscopy (TEM) and 
atomic force microscopy (AFM) (Figure 1.9) can be employed to measure and analyse 
nanoparticles size and morphology.280 Electrophoretic mobility (EPM) is employed to 
characterise the zeta potential of nanoparticles, hence providing the information on the 
stability of the colloidal system.281, 282   
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Figure 1.9. A: Schematic representation of the AFM method. B: Close-up images of an AFM 
tip. Reproduced from 283. 
 
1.2.3.1. Dynamic light scattering 
Measuring the size is one of the important steps in characterising nanoparticles. Dynamic 
light scattering (DLS), also known as photon correlation spectroscopy, is a technique that is 
commonly used to analyse nanoparticles. The measurement is performed based on particle 
motion which further will be converted into particle size.284 Particles in suspension move 
randomly due to collisions of particles that caused by bombardment of the solvent molecules 
- this random motion is called Brownian motion. The speed at which the particles move is 
measured by recording the fluctuation rate of scattered light intensity. Stokes-Einstein 
equation (Eq. 1)  
 
𝑑 =
𝑘𝑇
3𝜋𝜂𝐷
           (Eq. 1) 
 
where d is the hydrodynamic diameter (in m), k is the Boltzmann constant (J K−s), η is the 
dynamic viscosity (kg s−s m−m) and T is the thermodynamic temperature (K), is used to model 
the random movement of particles which will provide information on particle size. As smaller 
particles move faster than the larger ones, therefore smaller particles will produce fluctuation 
of intensity more rapidly.278 The analysis of particles starts when laser light illuminates the 
sample (normally in a cuvette) and the particles will scatter some light. The scattered light 
will be collected by collectors, either at right angle 90o or back angle 173o scattering angle. 
The calculations are done by the instrument software, however important parameters need to 
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be known such as liquid (solvent) refractive index and viscosity, as well as sample 
temperature (which will affect the viscosity of the sample).285, 286  
 
 
Figure 1.10. Typical correlation function obtained with DLS, represented as correlation 
coefficient over time. Reproduced from 287. 
 
The resulting signals can be expressed as correlation function of the scattered intensity as a 
function of time (namely correlogram) (Figure 1.10). Particle size and polydispersity of the 
sample can be represented by the time needed for the curve to decay and the curve gradient. 
The longer time needed, the larger the particles are and the steeper the curve, the more 
monodisperse the sample is.288 From the correlation function, size can be obtained by means 
of various algorithms; Cumulants analysis and non-negative least squares (NNLS). Cumulant 
analysis is used to fit a single exponential in order to measure the Z-average diameter (mean 
size) and polydispersity index (estimation of the distribution width). To fit a multiple 
exponential to the correlation curve, non-negative least squares are more preferable.289  
 
1.2.3.2. Nanoparticle tracking analysis 
Nanoparticle tracking analysis (Figure 1.11) has been used to measure the particle size, as 
well as visualise the nanoparticle in the colloidal system, in real time. The measurement of 
the particle size involve the analysis of individual particles movement under Brownian 
motion, therefore it can size and measure multiple particles at the same time and produce 
results as average size distribution. Laser light of the instrument is used to illuminate the 
samples and the software will analyse each particle by calculating the mean squared 
displacement for each individual particle. By applying the Stokes-Einstein equation, the 
hydrodynamic diameter of particles can be measured.290, 291  
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Figure 1.11. Schematic representation of the Nanoparticle Tracking Analysis. 
Reproduced from 292. 
Compared to the DLS measurement which is ideal for monodisperse samples, NTA is better 
suited for polydisperse samples or samples with unknown size distribution. NTA 
measurement is based on the movement of individual particles, however for DLS, the result is 
expressed as intensity weighted Z-average distribution.293 NTA requires particle 
concentrations within the range of 107–109 particles per mL, while for DLS, the concentration 
range is less critical as the measurement depends on instrumental and sample properties.290 
However, sample dilution sometimes may destroy or create new aggregates due to the 
instability of the particles and affect the size distribution though it is more likely to affect 
protein aggregates than nanoparticles.294 Apart from that, NTA offers less reproducibility of 
results as it measure less particles than DLS (the results are due to average particle size from 
many more particles), as well as smaller range of detection limit (10–1000 nm) as compared 
to DLS (2–3000 nm).295 The technique records particles intensity and this will be useful to 
differentiate particles having similar size but different refractive index (Figure 1.12). Many 
researchers usually use both techniques in parallel to characterise nanoparticles in order to get 
a better and more accurate picture of the size distribution.  
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Figure 1.12. Nanoparticle size distribution in a 3D projection obtained from NTA. Colour 
coding is used to differentiate nanoparticle populations based on size and intensity. 
Reproduced from 292. 
 
1.2.3.3. Zeta potential 
The electrokinetic potential of particles in a colloidal system is another important parameter 
to indicate the stability of a dispersed system against aggregation.296 The surface of particles 
is surrounded by the environment where two layers exist; an inner layer (Stern layer) where 
the ions are strongly bound; and an outer layer (diffuse layer) where the ions are relatively 
looser bound (Figure 1.13).297, 298  
 
 
Figure 1.13. Schematic representation of the electric double layer (EDL).  
Reproduced from 299. 
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Since the ions in diffuse layer are loosely bound, therefore when the particles are moving in a 
liquid environment perhaps due to gravity, the ions will not move together, as opposed to the 
inner layer where the ions are firmly associated and move. The electric potential at the diffuse 
layer boundary (also called the surface of hydrodynamic shear) is measured as zeta 
potential.299 Particles with adequate zeta potential (normally outside the range between -
30mV and +30mV) are considered to have a stable dispersion system. Same charge particles 
will repel each other, therefore avoiding from aggregation.300, 301 
 
1.2.3.4. Imaging techniques /microscopy 
Another way to characterise nanoparticles is by visualisation, however normal optical 
microscopy is not possible owing to the very small size of nanoparticles. Therefore, 
techniques employing a beam of electrons like TEM and SEM were discovered to facilitate 
the visualisation of nanoparticles.302, 303 Apart from those techniques, atomic force 
microscopy (AFM) is also an alternative method to characterise the morphology of a sample. 
Employing a probe to monitor sample surface, aspects such as sample height, friction or 
magnetism can be examined using this method. Size of nanoparticles can be studied by 
measuring the image height of the nanoparticles, provided that the spherical nanoparticles are 
deposited on a flat substrate.304, 305  
 
Scanning electron microscopy  
A scanning electron microscopy (SEM) that was developed by Oatley in early 1948 employs 
a high energy electron beam which is scanned over the surface of sample and the back 
scattering of the electron beam is recorded (Figure 1.14).306, 307 Prior to introduction to the 
microscope, the sample must be coated (usually done by sputter coating of non-conductive 
sample) in order to provide electrical conductive at the surface of the sample. Metal samples 
do not require coating as they are already conductive. The coating process must be done 
properly throughout the sample surface, in which can be time consuming and expensive. The 
samples then is fixed on a stub and placed under high vacuum chamber.308 The environmental 
SEM technique allows visualisation of samples without coating, or in a wet state, which can 
be achieved in a low pressure gas environment as opposed to a vacuum.309 
 
34 
 
  
Figure 1.14. Schematic representation of a Scanning Electron Microscope. Reproduced from 
310. 
 
Transmission electron microscopy 
The technique that was developed by Ruska in 1930’s has been used as another alternative 
for visualisation.311 A beam of electrons are transmitted through the sample and interact with 
the sample as they pass through to produce an image on a photographic plate or camera. The 
sample is placed inside a high vacuum chamber prior to visualisation. The sample preparation 
can be sometimes challenging in which a tiny amount of sample (for electron-beam 
penetration) needs to be placed onto a support grid.312 Comparing with SEM, TEM uses more 
powerful electron beams, therefore provides higher resolution of images, in which beneficial 
for studying nanoscale samples. Environmental TEM is available for samples to be analysed 
by TEM under low pressure gas as opposed to the vacuum used for TEM.313 
 
1.3. Chemical modifications of polysaccharides 
Natural polysaccharides and their derivatives are a group of polymers that have been used in 
the pharmaceutical and biomedical applications. Polysaccharides are molecules with a 
molecular chain of repeating monomers possessing unique chemical properties that provide 
functional groups for various chemical interactions. Large quantities of functional groups 
presence in polysaccharides (due to repeating of monomers) may ease a specific chemical 
modification or interaction. Exploiting these properties of polysaccharides, therefore 
nanoparticles prepared from the materials may possess drug release property that can be 
modified and suitable for a number of drug delivery applications.  
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1.3.1. Common types of polysaccharide chemical modifications 
Chemical modifications of polysaccharides have been performed in order to modify the 
original characteristics of naturally occurring biopolymers for certain drug delivery 
applications. The source of polysaccharides can be from different origins: algal, such as 
alginate314; microbial, such as dextran315; from plants, such as pectin or guar gum or 
pullulan316; or from animals such as chitosan,317 hyaluronan318 and chondroitin.319 By 
introducing substituent groups, it can change the property of the polysaccharides, for 
instance, the solubility in water. Most common chemical modifications that have been done 
to polysaccharides include sulphation, carboxymethylation, phosphorylation, acetylation and 
alkylation 
 
1.3.1.1. Carboxymethylation 
Introducing the carboxymethyl group to the polysaccharidic chain by reaction in either 
aqueous or solvent medium leads to a chemical reaction called carboxymethylation (Figure 
1.15). In aqueous method, polysaccharide will be dissolved in an alkaline solution, followed 
by the addition of monochloroacetic acid. The mixture will be allowed to react for a few 
hours before neutralised using acetic acid. Meanwhile, for the solvent method, polysaccharide 
solution will be added with alcohol to cause precipitation, which is then washed with acetone 
and ethanol, and dried to give carboxymethyl derivatives of polysaccharides.320 
 
As some polysaccharides (ie. cellulose and scleroglucan) have limited applications due to 
poor water solubility, existing studies have shown that carboxymethylation can improve 
water solubility.321 Successful carboxymethylation of cellulose and scleroglucan has been 
performed, yielding more water soluble products.322, 323  Previous studies reported that 
carboxymethylation have been done on pullulan by modifying with monochloroacetic acid. 
Hydroxyl groups of pullulan are activated as alcoholate in an alkaline solution to allow the 
nucleophilic substitution of chloride from the monochloroacetic acid. Carboxymethyl 
pullulan has been developed for the application in tissue engineering, as well as for 
nanoparticles for drug/gene delivery cancer therapy.324, 325 
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Figure 1.15. Carboxymethylation of microfibrillated cellulose (MFC). Reproduced 
from 326.  
 
Carboxymethylation of polysaccharides from Ganoderma lucidum performed by Xu et al. 
was found to increase water solubility to reach 100 mg/mL, which is 1000 times higher than 
the original polysaccharide.327 Chen et al. investigated carboxymethylation of polysaccharides 
from Ganoderma atrum and based on the results, the molecular weight was reduced perhaps 
due to degradation during the reaction.328 
 
1.3.1.2. Acetylation 
The reaction of acetylation can be achieved by introducing acetyl groups into polysaccharide 
chain by reaction with acetic anhydride acid, which acts as positive electrophilic reagent that 
attacks polysaccharide. (Figure 1.16) This chemical modification has been used mainly for 
the treatment of polysaccharide branches. Stretching and changing of polysaccharide 
branches orientation can lead to adjustment of arrangement of polysaccharide chain which 
results in an increase in water solubility,329 as demonstrated by Barud et al. in cellulose 
modification.330 Zhangand et al. prepared acetylated polysaccharides via electrophilic 
substitution. Acetic anhydride acid used in this reaction acts as positive electrophilic reagent 
that attacks the polysaccharide. Typical acetylation reaction requires polysaccharide to be 
dissolved in some solvents (such as H2O, DMSO or formamide), before being added 
dropwise with NBS/Ac2O or pyridine/Ac2O solution. Later, the solution is cooled, adjusted 
for pH, added with 95 % ethanol for precipitation, and lastly filtered. 331 
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Figure 1.16. Acetylation of cellulose. Reproduced from 332.  
 
Chen et al. reported that acetylated derivative of water soluble polysaccharide from 
Ganoderma atrum was degraded during the reaction, therefore resulted in reduced molecular 
weight material.328 Polysaccharide from Enteromorpha linza has been acetylated and 
compared to its unmodified form, as reported by Zhang et al..333 It was found that the 
intrinsic viscosity was decreased as the degree of substitution increased, perhaps due to a 
decrease in the number of hydrogen bonds. In addition, spatial arrangement and extension of 
sugar chain can be altered by the presence of acetyl, thus promoting the exposure of hydroxyl 
groups and increase solubility in water which can lead to an increase in antioxidant activity. 
 
1.3.1.3. Sulphation 
Introducing sulphate group to a polysaccharide will produce sulphated polysaccharide, under 
a reaction called sulphation (Figure 1.17). CSA-pyridine method is often used for this 
particular modification, as described by Chen et al.334 In this method, the mixture of 
polysaccharide solution and CSA-pyridine complex is treated at certain temperature for a 
period of time, under a controlled ratio of CSA to pyridine. As for insoluble polysaccharides, 
they need to be dissolved in an ionic liquid prior to mixing it with CSA-pyridine complex.  
 
 
Figure 1.17. Sulphation of cellulose. Reproduced from 335. 
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Functional groups of polysaccharide such as hydroxyl, carboxyl, or amino groups can be 
substituted with sulphate moieties to synthesise sulphated polysaccharide, with enhancements 
of biological activities.336 It is reported that sulphate group plays an essential role in affecting 
the biological activities of polysaccharide such as antiviral activity.  
 
Jungand et al. has demonstrated sulphation on polysaccharides in Pleurotus eryngii which 
resulted in an increase in water solubility, increasing from 56 % to 86 %. This is possibly 
owing to an increase in the number of attached ionic groups following sulphation.337 
Vasconcelos et al. also noticed the same effect after sulphation of fungal exocellular β-(1
6)-D-glucan.338 Sulphation was reported by Wu et al. to decrease the molecular weight of 
glycosaminoglycan prepared from Achatina fulica. The molecular weight of sulphated 
polysaccharide was reduced to 8000 Da as opposed to its original 29000 Da. This was due to 
hydrolysis of the glycosidic linkages caused by acid produced in the reaction.339 
 
1.3.1.4. Phosphorylation 
Phosphorylation requires the introduction of phosphate groups to polysaccharides in the 
presence of strong acid as catalyst (Figure 1.18). Though this may lead to degradation of the 
polysaccharide, however it does not affect the immune activity brought by the phosphate 
groups.335 The presence of charged phosphate groups was reported by Chen et al.340 can 
improve water solubility and change molecular weight, as well as chain conformation of 
polysaccharides.  
 
It has been demonstrated that natural biological activities of polysaccharides can be activated 
after phosphorylation.335 The use of strong acid as catalyst in phosphorylation reaction often 
leads to the degradation of polysaccharides, which limits the application of the reaction. 
However, it gives no effect to the immune activity resulted from the phosphate groups. 
Several ways have been identified for the phosphorylation of polysaccharides, including the 
use of phosphoric acid of phosphoric anhydride, phosphorus oxychloride, and phosphate 
(such as sodium hydrogen phosphate, sodium tripolyphosphate, sodium hexametaphosphate, 
or their mixed salts).341 
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Figure 1.18. Phosphorylation of dextran. Reproduced from 335. 
 
Phosphorylation can be performed in several ways; firstly by reacting the solution of 
polysaccharide in DMSO with phosphoric acid or phosphoric anhydride. The reaction 
mixture then will be heated at certain temperature for a period of time. This approach 
however, may lead to hydrolysis of the polysaccharides. The second approach requires the 
use of phosphate (such as sodium hydrogen phosphate, sodium dihydrogen phosphate, 
sodium tripolyphosphate and sodium hexametaphosphate) which does not cause degradation 
of polysaccharide. However, this approach was reported to have low reactivity to 
polysaccharides, therefore reduce the possibility to get high degree of substitution.341  
 
Williams et al. has demonstrated the chemical modification of insoluble microparticulate 
glucan (β-D-glucan) to become glucan phosphate with improved water solubility.342 
Phosphorylation of galactomannan derivatives from guar gum at high temperature (above 60 
oC) has resulted in an increase of molecular weight, perhaps due to cross-linkages of 
polysaccharide, as described by Wang et al..343 
 
1.3.1.5. Alkylation  
Introduction of alkyl groups to the polysaccharides has been performed to increase 
bioactivities, which normally may result in the modification of  their solubility and viscosity 
properties.335 Several reactive agents can be used for this particular modification, including 
alkyl halides (such as chlorides or bromides), alkyl or aryl epoxides in which will react with 
the free hydroxyl moieties of the polysaccharides (Figure 1.19).  
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Figure 1.19. Common alkylating agents used for chemical modifications of polysaccharides. 
Reproduced from 344. 
 
Alkylation using halogenated derivatives (a) 
Chemical modification of polysaccharides using alkyl halides, yielding alkyl ethers can be 
done via irreversible nucleophilic substitution reaction, as shown in Figure 1.20. Firstly, 
polysaccharides will be mixed with strong alkali (such as aq. NaOH) under nitrogen 
atmosphere, followed by reaction with alkylating agent (alkyl halides). 
 
Figure 1.20. Chemical reaction between polysaccharides and alkyl halides. Reproduced from 
344. 
This approach has been performed on several polysaccharides, as summarised in Table 1.5, in 
which alkyl halides are represented by R-X, and R is a long alkyl chain containing from 8 to 
22 carbon atoms. For reaction with short alkyl chain of alkyl halides (C1–C4), water can be 
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used as the solvent345 as opposed to long alkyl chain which employs organic solvents such as 
isopropanol (IPA), tert-butyl alcohol (TBA), acetone, N,N-dimethylacetamide (DMAc) or 
dimethylsulfoxide (DMSO) due to their insolubility in water. As the polysaccharides are 
suspended in the solvent, these reactions are always performed under heterogenous 
conditions.346 In certain cases, in order to enhance reaction efficiency, a mixture of water and 
organic solvents is used in order to allow the polysaccharides to swell.347-349  
 
Table 1.5. Chemical modification of polysaccharides with alkyl halides. 
Polysaccharides Alkyl halides (R-X, 
R=alkyl chain, X=Cl/ Br) 
Reaction condition: 
Solvent, Alkali, 
Temperature, Time 
Degree of 
substitution 
(%) 
Ref. 
Cellulose CH3(CH2)nCH2Br, n=6–16 DMSO, NaOH or NaH,         
22 oC, 15–92 h 
11–30 350 
Hydroxyethyl 
cellulose (HEC) 
CH3(CH2)7CHCH(CH2)8Cl DMAc, RT, 24 h 1.4 351 
Hydroxyethyl 
cellulose (HEC) 
CH3(CH2)n Br, n=7, 8, 12 
or 16 
DMAc, RT, 24 h 0.17–2 352 
Hydroxyethyl 
cellulose (HEC) 
CH3(CH2)nCH2Cl, n=16 88% (wt) IPA/water, NaOH 
(pH 13), 80 oC, 8 h 
1 347 
Hydroxypropyl 
cellulose (HPC) 
CH3(CH2)nCH2Cl, n=16 DMAc, RT, 24 h 1.5 351 
Carboxymethyl 
hydroxyethyl 
Cellulose 
(CMHEC) 
CH3(CH2)nCH2Br, n=14 Water/tert-butanol/acetone, 
NaOH (pH 14), 95 oC, 2.5 h 
0.1–4 348 
Hydroxybutyl 
guar 
CH3(CH2)nCH2Br, n=14 IPA/water, KOH (pH 13.5), 
70 oC, 1–3 h 
0.5–10 349 
 
The medium must be made alkaline by adjusting the pH to be higher than 11 (usually 13) 
using strong alkali such as lithium hydroxide (LiOH), sodium hydroxide (NaOH) or 
potassium hydroxide (KOH), except if the solvent is DMAc, where extra base is not 
necessary.351, 352 The reactions are often performed between 70 and 105 oC for 1 to 8 h; 
reactions done for lower temperature may require longer times (between 24 and 92 h).346 For 
instance, cellulose was alkylated with octyl bromide at 22 oC and based on the results, no 
significant substitution was recorded after 3 h, however after extending the reaction to 25 h, 
the degree of substitution (DS) was recorded to be 0.11.350 
 
Alkylation using epoxide derivatives (b, c) 
The chemical reaction with epoxides derivatives (such as alkyl epoxide and alkylglycidyl 
ether; Figure 1.21) can be performed to yield hydrophobically modified polysaccharides via 
ether linkages. Having abbreviated to ‘R-glycidyl ether’, the R can be not only long alkyl 
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chain, but also phenyl, poly(ethylene oxide) alkyl chain, or poly(ethylene oxide) phenyl alkyl 
chain.344 
 
 
Figure 1.21. Epoxide derivatives employed for the alkylation of polysaccharides. Reproduced 
from 344. 
 
The modification requires the opening of epoxides ring in the presence of a catalyst in order 
to facilitate nucleophilic addition (Figure 1.22). In general, the selected polysaccharides will 
be reacted first with alkali base such as potassium tert-butoxide, NaOH, KOH, NaH or 
tetrabutylammonium hydroxide (TBAOH), under nitrogen condition prior to the addition of 
alkylating (or etherifying) agent. In some cases, the use of strong base however, might induce 
partial degradation of polysaccharides, therefore leading to the formation of polysaccharides 
derivatives with lower mass than expected.344  
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Figure 1.22. Chemical reaction of polysaccharides with alkyl epoxide (R-epoxide) and 
alkylglycidyl ether (R-glycidyl ether). Reproduced from 344. 
 
Examples of alkylation of polysaccharides with epoxide derivatives are summarised in Table 
1.6. The opening of epoxides ring can be done under either homogenous or heterogenous 
conditions. In the heterogenous condition, a mixture of alcohol/water is used, with 
concentration ranging from 50 % to 100 %; these concentrations allow swelling of the 
polysaccharides, as well as dissolving the long chain epoxides and base at the same time.351, 
353 
 
Table 1.6. Chemical modification of polysaccharide with epoxide derivatives. 
Polysaccharides Epoxide derivatives Reaction condition: 
Solvent, Alkali, Temperature, 
Time 
Degree of 
substitution 
(%) 
Ref. 
Hyaluronic acid CH3(CH2)n-1 glycidyl 
ether, n=4, 6, 8, 12 or 
14 
DMSO/water = 1/1, NaOH (pH 
9.0–10.0), 30 oC, overnight 
11 354 
Dextran Phenyl glycidyl ether DMSO, TBAOH, RT, 96 h 17–250 355 
Amylose or 
starch 
CH3(CH2)n-1 epoxide, 
n=6 or 12 
DMSO, NaH, RT, 6–286 h 30–230 356 
Dextran CH3(CH2)n-1 epoxide, 
n=10 
DMSO, TBAOH, 50 oC, 96 h 164 357 
 
In theory, reactions done in homogenous condition yields higher reaction efficiency and 
degree of substitution than the heterogenous one. It is also assumed that random distribution 
of alkyl groups may be found along the polysaccharides chain in homogenous reaction 
condition, due to solubility of polysaccharides and the alkylating agents in the same reaction 
solvent. Durand et al. has demonstrated the difference in the DS of dextran modified with 
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phenyl glycidyl ether (PGE), in which higher value of 70 % was recorded for homogenous 
condition compared to only 10 % with the heterogenous one.355 
 
Alkylation of chitosan with alkylating agent such as alkylglycidyl ether has been reported to 
enhance penetration across the blood-brain barrier. In this study, nanoparticles were 
formulated from the alkylglyceryl-modified chitosan and were assessed in vitro for the effect 
on permeability towards mouse brain endothelial cells (bEnd3).358 This study was supported 
by previous finding that demonstrated the potential of alkylglycerols in opening the blood-
brain barrier, hence facilitate the passage to the brain.64, 359 Therefore, this positive finding 
has led to further investigation on alkylation reaction using alkylglycidyl ether derivatives 
(such as butylglycidyl ether) onto other polysaccharides (having hydroxyl groups) such as 
pectin, guar gum, pullulan and chitosan that have been selected as starting materials for this 
study. 
 
1.3.2. Polysaccharides used in this study 
 
Pectin 
Commercial pectin is commonly found in the primary cell wall obtained from citrus peel or 
apple pomace, as well as in the middle lamella of plant cells.360, 361 Pectin molecules (Figure 
1.23) are composed from mainly esterified D-galacturonic acid residues in an α-(1-4) chain, 
with molecular weight of 30,000–100,000 Da.362 Pectin has good solubility in water but not 
in ethanol 95% or other organic solvents.363 Being known for its excellent biodegradability 
and biocompatibility, pectin has been used in targeting various proteins and drugs in various 
formulations such as in hydrogel, films, microspheres and nanoparticles.364 Pectin-based 
systems are used primarily for targeted colonic delivery,319, 365-368 however some of them 
have been reported to be used for brain delivery, as described by Charlton et al. 369, 370 Low-
methylated pectins have been investigated as delivery systems for direct nose to brain 
pathway for CNS disorders treatment. In vitro assays using MDCK1 cell monolayers were 
performed to study drug transport; an increase in drug transport across the epithelial was 
observed. 
45 
 
 
Figure 1.23. Chemical structure of pectin. 
 
Alkylation has been done on pectin previously using alkyl bromide of various length chains 
(butyl, octanoyl, dodecyl, and cetyl) in order to increase the hydrophobicity.371 Octanoyl 
pectin (7 to 15 % DS) appeared to be the best, illustrating high stability and drug release that 
can be sustained up to 80 h (for 15 % DS) and was suggested to be a suitable excipient for 
controlled drug release. Another work on alkylated pectin was also demonstrated by Liang et 
al.,372 where he investigated the viscosity and emulsifying properties of the polysaccharide. It 
was found that alkylated pectin with DS 0.6–4 % appeared to have lower intrinsic viscosity, 
but better emulsifying properties. 
 
Guar gum 
Having found in the seed endosperm of Fabaceae family plants, guar gum (GG) is a naturally 
occurring galactomannan polysaccharide having the average molecular weight approximately 
around 220,000 Dalton.373 GG, as a hydrophilic polysaccharides composed of linear chains of 
(1→4)-β-D-mannopyranosyl units with α-D-galactopyranosyl units connected by (1→6) 
linkages (Figure 1.24). The ratio of D-galactose to D-mannose is between 1:1.4 and 1:2.363 
Due to its drug release retarding property and susceptibility to microbial degradation, several 
GG formulations (such as microspheres and nanoparticles) have been extensively used for 
colon delivery application.374 Since the application of GG is more to colon delivery, its 
novelty aspect towards delivery to the brain is really promising. GG is a useful material in 
drug delivery systems due to its biocompatibility, degradability, and non-immunogenicity 
properties. Moreover, it has been approved by FDA for pharmaceutical applications.375 
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Figure 1.24. Chemical structure of guar gum. 
 
Alkylation of guar gum was demonstrated by Jackson,376 where hydroxyalkyl guar gum was 
prepared  by reaction with ethylene (propylene or butylene) oxide under alkaline conditions. 
The alkylated guar gums are mainly used as oil shale inhibitors in oil drilling fluids as it can 
provide non-thixotropic viscosity to wellbore fluids. Hydroxyalkyl guar gum can also be 
synthesised via reaction with alkylating agents such as dimethylsulfate and methyl iodide; it 
was found that by increasing the concentration of alkylating agent, the degree of substitution 
increases.377  
 
Pullulan 
Pullulan is produced from starch by Aureobasidium pullulans fungus that is commonly found 
in phyllosphere of crop plants and on many tropical fruits.378, 379 It is a non-ionic 
polysaccharide comprising of maltotriose units connected by 1,6 glycosidic bonds with an 
average molecular weight of about 200,000 Dalton (Figure 1.25).325, 380 Being produced from 
starch by Aureobasidium pullulans fungus, pullulan is a water soluble polysaccharide, 
therefore attempts to produce more hydrophobic pullulan have been undertaken for the 
benefit of a variety of drug delivery applications. Pullulan is non-toxic, non-immunogenic, 
non-carcinogenic, and non-mutagenic, therefore it has been investigated for various 
biomedical applications, for instance in tissue engineering, gene delivery, targeted drug 
therapy, and wound healing,325 as well as for brain delivery.381, 382 Ease of chemical 
modification and its potential in nanoformulation allow pullulan to be among the best 
candidates for a good drug carrier.380 
 
47 
 
 
Figure 1.25. Chemical structure of pullulan. 
 
Alkylation of pullulan was performed specifically to increase its hydrophobicity for drug 
delivery applications. Pullulan can undergo several alkylation modifications including 
reaction with 1-bromopropane and 1-bromobutane, yielding propyl- and butyl-etherified 
pullulans (PrPL and BuPL) with various degree of substitution (DS 1.02–2.61 %).383 Another 
alkylation of pullulan was performed by reacting the polymer with different alkyl bromides 
(C10, C12 and C16) in order to produce cationic and amphiphilic pullulan.
384  
 
Chitosan 
Chitosan (CS) can be produced commercially from the deacetylation of chitin, a naturally 
occurring polysaccharide isolated mainly from marine crustaceans.317 It chemical structure 
comprises of a 2-acetamido-2-deoxy-β-D-glucan (1→4) linked to 2-amino-2-deoxy-β-D-
glucan (Figure 1.26). 
 
Figure 1.26. Chemical structure of chitosan. 
 
Investigations of chitosan are not only focused on cosmetics, food industry and agriculture,385 
but it is also found to be suitable for drug delivery and biomedical applications.317, 386 
Chitosan can be formulated into nanoparticles by various ways, including the use of 
glutaraldehyde that can covalent cross-link the polysaccharide. However, glutaraldehyde is 
claimed to increase the toxicity of the nanoparticles. 163, 387 Alternatives to formulate chitosan 
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nanoparticles has been investigated by exploiting the positive charges due to protonation of 
amino groups of chitosan in acidic medium. Protonated amino groups can generate 
electrostatic complexes with polyanions, yielding nanoparticles. The approach, that is called 
ionotropic gelation, may employ different counter ions (or cross-linker) such as sodium 
tripolyphosphate255, 388-391 or dextran sulphate.268, 392, 393 Apart from that, chitosan can also be 
conjugated with other polymers to formulate nanoparticles, such as with PLGA394 or PLA.395, 
396 
 
Hombach et al. reported the potential of chitosan solution or particles of various molecular 
weights (20, 150, 400 and 600 kDa) to enhance the transport of FITC-dextran across the BBB 
model.397 Nanoparticles formulated from alkylglyceryl-modified chitosan has been 
demonstrated by Lien et al.207 and Molnar et al.255 to increase the permeability of the BBB 
model. Wang et al. prepared nanoparticles formulated from trimethylated chitosan (TMC) 
that has been conjugated with PLGA as a drug carrier for brain delivery; the conjugation with 
PLGA was found to increase concentration of the nanoparticles in the brain.398 
 
The synthesis of alkylated chitosan can be achieved by reacting chitosan with alkylating 
agent, as demonstrated by Elena et al., who prepared N-alkyl chitosan for papermaking 
application. This particular modification involves reaction of an aldehyde with an aminic 
group of chitosan in acidic solution, followed by reduction with sodium cyanoborohydride. 
The modification of chitosan with alkyl group increased the solubility of chitosan at neutral 
and alkaline pH values, without affecting its cationic property.399 N-alkylated chitosan also 
was investigated as a potential vector for gene transfection, by modifying chitosan with alkyl 
bromide.230, 400 
 
Another study has reported antibacterial activity of alkylated chitosan that was synthesised by 
modifying the polymer with various alkyl halides under alkaline environment.401 In another 
research, alkylgyceryl-modified chitosan has been prepared by reaction with alkylglycidyl 
ether derivatives in order to enhance drug penetration to the brain. The modification with 
alkylglycerols was justified by the finding that alklyglycerols can enhance penetration of co-
administered drugs to the brain.207 
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1.3.3. Brief summary of physical characterisation techniques 
To characterise and confirm the chemical modifications of selected polysaccharides, 
techniques such as fourier transform infrared spectroscopy (FT-IR), nuclear magnetic 
resonance (NMR) and thermal analysis have been employed. Each technique comes with 
different principle of characterisation, therefore yielding various useful information on the 
materials. 
 
Fourier transform infrared spectroscopy (FT-IR) 
Fourier transform infrared spectroscopy (FT-IR) is a technique which is used to analyse 
absorption or emission of a solid, liquid or gas in a form of  infrared spectrum. The Fourier 
transform infrared spectroscopy (Figure 1.27) term arises owing to the fact that a 
mathematical process. Fourier transform is needed to process the raw data to become an 
actual spectrum. At a specific wavelength range, IR radiation will excite molecules, causing 
the chemical bonds in the samples to vibrate and the changes of vibrational energy in IR 
region are recorded to generate spectral peaks. Functional groups of a molecule prone to 
absorbing IR radiation in the same wavenumber range.402  
 
Figure 1.27. Schematic representation of a typical FT-IR instrument. Reproduced from 403. 
 
The infrared region of the electromagnetic spectrum (10–14000 cm-1), is divided into three 
spectral sub-regions, near- (4000–14000 cm-1), mid- (400–4000 cm-1), and far-IR (10–400 
cm-1). The mid-IR region is the most common portion of spectrum has been used since 
characteristic absorbance frequencies and main molecular vibrations lie within this range. 
Therefore, by identifying the IR band positions, chemical structures of any organic 
compounds such as polysaccharides can be predicted.404  
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The use of FT-IR to characterise polysaccharides has been performed by Thirumavalavan et 
al. to characterise pullulan produced from coconut water and coconut milk by Aureobasidium 
pullulans. 405 The samples were blended with KBr powder prior to analysis and the results 
were compared with the spectra of commercial pullulan. The presence of signals at 3386 cm-1 
(O-H groups), 2928 cm-1 (sp3 C-H bond of alkane compounds) and in the specific area of 
1500–650 cm-1 (the characteristic for pullulan molecule as a whole) confirmed the identical 
chemical structure of the samples. The technique has also been used to characterise 
polysaccharide nanoparticles such as chitosan nanoparticles prepared by cross-linking with 
tripolyphosphate as reported by Vimal et al.406 The FT-IR spectra showed the presence of 
P=O and P-O groups at 1203 and 1240 cm-1 and the band shifts corresponding to C-O and N-
H stretching (from 1647 and 1588 cm-1 in pure chitosan to 1738 and 1643 cm-1 for CS-TPP 
NPs), confirming the interaction between chitosan and tripolyphosphate. The FT-IR has also 
been mentioned as a powerful tool to analyse the quality and purity of polysaccharides such 
as pectin407-409 and guar gum.410, 411 
 
Besides being a fast and simple technique to use, FT-IR spectroscopy also requires small 
amount of samples for the analysis. Being able to analyse samples within multiple 
environment (either in the form of liquid, gas, powder, solid, or film), it may also perform a 
nondestructive analysis which allows the samples to be recovered after the measurement. 
However, background scans and repeated scans of sample are required as FT-IR spectrometer 
in most cases can generate variations in the spectra due to ambient conditions around the 
instrument.412  
 
Nuclear magnetic resonance (NMR) 
NMR spectroscopy is a powerful technique that can provide critical information about the 
structure and conformation of organic compounds including polysaccharides. It is an 
analytical technique often used in quality control, purity and content determination, as well as 
the molecular structure (either for known or unknown compounds). Nuclei in most cases 
possess spin, and when an external magnetic field is applied, a transfer of energy from base to 
higher energy level takes place at a wavelength correlate with radio frequencies.413 
 
When the nucleus relaxes back to its base level, energy is released at the same frequency. The 
signal that corresponds to this energy transfer is measured and processed in order to give an 
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NMR spectrum. As in some cases, the structure of polysaccharides concerned is quite 
complex, therefore, the use of 1D, 2D and 3D NMR experiments is useful to determine the 
molecular structure.414 
 
The use of NMR spectroscopy to characterise modified polysaccharides has been 
demonstrated by Toman, where he confirmed the chemical modification of chitosan with 
alkylglycerols, yielding chitosan derivatives such as butylglyceryl-, pentylglyceryl-, and 
octylglyceryl-modified chitosan.209 Synytsya et al. has employed the technique to confirm the 
presence of alkylamide substituents bound to pectin for the analysis of N-Alkylamides of 
highly methylated (HM) citrus pectin that were prepared using heterogenous amino-de-
alkoxylation with selected n-alkylamines.415 Characterisation using NMR techniques has also 
been demonstrated on a number of polysaccharides such as guar gum411, 416, 417 and 
pullulan.316, 418-420 
 
Thermal analysis 
Thermal analysis is a common technique to study physicochemical interaction of components 
in a system, by analysing the characteristics as a function of temperature.421 
Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) are among 
the techniques to study thermal behaviour of a system. TGA provides information about 
decomposition and thermal stability of a sample, however it cannot investigate the reactions 
that do not involve mass change such as polymorphic transformations, in which can be 
determined using DSC. Therefore, TGA may not be the ideal tool for identification of a 
substance or a mixture of substances.422  
 
Results from TGA is recorded in a thermogram, in which obtained by using a thermobalance. 
This instrument allows the determination of a reaction that involves mass change over a range 
of temperature. The analysis can be influenced by several factors, including thermodynamic 
and kinetic factors, as well as procedural parameters such as sample mass, sample 
preparation, heating rate, and the crucible. The thermogram or thermogravimetric curve can 
be expressed as; TGA curve, where a plot of the mass against time or temperature is 
recorded, or derivative thermogravimetric (DTG) curve, in which a plot of the first derivative 
of the rate of mass change as a function of time or temperature is observed. In analysing 
polymers, aspects such as the thermal stability of polymers, compositional analysis and 
decomposition pattern are studied.423  
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DSC can give information about all the processes that require or release energy, including 
endothermic or exothermic phase transition. The principle in DSC analysis is by measuring 
the amount of heat difference required to increase the temperature of a sample and reference 
with respect to temperature. Physical transformation of a sample, including phase transitions 
often involve energy changes. When a solid sample melts becoming a liquid, it will absorb 
heat to increase its temperature, however the heat required to increase the sample temperature 
is higher than the reference. This heat difference is therefore is recorded by DSC. The results 
obtained from DSC can be expressed as a plot of heat flux versus temperature (or time). In 
examining polymers, aspects such as melting points, glass transition temperatures, and 
crystallisation temperature can be observed from the analysis.424  
 
Teramoto et al. has performed thermal study on pullulan acetate of various degree of 
substitution (synthesised by the reaction of pullulan with acetyl chloride in the presence of 
pyridine) by means of TGA and DSC.425 The TGA results were compared with unmodified 
pullulan which revealed that pullulan acetate exhibited higher decomposition temperature 
(306–363 oC) than the unmodified one (295 oC). DSC analysis of the polymer indicated that 
all pullulan acetate derivatives have a clear Tg and the number decreased with an increase in 
degree of substitution. Jadhav et al. has characterised rizatriptan benzoate-loaded chitosan 
nanoparticles prepared via electro-spraying with DSC to investigate the pattern of 
crystalline/amorphous of nanoparticles.426 From the results, it was concluded that the drug 
within the nanoparticles was in crystalline state and there was no interaction between the drug 
and polymer. Other polysaccharides such as pectin427-429 and guar gum430-432 have also been 
analysed using this techniques. As the physical characterisation focuses on the determination 
of all the physical properties of the materials used in this study, the influence and effects of 
the materials towards human body can be assessed by performing biological characterisation. 
 
1.4. Biological interactions with nanoparticles  
Investigation of the biophysicochemical interaction between nanoparticles and cells helps to 
understand their biological effects towards human body that may result in toxicity and 
affecting their biomedical functions. In vitro assays can be performed employing a particular 
cell line to give preliminary information that is necessary in predicting the possible biological 
fate of nanoparticles in the body when used as drug carriers. These assays will cover the main 
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biological effects of nanoparticles such as cytotoxicity, intracellular uptake, and nanoparticle 
permeability through the BBB. 
 
1.4.1. Cytotoxicity 
Nanoparticles are designed to have unique surface characteristics, therefore it is important to 
investigate the toxicity of the nanoparticles themselves, owing to the fact that their 
physicochemical properties may differ compared to the starting polysaccharide material. 
Moreover, physicochemical characteristics of nano-sized drug carriers are relatively different 
when compared to micron-sized particles. In fact, when comparing nanoparticles and other 
drug carrier systems, aspects such as body distribution, movement across the BBB and effect 
on blood coagulation pathways may be significantly different. 
 
The accumulation of nanoparticles at the site of the drug delivery may finally cause 
deleterious side effects.123 To assess the cytotoxicity of various nanoparticles on cellular 
systems, cell culture in vitro assays have been employed and shown a great potential in 
providing a preliminary data on cytotoxicity of nanoparticles. As there are a number of 
cytotoxicity assays available, selecting the appropriate ones is important to ensure that valid 
conclusions can be drawn. 
 
Cytotoxicity assays within the nanocarriers field commonly measure cell death 
colorimetrically. Exposure to cytotoxic agents, including NP-induced toxicity may lead to 
cell membrane alteration, thus allowing its content to leak out. This can be exploited for 
viability tests using neutral red and Trypan blue. Neutral red (or toluylene red) is a weak 
cationic dye that is capable of crossing the plasma membrane and has the tendency to localise 
in cell lysosomes. When cell membrane is altered, the dye will leak out, allowing 
differentiation between live and dead cells.  
 
A study by Huang et al.433 using neutral red assay described the influence of molecular 
weight and degree of deacetylation (DD) on the cytotoxicity of chitosan nanoparticles upon 
A549 cells (human lung adenocarcinoma epithelial cell line), in which the toxicity was found 
to be mainly influenced by chitosan DD than the molecular weight, as shown by the cell 
viability and the IC50. Reducing the DD from 88 % to 46 % increased the cell viability from 
less than 10 % to 60 %, as well as the IC50 from 1.2 mg/mL to 2.2 mg/mL. However, the IC50 
was not affected when the molecular weight was reduced from 213 kDa to 10 kDa. Another 
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study by Wu et al. also used neutral red assay to investigate the cytotoxicity of chitosan 
nanoparticles against MC3T3-E1 (mouse pre-osteoblasts).434 Trypan blue is permeable to 
cells with damaged membranes, therefore it can enter and blue-stain dead cells while live 
cells remain colourless (unstained). The number of dead cells can be easily established using 
light microscopy.435 This assay was used by Mansour et al.436 and Nur et al.437 to determine 
cytotoxicity of pectin and chitosan nanoparticles. 
 
Tetrazolium salts can be used to investigate mitochondrial activity due to the presence of 
mitochondrial dehydrogenase enzymes that cleave the tetrazolium ring, hence only viable 
cells can react it.438 The most widely used colorimetric technique is the MTT assay, where a 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) is reduced from its 
soluble form (yellow) to insoluble formazan (purple) inside the cell mitochondria. The 
reduction process only takes place in viable cells and the intensity of the purple formazan 
measured by absorption spectrophotometry corresponds to the number of viable cells, 
therefore allowing to assess the viability and the proliferation of cells.439-441 .  
 
Toman et al. has demonstrated the use of MTT assay to evaluate the cytotoxicity of 
nanoparticles formulated from alkylglyceryl-dextran-graft-poly(lactic acid) for brain delivery 
against bEnd3 cells. 209, 287 A study to investigate anti-tumor effect of Ganoderma lucidum-
loaded chitosan nanoparticles was performed by Li et al. using MTT assay against HepG2, 
HeLa and A549 cancer cell lines. G.lucidum (GLP) is known to inhibit cell proliferation, 
induce apoptosis and supress cell migration of several types of cancer cells.442-444 Higher 
inhibition response was observed in all three cell lines as compared to controls; GLP solution 
and the empty nanoparticles.445 
 
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay is the modification of the MTT assay based on tetrazolium salt conversion 
into a coloured soluble formazan.446, 447 WST is another tetrazolium-based assay used for 
cytotoxicity study, in which WST-1 or WST-8 will produce a highly water soluble formazan 
upon cellular reduction.448 Resazurin or Alamar blue has been used to characterise the 
cytotoxicity of nanoparticles such as carbon nanotubes and quantum dots against human 
keratinocyte and mesenchymal stem cells, respectively, as demonstrated by Shvedova et al.449 
and Seleverstov et al.450 The blue dye will be transformed into a pink fluorescent dye upon 
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reduction by cell metabolic activity, mainly by acting as an electron acceptor for enzymes 
during oxygen consumption.451 
 
As for the LDH (lactate dehydrogenase), this assay can be employed for measuring cell 
membrane integrity. This leakage assay measures quantitatively the LDH that is released 
from the damaged cells into the medium.452, 453 LDH oxidises lactate to pyruvate, hence 
converting tetrazolium salt into formazan; the concentration of LDH released is proportional 
to the number of damaged or lysed cells.454 Several nanoparticles studies have employed 
LDH assay for their cytotoxicity studies.455-457  
 
1.4.2. Permeability across the blood-brain barrier in vitro models 
The capability of nanoparticles and drugs to move across the BBB and reach the brain cells is 
a major concern in drug delivery to the brain. As the main objective of this research is to 
formulate nano-drug carriers that can facilitate drug penetration into the brain, in vitro assay 
employing blood-brain barrier model must be performed to investigate their potential in 
modulating the permeability of the barrier. Examples of in vitro assays of nanoparticles using 
brain endothelial cells are listed in Table 1.7. 
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Table 1.7. In vitro assays of nanoparticles using brain endothelial cells. 
NP type NP composition Targeting 
ligand or 
coating 
Model 
actives 
Size of 
NPs (nm) 
Composition 
of brain 
endothelial 
cells (BEC) 
Applications Ref. 
Lipid NPs Fe3O4, egg 
phosphatidylcholine, 
cholesterol, 
mPEG2000-DSPE 
Transferrin No 130 Human BEC, 
Human 
astrocytes 
Permeability 458 
Solid lipid 
nanoparticles 
(SLN) 
Dynasan, palmitic acid, 
DSPE-PEG2000, 
cholesteryl 
hemisuccinate 
Anti-
insulin 
receptor 
mAb 
Saquinavir 120–450 Human BEC, 
Human 
astrocytes 
Cellular 
uptake, 
permeability 
459 
Metal NPs Gold, citrate Peptide 
recognizin
g 
trasferrin 
receptor 
β-sheet 
breaker 
peptide 
15 Bovine BEC, 
Rat astrocytes 
Permeability 460 
Titanium oxide (TiO2) No No 25 Rat BEC, Rat 
astrocytes 
Cellular 
uptake, 
transport, 
toxicity 
461 
Polymer NPs Alkylglyceryl chitosan, 
tripolyphosphate 
No No 100–200 Mouse BEC Cellular 
uptake, 
permeability, 
toxicity 
207 
Alkylglyceryl dextran No No 100–200 Mouse BEC Cellular 
uptake, 
permeability, 
toxicity 
209 
Poly(butyl 
cyanoacrylate) (PBCA) 
Tween-80 Dalargin 200 Bovine BEC, 
Rat astrocytes 
Permeability 462 
Quantum dots 
(QDs) 
QDs Amino-, 
carboxyl-, 
PEGylated
- 
No 30, 100, 
400 
Rat BEC, Rat 
astrocytes and 
pericytes 
Permeability 463 
QDs No siRNA 15–20 Human BEC, 
human 
astrocytes 
Cellular 
uptake 
464 
 
The attempts at developing an in vitro BBB model started in 1973 by Joó et al., who 
successfully isolated brain capillaries from rat;465 this was followed by the first cerebral 
endothelial cultures achieved by Panula et al.466 and DeBault et al.467 in 1978 and 1979, 
respectively. Primary brain cells such as rat endothelial cells, pericytes and astrocytes can be 
employed as blood-brain barrier models, as suggested by Nakagawa et.al, with the 
transendothelial electrical resistance (TEER) value of 400 Ω cm2 on average.468 This value 
however is considered as relatively low when compared to the TEER value measured in vivo 
that have been reported to be as high as 5900 Ω cm2.469 Another study on the electrical 
resistance measured in vivo was performed by Crone employing frog brain, giving the TEER 
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value of 1870 Ω cm2 on average.470 Table 1.8 presents a range of TEER values reported for in 
vitro BBB models. Even though the in vitro model was believed to be able to mimick the 
anatomical situation in vivo however, primary cells can be sometimes hard to be obtained, 
therefore the use of manipulated cell lines as an alternative was discovered.  
 
Table 1.8. TEER values for in vitro BBB models. 
Cell type TEER (Ω cm2) Equipment used to measure TEER Ref. 
Primary human brain microvascular 
endothelial cells (HBMEC's) 
100 EVOM/Chopstick 471 
Immortalized human brain 
endothelial cell line (hCMEC/D3) 
36.0–37.8 Impedance analyzer/Pt electrodes 472 
hCMEC/D3 100 EVOM/Chopstick 471 
hCMEC/D3 and primary human 
astrocytes 
140 EVOM/Chopstick 471 
Bovine brain microvascular 
capillary endothelial cells 
(BBMCE) and Madin-darby canine 
kidney (MDCK Epithelial Cells) 
2020 EVOM/Endohm 473 
Endothelial (RBE4) and rat 
astrocytes 
490–510 Millicell-ERS/Endohm 474 
Endothelial (BMCE) and rat 
astrocytes 
250–300 Millicell-ERS/Endohm 474 
bEnd3 endothelial cells and C8-
D1A astrocytes (microfluidic) 
250 EVOM2/Custom electodes 475 
bEnd3 endothelial cells and C8-
D1A astrocytes (Transwell) 
20 EVOM2/Endohm 475 
Porcine brain microvessel 
endothelial cells 
300–500 (serum), 
600–800 (serum free) 
EVOM2/Endohm 476 
Porcine brain microvessel 
endothelial cells 
1200–1800 Impedance analyzer 477 
Co-culture of primary human brain 
pericytes, human astrocytes and 
neurons derived from human neural 
progenitor cells 
4000 EVOM/STX-2 478 
 
Endothelial cells from different sources, such as porcine,479 human (hCMEC/D3,480, 481 or 
murine (bEnd3 358, 482) were used to provide the model that can mimic the barrier function . In 
some cases, the co-culture of endothelial cells with astrocytes (Figure 1.28)483 and pericytes 
has been used as the presence of these cells can strengthen the tight junction,484, 485 and is 
therefore recommended in order to create a more effective BBB model. Apart from pericytes 
and astrocytes, co-culturing endothelial cells with neurons has also been shown to induce 
blood brain-barrier related enzymes, as well as tight junction.486, 487 
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Figure 1.28. Schematic representation of a blood-brain barrier model. Reproduced from 483. 
 
Lien et al. using bEnd3 cells as the BBB model performed an in vitro assay to investigate the 
influence of nanoparticles formulated from alkylglyceryl-modified chitosan (CS-OX4 NPs) 
upon the barrier permeability. The concentration of FITC-dextran (as the tracer) that passed 
through the BBB model was determined and it was found that the permeability was increased 
by the presence of the nanoparticles.207 
 
Malmo et al. has performed permeation studies to investigate if siRNA-chitosan 
nanoparticles could have effect in silencing P-gp in an in vitro BBB model. A cell line of 
endothelial cells origin from rat (RBE4) was used to evaluate the nanoparticle uptake and 
transfection efficiency. It was found that the transfection of RBE4 mediated knockdown of P-
gp and decreased the efflux of P-gp substrate, therefore enhanced cellular delivery and 
efficacy of the model drug doxorubicin.488   
 
Toman et al. also used bEnd3 cells to evaluate the effect of alkylglyceryl-dextran-graft-
poly(lactic acid) nanoparticles (PLA-DEX-OX4 NPs) in modulating the BBB permeability.209 
The cellular transport of FITC-dextran (as the tracer) across the endothelial cell monolayer 
was measured and it was reported that PLA-DEX-OX4 NPs increased the amount of this 
marker moving across this BBB model. 
 
1.4.3. Cellular uptake 
The increased number of applications in medicine that use nanoparticles has led to the need 
for investigating the fate of nanoparticles at the cellular level, and toxicity assays are usually 
not enough to portray the whole picture. Investigations on the cellular uptake of nanoparticles 
are important in predicting the behavior of nanoparticles, as well as the potential toxicity that 
may be induced.489 It is reported in the literature that the particle uptake can be enhanced by 
increasing the surface charges of particles (either positive or negative).490 Techniques that are 
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commonly used to investigate the cellular uptake of nanoparticles are confocal microscopy, 
flow cytometry, as well as mass spectroscopy and electron and light microscopy.441, 491 
 
Coherent anti-stokes Raman scattering (CARS) microscopy is a label-free imaging technique 
in which image contrast is based on the intrinsic chemical makeup of a specimen.492 The use 
of fluorescent labelling is always related to several issues; photobleaching, the labels are 
often toxic, introduction of the labels may change the biological properties of the particles. 
Therefore, an alternative labelling system used in this technique employing isotopic labelling 
(using deuterium) system, which is unaffected by photobleaching and does not influence the 
chemical interactions of the particles may be considered as an option.493 CARS microscopy 
has been applied to visualise trafficking of nanoparticles, as reported by Garrett et al. in 
investigating the intra-organ and cellular distribution of quaternary ammonium palmitoyl 
glycol chitosan (GCPQ).494 Employing deuterated GCPQ as a model nanoparticulate system, 
the technique was able to visualise the nanoparticles in the small intestine, liver and brain 
following oral and intravenous administration. 
 
Nanoparticles containing radioactive functionality can also be used in biomedical imaging. 
The radiolabeling was performed by incorporating radioactive nucleus (radionuclide) in a 
nonradioactive nanoparticles. The dosage and nature of radionuclide is selected in such a way 
it can give reliable radio imaging signal without inducing radiotoxicity.495 Ekinci et al. 
investigated the use of radiolabeling to evaluate in vitro the cellular uptake of methotrexate 
loaded chitosan nanoparticles in 2 different cell lines; human breast cancer (MCF-7) and 
human keratinocyte cell lines (HaCaT).496 The uptake of the nanoparticles radiolabeled with 
Technetium-99m (>90 % labeling efficiency) were assessed and the results showed that the 
uptake in MCF-7 was 2 times higher than in normal cells (HaCaT).  
 
Flow cytometry  
Flow cytometry (FCM) is a qualitative and quantitative analysis technique based on focusing 
a laser beam on individual cells and measuring the scattered light and fluorescence intensity 
(Figure 1.29); the results are usually presented as histograms or dot plots (see example in 
Figure 1.30). From the magnitude of the forward scattered light (FSC) one can obtain 
information regarding certain cell properties such as size, while the magnitude of side 
scattered light (SSC) can be related to cell granularity and internal structure.497, 498  
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Figure 1.29. Schematic representation of flow cytometry equipment. 
 
Labelling the cells with fluorescent molecules can facilitate the analysis of multiple cellular 
parameters. The ability to generate excitation using several lasers of different wavelengths 
simultaneously makes it possible to measure more than one cellular parameter at a time. The 
applications of FCM are mainly aimed at investigating cell size, auto fluorescence, cell cycle 
analysis, measurement of viability, and extra- or intracellular protein expression 
identification.499, 500 
 
Figure 1.30. Typical flow cytometry results: histogram (left), and dot plot (right). 
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A study employing flow cytometry was performed by Wagner et al., who investigated the 
glioma cellular uptake of nanoparticles that have been modified with apolipoprotein E 
(ApoE) targeting ligand at 2 different temperatures; 4 oC and 37 oC. Non-targeted 
nanoparticles were used as the control and based on the results, the ApoE-modified 
nanoparticles were uptaken by 36.7 % of glioma cells at 37 oC, as opposed to only 3.1 % was 
recorded for the control. Meanwhile, incubation at 4 oC resulted in less than 2 % cellular 
uptake for the ApoE-modified NPs and the control.501 
 
Confocal laser scanning microscopy (CLSM) 
Confocal microscopy is often used for imaging fluorescently labeled biological samples. A 
laser beam is reflected by a dichromatic mirror and focused onto the specimen (Figure 1.31). 
Fluorescent photons are produced due to excitation after the laser beam interacts with the 
specimen and the intensity of the fluorescent photons detected by the photodetector will be 
translated into a voltage signal, digitalised and eventually displayed on the monitor.502-504  
 
Figure 1.31. Schematic representation of confocal microscopy equipment. 
 
To investigate cellular uptake of nanoparticles, fluorescently labeled nanoparticles are 
employed to facilitate the visualisation. The microscope always comes with various filters 
and lasers that can be employed to detect more than one fluorescent probe at the same time. 
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Therefore, cell nucleus can be labeled with different fluorescence with the nanoparticles to 
investigate if the nanoparticles enter the nucleus or just accumulate within cytoplasm of the 
cell.   
 
Figure 1.32. Confocal microscopy images of BBMVEC after incubation with 
aminofluorescein-labelled QAβCD nanoparticles. Accumulation of FITC-labelled dextran 
(MW 4000 g mol-1) at 100 µg mL-1 (A) and aminofluorescein-labelled QAβCD nanoparticles 
at 100 (B) and 200 (C) µg mL-1. Reproduced from 212.  
 
Gil et al. employed confocal microscopy to study cellular uptake of aminofluorescein-
labelled quaternary ammonium β-cyclodextrin (QAβCD) nanoparticles using bovine brain 
microvessel endothelial cells (BBMVEC). FITC-dextran (MW 4000 g mol-1) was used as a 
control and the permeation of the nanoparticles across the cell monolayers was observed 
using confocal microscopy. Images from confocal microscopy evidenced the cellular uptake 
of the nanoparticles at 100 and 200 µg mL-1 by the BBMVEC after 2 h, with improved 
cellular uptake shown when an increased number of quaternary ammonium groups of 
nanoparticles were used (Figure 1.32).212 
 
1.5. Aim and objectives  
Rationalised by the fact that short chain alkylglycerols that were administered intracarotidally 
were able to enhance drug access into the brain in vivo,80, 359 polysaccharides such as chitosan 
have been previously modified with short chain alkylglycerols and formulated into 
nanoparticles; subsequent studies demonstrated the nanoparticles efficient cellular uptake in 
brain cells and their ability to increase drug permeability in an in vitro BBB model.207 
Therefore, investigation on the potential of alternative polysaccharides which can be similarly 
modified with alkylglycerols to yield nanoparticles with improved stability has been 
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performed, on the hypothesis that the nanoparticles can enhance drug permeation across the 
BBB. 
 
A series of biocompatible and biodegradable materials that display good drug carrier 
properties and offer easily modifiable functional groups was considered. The main objectives 
of this project were to: 
 synthesise and fully characterise a range of butylglyceryl-modified polysaccharides 
such as guar gum, pectin, pullulan and chitosan; 
 employ the prepared butylglyceryl-modified polysaccharides to develop and fully 
characterise novel nanoparticulate formulations; 
 explore the potential of these nanoparticulate systems for drug delivery to the brain, 
by assessing their stability in simulated physiological conditions; fluorescent markers 
and model drugs were employed to assess drug loading and release from the 
nanofomulations of interest;  
 study in vitro the interactions between the prepared nanoparticles and mouse brain 
endothelial cells in terms of cytotoxicity, cellular uptake and model membrane 
permeability. 
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2 
 
CHEMICAL MODIFICATIONS OF POLYSACCHARIDES 
 
Alkylation of selected polysaccharides (pullulan; pectin; guar gum; chitosan) with n-
butylglycidyl ether (BGE) under different reaction conditions - varying with the nature of 
each polymer - yielded a series of butylglyceryl modified polysaccharides (PUL-OX4; P-
OX4; GG-OX4; CS-OX4) displaying various degrees of substitution. The modified 
polysaccharides were characterised using FT-IR, 1H- and 13C- NMR spectroscopy, thermal 
analysis, and gel permeation chromatography.  
 
2.1. Materials and instrumentation 
Pectin from citrus fruit (MW 17 kDa; 20-34 % esterification; cat. no. P9311; batch no. 
051M1378V), low MW chitosan (MW 50–190 kDa; 75-85 % deacetylation; cat. no. 448869; 
batch no. MKBD0020), pullulan (MW 100 kDa; cat. no. 91335; batch no. BCBK3803V), 
guar gum (MW 220 kDa; cat. no. G4129; batch no. 041M0058V), dimethylformamide 
(DMF; anhydrous, 99.8 %), dimethyl sulfoxide (DMSO; anhydrous, ≥ 99.9 %), n-
butylglycidyl ether (BGE; reagent grade 95 %; cat. no. 377031), Zn(BF4)2, potassium tert-
butoxide (t-BuOK; reagent grade > 97 %), phthalic anhydride (reagent grade ≥ 99.9 %), and 
sodium hydroxide (NaOH) were sourced from Sigma Aldrich (Gillingham, UK). 
Tetrahydrofuran (THF; anhydrous, ≥ 99.9 %, contains 250 ppm BHT as inhibitor), hydrazine 
monohydrate, and the organic solvents such as diethyl ether and dichloromethane (DCM) 
were purchased from Fisher Scientific (Loughborough, UK).  
 
Where required, organic solvents were removed under reduced pressure using a Büchi 
Rotavapor R-200 powered with a Sogevac Saskia PIZ 100 vacuum pump equipped with a 
liquid nitrogen cold trap. Dialysis was carried out using Visking dialysis tubing (Medicell 
International Ltd., London, UK) with a molecular weight cut-off either 12-14 kDa or 3.5 kDa. 
A Grant ultrasonic bath XB3 (Grant Instruments, Cambridge, UK) was employed for 
sonication. A Jouan B4i centrifuge equipped with a S40 rotor was employed for low speed 
centrifugation (4,000 rpm; 2,880 g; 15 min, unless otherwise specified). Lyophilisation of 
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aqueous samples was performed using a VirTis SP Scientific Sentry 2.0 freeze drier 
(Genevac Ltd., Ipswich, UK) attached to an Oerlikon Leybold vacuum pump. 
  
The freeze dried products were characterised by NMR spectroscopy using a JEOL Eclipse 
400+ instrument (JEOL, UK; 400 MHz for 1H- and 100 MHz for 13C-NMR); samples were 
dissolved in either CDCl3, D2O, CD3OD, or DMSO-d6, employing either 0.2 % v/v TMS or 
TSP as reference. The degree of substitution was calculated from the 1H-NMR spectra of the 
modified polysaccharides. FT-IR spectra were recorded on a Nexus Euro spectrophotometer 
(Thermo Fisher Scientific, Hemel Hempstead, UK) using a diamond crystal ATR Smart Orbit 
accessory. Thermal analysis involved thermogravimetry (TGA) and differential scanning 
calorimetry (DSC), which were performed using TG 209 F1 Libra (NETZSCH, Germany) 
and DSC 214 Polyma (NETZSCH, Germany) instruments, respectively. Gel permeation 
chromatography (GPC) was performed (in order to estimate the molecular weight of 
butylglyceryl-modified polysaccharides) using a Waters Alliance GPC 2000 system equipped 
with a PL-aquagel-OH column (8 μm particle size; 40 Å pore type) and a refractive index 
detector, under controlled temperature conditions (30 °C). Either water/methanol (8:2, v/v) or 
100 % water (HPLC grade) was run as eluent at a flow rate of 0.5 mL/min. The molecular 
weight was estimated based on the calibration that was conducted with pullulan standards 
(Shodex Denko) of MW 0.6 × 104, 1 × 104, 2.17 × 104, 4.88 × 104, 11.3 × 104, 21 × 104, 36.6 
× 104 and 80.5 × 104 g/mol.  
 
2.2. Methods 
2.2.1. Synthesis of butylglyceryl-modified pectin derivatives 
Alkylation reactions of pectin using n-butylglycidyl ether (BGE) were investigated in two 
different environments: strong aqueous alkaline (A) and aqueous acidic with zinc 
tetrafluoroborate hydrate catalyst (B). 
 
A. Alkylation in aqueous alkaline conditions 
A solution of pectin (0.40g; 2.06 mmol) in deionized water (110 mL) was made alkaline (pH 
12) using NaOH (33 %; w/v) and was kept in a freezer at -18 oC for 7 days. After 
equilibration at room temperature, n-butylglycidyl ether (either 5.60 mL, 39.14 mmol; 18.56 
mL, 129.78 mmol; or 31.82 mL, 222.48 mmol) was added dropwise into the solution under 
magnetic stirring, which was then maintained for an additional 16 h at 45 oC. The solution 
was then neutralized using HCl (10 %, v/v) prior to washing with DCM three times in order 
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to remove any water insoluble impurities. Further purification was performed by dialysis 
against deionized water (10.0 L; exchanged 3 times per day) for 72 h followed by removal of 
volatile solvent traces using a rotary evaporator and lyophilization (with flash freezing in 
liquid N2). Butylglyceryl pectin (P-OX4) was yielded as white cotton-like material (yields 
85–88 %), which was then characterised by FT-IR, 1H- and 13C- NMR spectroscopy, GPC 
and thermal analysis. 
 
B. Alkylation in aqueous acidic conditions 
A solution of pectin (0.20 g; 1.03 mmol) in deionized water (60 mL) was made acidic (pH 1) 
using conc. HCl (37 %), Zn(BF4)2 x H2O (0.49 g; 2.05 mmol) was added and the mixture was 
kept under stirring for 2 h. N-butylglycidyl ether (1.47 mL, 10.30 mmol) was added dropwise 
under stirring, which was then maintained for an additional 16 h, at room temperature. The 
reaction mixture was neutralized using aq. NaOH (10 %, w/v), washed with DCM three 
times, dialyzed (MWCO 12 kDa) against water (10.0 L; exchanged 3 times per day) for 72 h 
and finally lyophilized (with flash freezing in liquid N2). The white cotton-like products 
obtained (yield 82–85 %) were further characterized by FT-IR, 1H- and 13C- NMR 
spectroscopy. 
 
2.2.2. Synthesis of butylglyceryl-modified guar gum derivatives 
Similar to chapter 2.2.1, alkylation reactions of guar gum using n-butylglycidyl ether (BGE) 
were investigated in two different environments: strong aqueous alkaline (A) and aqueous 
acidic with zinc tetrafluoroborate hydrate catalyst (B). 
 
A. Alkylation in aqeuous alkaline environment 
Guar gum (0.5 g; 2.78 mmol) was dissolved in deionised water (110 mL). The solution was 
made alkaline (pH 12) by means of NaOH (33 % w/v), stirred for 2 h and kept in a freezer at 
-18oC for 7 day. After equilibration at room temperature, n-butylglycidyl ether at varying 
concentration (2.78 mmol, 0.40 mL; 13.9 mmol, 2.00 mL; 22.24 mmol, 3.18 mL; 52.82 
mmol, 7.55 mL; 83.4 mmol, 11.93 mL; 113.98 mmol, 16.30 mL) was added drop wise into 
the solution under stirring and maintained for 16 h at 45oC prior to neutralisation by HCl (10 
% v/v). After washing with DCM three times, the aqueous phase was dialysed (MWCO 12 
kDa) against deionised water (10.0 L; exchanged 3 times per day) for three day, concentrated 
by rotary evaporator and lyophilised (flash freezing in liquid N2) affording a white and fluffy 
butylglyceryl guar gum (GG-OX4) with yields in range 86–88 %. The final products were 
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characterised by FT-IR spectroscopy, 1H- and 13C- NMR spectroscopy, GPC, and thermal 
analysis. 
 
B. Alkylation in aqueous acidic environment 
Guar gum (0.177 g; 0.983 mmol) was dissolved in deionised water (60 mL) and the solution 
was made acidic (pH 1) by concentrated HCl (37 %). Zn(BF4)2 x H2O (0.47 g; 1.963 mmol) 
was introduced to the polymer solution and stirred for 2 h prior to dropwise addition of n-
butylglycidyl ether (1.41 mL, 9.83 mmol). The reaction mixture was maintained under 
stirring for 16 h at room temperature. After neutralisation with aq. NaOH (10 % v/v), the 
mixture was washed with DCM three times, rotavaped, dialysed (MWCO 12 kDa) against 
deionised water (10.0 L; exchanged 3 times per day) for three day and subsequently freeze 
dried (flash freezing in liquid N2). The final products, obtained as a white and fluffy cotton-
like compound (yields 81–85 %), were used for characterisation.  
 
2.2.3. Synthesis of butylglyceryl-modified pullulan derivatives 
Following a two-step reaction mechanism, pullulan was treated with a strong base (either 
potassium tert-butoxide or sodium hydroxide), followed by reaction with n-butylglycidyl 
ether, BGE. Solubility of pullulan in both organic and aqueous environments led to the 
investigation of the chemical reaction in both environments, as described below.  
 
A. Alkylation in organic environment 
Pullulan (0.5 g; 3.05 mmol) was solubilised in anhydrous DMSO (100 mL). Potassium tert-
butoxide (1.0 g; 9.15 mmol) dissolved in anhydrous DMSO (50 mL) was added dropwise into 
the pullulan solution under stirring. The reaction mixture then was stirred for 2 h under 
nitrogen atmosphere, followed by dropwise addition of n-butylglycidyl ether of concentration 
either 3.05 mmol, 0.44 mL; 15.25 mmol, 2.18 mL or 24.40 mmol, 3.49 mL. The reaction 
mixture was stirred for another 24 h at 45 oC, dialysed (MWCO 12 kDa) against deionised 
water (10.0 L; exchanged 3 times per day) for 72 h, then washed with diethyl ether three 
times in a separating funnel before removing any traces of organic solvent in a rotary 
evaporator. Lyophilization (with flash freezing in liquid N2) afforded butylglyceryl pullulan 
(PUL-OX4) as beige powder (yield 69–75 %), further characterised by FT-IR, 1H- and 13C- 
NMR spectroscopy, GPC and thermal analysis. 
 
 
68 
 
B. Alkylation in aqueous alkaline environment 
A pullulan (0.5 g; 3.05 mmol) solution in deionised water (45 mL) was made alkaline (pH 
12) by NaOH (33 % w/v), stirred for 2 hours before it was then kept in a freezer at -18oC for 
7 day. After warming to room temperature, n-butylglycidyl ether of varying concentration 
(3.05 mmol, 0.44 mL; 15.25 mmol, 2.18 mL; 24.40 mmol, 3.49 mL; 57.95 mmol, 8.29 mL; 
91.5 mmol, 13.09 mL) was added drop wise into the solution under stirring, which was then 
vigorously stirred at 45 oC for another 16 h for reaction completion. The mixture was made 
neutral using HCl (10 % v/v) and after neutralised, the reaction mixture was washed with 
diethyl ether in triplicate in order to remove water insoluble impurities. The aqueous phase 
was dialysed against deionised (MWCO 12 kDa) water (10.0 L; exchanged 3 times per day) 
for three day and lyophilized (flash freezing in liquid N2). The final products, obtained as a 
white and fluffy cotton-like material (yields 81–84 %), were characterised by FT-IR 
spectroscopy, 1H- and 13C- NMR spectroscopy, and thermal analysis. 
 
2.2.4. Synthesis of butylglyceryl-modified chitosan derivatives 
A three-step protocol for chemical modifications of chitosan with n-butylglycidyl ether was 
performed; the protection of free amino groups by phthaloyl groups followed by the 
attachment of butylglyceryl pendant chain to the available polysaccharidic hydroxyl groups 
prior to the deprotection of the amino groups by hydrazine.  
 
Step 1. Protection of amino groups by phthaloylation 
Ultra-low molecular weight (ULMW) chitosan (5.00 g; 7.3 mmol) was gradually added to a 
phthalic anhydride (14.40 g; 93.3 mmol) solution in anhydrous DMF (140 mL), which was 
then refluxed for 18 h under nitrogen atmosphere. The reaction mixture was poured into iced 
water (1 L) and filtered. The precipitate retained on the filter paper was washed with ethanol 
and diethyl ether prior to purification via Soxhlet extraction with ethanol. The product was 
finally dried in a desiccator, yielding a light brown powder phthaloyl chitosan (yields 67–73 
%). 
 
Step 2. Addition of n-butylglycidyl ether  
A solution of tBuOK (6.58 g; 60.2 mmol) in anhydrous THF (70 mL) was added dropwise 
into a phtaloyl chitosan (1.20 g; 4.39 mmol) solution in anhydrous DMF (120 mL) under 
nitrogen atmosphere. The mixture was stirred for 30 min before the addition of n-
butylglycidyl ether (4.39 mmol, 0.63 mL; 21.95 mmol, 3.14 mL; 35.12 mmol, 17.71 mL) in 
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DMF (15 mL); the resulting reaction mixture was maintained under stirring for another 16 h 
at room temperature prior to being poured into iced water (500 mL). Volatile solvents were 
removed using a rotary evaporator and the resulting product was washed with DCM (3 times) 
and dialysed (MWCO 3.5 kDa) against deionised water (10.0 L; exchanged 3 times per day) 
for 4 days. The products were then lyophilised (with flash freezing in liquid N2) to afford 
butylglyceryl-modified phtaloyl chitosan as beige powder (yield 63–69 %). 
 
Step 3. Deprotection of amino groups 
Butylglyceryl phtaloyl chitosan (4.00 g; 0.96 mmol) was dispersed in a solution of hydrazine 
monohydrate (45 mL, 900 mmol) in deionised water (90 mL) and refluxed for 15 h. The 
mixture was diluted with deionised water (10 mL) and then centrifuged (Jouan B4i, 4,000 
rpm; 2,880 g; 15 min) with ethanol/ether (5:5, v/v). Further purification was performed via 
dialysis (MWCO 3.5 kDa) against deionised water (10.0 L; exchanged 3 times per day) for 
four day. The final product was then lyophilised (flash freezing in liquid N2) to yield 
butylglyceryl-modified chitosan (CS-OX4), obtained as a beige powder (yields 58–65 %), 
which were further characterised by FT-IR spectroscopy, 1H- and 13C- NMR spectroscopy 
and thermal analysis. 
 
2.3. Results and discussion 
n-butylglycidyl ether (BGE) was employed for the same chemical modification of a series of 
polysaccharides. The reagent was obtained commercially and characterised by 1H-NMR 
spectroscopy to confirm the product structure and was found consistent with previously 
reported in the literature,505 where the spectra presented in Figure 2.1 showed the 
characteristics of alkyl peaks at 0.87, 1.28 and 1.48 ppm (ratio ca. 3:2:2). An example of 13C- 
NMR spectra of BGE was shown in APPENDIX L. 
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Figure 2.1. 1H-NMR spectra of n-butylglycidyl ether (BGE) in CD3OD (10mg/mL). 
 
2.3.1. Synthesis of butylglyceryl-modified pectin derivatives 
The synthesis of butylglyceryl-modified pectin (P-OX4) was carried out by reacting 
commercially available pectin (low degree of esterification) with n-butylglycidyl ether 
(BGE), as described in chapter 2.2.1; (the main reagent for the synthesis of butylglyceryl-
modified polysaccharides) owing to the fact that chemical modification with short chain 
alkylglycerols can increase permeability through the blood-brain barrier.64, 65, 80, 359  
 
Pectin solution was made alkaline and kept in a freezer prior to the alkylation following the 
protocol reported by Liu et al. and Feng et al., where it was reported can be beneficial for 
further modification of chitin, enhance its solubility and accelerate the chemical reaction rate 
while still maintaining its main molecular chains.506, 507 The gradual freezing process in 
alkaline helped the chitin to break the intra- and intermolecular hydrogen bonds, disturbed the 
ordered molecular structure and decrease the crystallinity, though those effects were unstable 
and reversible. Two different chemical reactions, as represented in Figure 2.2 were 
investigated for the synthesis of P-OX4; alkaline (A) and acidic environments (B), following 
methods described in the literature.255  
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Figure 2.2. Synthesis of butylglyceryl-modified pectin. 
 
The attachment of butylglyceryl-pendant chain to the polysaccharidic structure of pectin was 
achieved via a nucleophilic substitution reaction in strong alkaline condition. The strong 
alkaline conditions provided by the aqueous NaOH solution (pH 14) converted the hydroxyl 
groups of pectin into alcoholates that react further with the oxirane ring via a nucleophilic 
substitution reaction, as previously described in the literature.255, 508 Butylglyceryl-modified 
pectin (P-OX4) was obtained as white, fluffy, cotton-like solid with yields of 85–88 %.  
 
The chemical modification of pectin was confirmed by FT-IR spectroscopy. The broad and 
intense absorption band at 3331–3281 cm-1 for unmodified and modified pectin (Figure 2.3) 
can be assigned to O-H stretching absorption due to inter- and intramolecular hydrogen 
bonding of the galacturonic acid units. Bands at 2930–2928 cm-1 are due to C-H vibrations 
(which include CH, CH2, and CH3 stretching). Low esterified pectin was employed in this 
study and did not exhibit a distinct O-CH3 stretching band (normally between 2950 and 2750 
cm-1 owing to methyl esters of galacturonic acid) as reported in the literature, 509, 510 which is 
likely masked by the large O-H stretching bands appearing in the region (3600–2500 cm-1). 
Carboxylate groups (COO-) bands were observed in both unmodified and modified pectin, 
showing two bands: an asymmetric stretching band near 1609–1601 cm-1, and a weaker 
symmetric stretching band near 1409–1402 cm-1.509, 511 Comparing the FT-IR spectra of the 
modified pectin with that of unmodifed pectin, the intensity of the band at 1027 and 1098 cm-
1 attributed to the formation of ether linkage (C-O-C) would be expected to be more in the 
modified pectin, as shown in Figure 2.3. 
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Figure 2.3. FT-IR spectra of; A) unmodified pectin; also B) butylglyceryl pectin, P-OX4 (DS 
9.3 %). 
  
 
 
Figure 2.4. 1H-NMR spectra of butylglyceryl pectin (P-OX4) in D2O (5 mg/mL). 
 
The successful chemical modification of pectin was also confirmed by NMR spectroscopy. 
1H-NMR spectra of butylglyceryl pectin (P-OX4) (Figure 2.4) revealed the presence of peaks 
characteristic to the sugar repeating unit (δ 5.0 ppm for the anomeric proton, δ 3.7 ppm for 
the methoxy groups of esterified pectin and δ 3.5–4.8 for the backbone protons)511 and the 
alkyl group of the butylglyceryl-pendant chain (δ 0.9, 1.3 and 1.5 ppm). Examples of 13C- 
and 2D COSY 1H-NMR spectra of P-OX4 was shown in APPENDIX M. 
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The 1H-NMR spectra was also used to calculate the degree of substitution (i.e. how many 
butylglyceryl chains were attached to the polysaccharidic backbone). The degree of 
substitution is expressed here as the number of butylglyceryl chains attached to 100 
glucopyranose  residues of pectin (Figure 2.4; e.g. 100 % means one OH group was 
substituted in each sugar residue, with a maximum of 200 % when all available OH groups in 
each sugar residue of pectin were fully substituted), using the equation below: 
 
𝐷𝑆 [%] =  
𝐴 × 100
3𝐵
            (Eq. 2) 
 
where; 
 
DS [%] Degree of substitution (the number of butylglyceryl chains attached to 100 
sugar residue of pectin)  
A  Integral value of the signal assigned to the alkyl chain end CH3 group (δ 0.9 
ppm) 
B  Integral value of the signal assigned to the anomeric C1 group proton of the 
glucopyranosic ring (δ 5.0 ppm) 
 
The formula used to calculate DS for modified pectin (P-OX4) was derived using the peak 
integrals attributed to the end CH3 alkyl chain (δ 0.9 ppm) and the anomeric proton at C1 (δ 
5.0 ppm). The influence of the molar ratio between starting/unmodified pectin sugar unit and 
n-butylglycidyl ether (BGE) on the degree of substitution is presented in Figure 2.5. As 
expected, the degree of substitution increased with an increasing excess of BGE, however it 
was found that the DS value was very low, even when particularly high excess of BGE were 
employed. Morris et al. performed alkylation reaction of pectin hydroxyl groups with p-
carboxybenzyl bromide in aqueous alkali, yielding low degree of substitution of about < 0.1 
%.512 Another study by Liang et al. presented the data of pectin alkylation with various length 
of alkyl chain (hexyl, dodecyl or octadecyl), yielding products with low DS ranged from 0.6 
to 4.372 The synthesis was performed by first neutralising the pectin with TBA+OH- and 
lyophilized. The resulting pectin TBA salt was then reacted with alkylglycerols prior to left in 
contact with NaCl for the residual exchange of TBA+ by Na+ ions. This protocol is 
rationalised by some studies that reported the preparation of ester of polysaccharides from an 
alkyl halide with carboxylic groups that have been transformed into their 
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tetrabutylammonium (TBA) salts.344, 513 The linearity response between the amount of BGE 
employed and the degree of substitution was obtained by plotting linear regression of degree 
of substitution (%) versus molar ratio of pectin sugar unit and BGE (y = 0.16x + 2.74, r2 = 
0.85).  
 
  
Figure 2.5. The effect of molar ratio between sugar unit of pectin and BGE on the degree of 
substitution (n=3; ±SD). 
 
Samples of butylglyceryl-modified pectin (P-OX4) with different degree of substitution (DS 
7.5 and 9.3 %) and starting pectin were analyzed by GPC and results (Table 2.1) indicate that 
the molecular weight increased after the modification, confirming the attachment of 
butylglyceryl-pendant chains to the polysaccharidic backbone of pectin, as investigated by 
Devedec et al..514 The alkylation of methoxy poly (ethylene glycol) with allylglycidyl ether to 
produce amphiphilic block copolymers was resulted in an increase in the molecular weight of 
the product, confirming the successful addition of the alkyl chain. The increase of molecular 
weight was found to be directly proportional to the degree of substitution. The polymer 
polydispersity index (PDI) as obtained by GPC is based on the ratio between molecular 
weight (Mw) and molecular number (Mn) and indicates the molecular weight distribution of 
a polymer, with values close to 1 indicative of a narrow polymer distribution (monodisperse). 
Results presented in Table 3.1 indicate that the polydispersity decreases following the desired 
modification, likely as a result of the additional purification steps that are part of the process. 
An example of GPC chromatogram of P-OX4 was shown in APPENDIX A. 
 
 
7.5 9.3
21.6
0
5
10
15
20
25
30
1 : 19 1 : 63 1 : 108
D
eg
re
e 
o
f 
su
b
st
it
u
ti
o
n
 (
%
)
Pectin (sugar unit) : BGE molar ratio
75 
 
Table 2.1. Molecular weight of butylglyceryl-modified pectin derivatives, as determined by 
GPC (n=3; ±SD). 
Compound Mn ± SD Mw ± SD PDI ± SD 
Pectin (Sigma, Mw ~ 17 kDa) 20569 ± 276 25037 ± 128 1.22 ± 0.10 
P-OX4 (DS 7.5 %) 27044 ± 222 29111 ± 321 1.08 ± 0.05 
P-OX4 (DS 9.3 %) 28803 ± 298 32541 ± 252 1.13 ± 0.06 
 
Figure 2.6 presents a typical TGA thermogram (% mass loss represented as a function of 
temperature) obtained for butylglyceryl-modified pectins (P-OX4). Two main steps 
corresponding to different mass loss processes can be identified: the first DTG peak appears 
at around 77 oC and is likely due to the evaporation of water still present in the freeze-dried 
product (approx. 11 % water content), while the second one (at about 245 oC and with a mass 
loss in excess of 53 %) is due to the thermal decomposition of the material, as suggested by 
Thakur.515 The residual mass at 500 oC (nitrogen atmosphere) was found to be around 34 %. 
 
 
Figure 2.6. Thermogravimetric analysis results for P-OX4 (DS 9.3 %); DTG (first derivative) 
represented as dotted line. 
 
Table 2.2. Results of thermogravimetric analyses of butylglyceryl-modified pectin derivatives 
(n=3; ± SD). 
Material Water evaporation Decomposition Residue 
(%)  DTG peak  
(oC)  
Mass loss  
(%)  
DTG peak  
(oC)  
Mass loss  
(%)  
Unmodified pectin 56.2 ± 6.9 16.32 ± 8.1 215.4 ± 6.1 17.62 ± 7.4 65.84 ± 7.2 
P-OX4 (DS 7.5 %) 72.6 ± 8.8 11.45 ± 7.7 225.4 ± 8.2 57.14 ± 7.8 30.73 ± 5.6 
P-OX4 (DS 9.3 %) 77.7 ± 7.4 10.72 ± 8.2 245.5 ± 8.9 53.99 ± 7.1 34.19 ± 8.6 
 
Table 2.2 summarizes also the results obtained for other samples, including the starting 
material (unmodified pectin). The data confirms the expected increase in hydrophobicity 
following the modification, with the measured water content being inverse proportional to the 
degree of substitution (unmodified pectin contained more water, about 16 %, compared to the 
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BGE-modified material, with less than 12 %). The storage condition of samples may also 
influence the water content, therefore the unmodified pectin was lyophilised together with the 
modified ones and kept in a desiccator prior to the analysis. The DTG peak of water 
evaporation appears at a higher temperature in the modified pectin derivatives. The main 
mass loss that corresponds to the decomposition process was observed at a higher 
temperature for higher DS modifications (Table 2.2) 
 
 
Figure 2.7 Differential scanning calorimetry curve for P-OX4 (DS 2 
7.5 %); red - first run (top), blue - second run (bottom); first derivative represented as dotted 
line. 
 
The glass transition temperature of pectin was shifted to higher temperatures following 
substitution with BGE (Figure 2.7; Table 2.3). This perhaps can be associated with an 
increase in molecular structure bulkiness following the addition of alkyl-pendant chain, in 
which leads to a decrease in mobility.15,16 Apart from that, moisture can act as a plasticiser, 
leading to an increase in free volume and weaken of interchain interaction, thus reduce the 
glass transition temperature of amorphous solids.516-518 Therefore, since P-OX4 derivatives 
contain less water than unmodified one, it is expected that P-OX4 to have higher Tg value.  
 
Tg values of pectin reported in the literature are varied; Basu et al. investigated the Tg of 
pectin in relation to moisture content, where it was found that the Tg decreased with an 
increase in moisture content from 16.8 to -24.6 oC with moisture content of 8–20 %.516 
Mishra et al. studied the effect of graft polymerization of pectin with polyacrylamide, where 
it was reported that the Tg of pure pectin decreased after the grafting from 95 oC to 53 oC.519 
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As Tg values depend on the composition of the carbohydrate, the differences in the Tg 
between the ones reported in the literature and the values recorded in this study was possibly 
due to the differences in solids composition that may come from the decomposition of the 
carbohydrate during processing and variations in the composition of raw materials that 
include molecular weight and water content.520 
 
Table 2.3 DSC results of butylglyceryl-modified pectin derivatives (n=3; ± SD). 
Material Glass transition, Tg (oC)  Evaporation peak (oC)  
Unmodified pectin 22.4 ± 1.5 97.7 ± 2.2 
P-OX4 (DS 7.5 %) 24.4 ± 1.4 100.7 ± 1.8 
P-OX4 (DS 9.3 %) 24.7 ± 1.6 108.4 ± 1.7 
 
Attempts to synthesise P-OX4 in acidic media (pH 1) using Zn(BF4)2 as catalyst - as reported 
by Shu et al. and Leonard et al.521, 522 - were not successful; 1H-NMR characterization of the 
materials isolated following purification (yields 82–85 %), could not evidence the presence of 
alkyl groups (indicating no positive modification via alkylation). A possible explanation may 
be related to the stability of pectin in the strongly acidic reaction medium employed (pH 1), 
as several studies reported that at pH 3.5 or lower, pectin can start to degrade via hydrolysis 
leading to the formation of reducing sugar. As the pH decreased, an increase in reducing 
sugar production was noticed.523, 524  
 
2.3.2. Synthesis of butylglyceryl-modified guar gum derivatives 
To synthesis butylglyceryl-modified guar gum (GG-OX4), experiments employing two 
different methods (chapter 2.2.2) were performed, as represented in Figure 2.8. The 
butylglyceryl-modified guar gum (GG-OX4) was synthesised following a chemical reaction 
between guar gum with n-butylglycidyl ether (BGE) under strong alkaline condition (aq. 
NaOH, pH 14) via a nucleophilic substitution reaction affording white and fluffy 
butylglyceryl guar gum (GG-OX4) products with yields in range 86–88 %.  
route A
NaOH
45 oC
route B
Zn (BF
4
)
2
Butylglycidyl ether
R
Figure 2.8. Synthesis of butylglyceryl-modified guar gum. 
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The reactivity sequence of hydroxyl groups of guar gum follows the order C6 > C2 > C3, as 
mentioned by Laskowski et al..525 The hydroxyl groups of polysaccharide are comparable 
with the primary and secondary hydroxyl groups of aliphatic alcohols, where the primary 
ones are the more reactive. With guar gum, from steric relations, it has been concluded that 
the C6 atom would most probably be attacked on the freely moving side galactose. These 
primary OH groups are more reactive than those on mannose. With regard to better steric 
accessibility, the OH groups on atom C2 of the straight mannose chain are slightly more 
reactive than the OH groups on atom C2 of the branched mannose and galactose sugar.526 
 
The chemical modifications were confirmed by FT-IR spectroscopy. The main bands of guar 
gum were found in unmodified and modified guar gum and recorded as follows: broad peak 
presents at 3357–3309 cm-1 (O-H stretching) indicates association due to -OH groups. Other 
important peaks are observed at between 1301 and 1082 cm-1 which are due to C-O-C 
stretching from glycosidic linkages and O-H bending from alcohols.527, 528 FT-IR spectra of 
unmodified guar gum, a physical mixture of guar gum and oxirane and GG-OX4 were all 
compared in Figure 2.9. GG-OX4 showed an increase in the intensity in ether band (1019, 
1089, and 1148 cm-1 ) when compared to unmodified guar gum owing to an increase in the 
formation of ether linkages (C-O-C) between guar gum and the butylglyceryl chain. The 
absorption band at 2919 cm-1 that was strengthened attribute to asymmetric stretching 
vibration of (-CH3), as compared to unmodified guar gum.  
 
N-butylglycidyl ether contains oxirane ring, where two characteristics absorption of the 
oxirane ring were observed in the range between 4000 cm-1 and 400 cm-1. The first one, at 
909 cm-1, is attributed to the stretching of C-O of oxirane group. The second band is located 
at 3050 cm-1 and is attributed to the stretching of C-H of the oxirane group. However the 
second band sometimes difficult to be seen since its intensity is low and it is also very close 
to the strong O-H absorptions.528 These two bands can be observed in the physical mixture of 
BGE and polymer spectra. In order for the BGE to be substituted to the polymer, the oxirane 
ring needs to be opened. The disappearance of these two bands in the spectra of modified 
polymer indicates the opening of epoxy rings, thus proves the modification of those polymers 
was successfully done.529 
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Figure 2.9. FT-IR spectra of; A) unmodified guar gum; B) a physical mixture of guar gum 
and BGE with molar ratio of 1 : 5 (GG sugar unit: BGE) ; and C) GG-OX4 with degree of 
substitution 12.6 %. 
 
The purified products of GG-OX4 were analysed by 1H-NMR spectroscopy to confirm the 
chemical modifications with n-butylglycidyl ether, where the spectra (Figure 2.10) recorded 
peaks for both guar gum (δ 4.8 ppm for anomeric proton and δ 3.5–4.2 ppm for sugar protons 
411 and alkyl group (δ 0.9, δ 1.3 and δ 1.5 ppm). The degree of substitution was calculated 
from the ratio of peak integrals using the signals assigned to alkyl chain end CH3 group (δ 0.9 
ppm) and to the anomeric C1 group proton of guar gum (δ 4.8 ppm). Examples of 13C- and 2D 
COSY 1H-NMR spectra of GG-OX4 was shown in APPENDIX N. 
 
A) 
B) 
C) 
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Figure 2.10. 1H-NMR spectra of butylglyceryl guar gum (GG-OX4) in DMSO-d6 (5 mg/mL). 
 
The DS (expressed and defined as the number of butylglyceryl chains attached to 100 
glucopyranose units of guar gum (Figure 2.10); i.e. 100 % means only one OH group was 
substituted, with a maximum of 300 % when all 3 possible sites for the substitution in one 
sugar residue were fully substituted) was calculated using equation: 
 
𝐷𝑆 [%] =  
𝐴 × 100
3𝐵
         (Eq. 3) 
 
where; 
 
DS [%] Degree of substitution (the number of butylglyceryl chains attached to 100 
sugar residue of guar gum)  
A  Integral value of the δ 0.9 ppm signal assigned to the alkyl chain end CH3 
group 
B  Integral value of the δ 4.8 ppm signal assigned to the anomeric C1 group 
proton of the glucopyranosic ring 
 
The molar ratio between guar gum sugar unit and BGE was varied in order to investigate the 
effect upon the degree of substitution; the results are presented in Table 2.4. It was suggested 
based on the results that the degree of substitution increased with an increase in the molar 
1
1
1
2
3
4
R
 
2 3 4 
1 
Impurities Solvent 
H at C2–6  
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ratio, as suggested by Risica et al.377 As the concentration of n-butylglycidyl ether in the 
reaction chamber goes high, the tendency for the alcoholates of the polymer to reach and 
attack the oxirane ring becomes high simultaneously, hence increase the degree of 
substitution of polymer with n-butylglycidyl ether. The excess of n-butylglycidyl ether was 
required to make the reaction feasible due to the property of water that could act as a 
nucleophilic substance which can react with the polymer, therefore act as a hindrance to the 
reaction between polymer and n-butylglycidyl ether.530 Alkylation of guar gum has been 
demonstrated in several studies, however with lower DS value; Boonstra et al. synthesised 
alkylated guar gum as a thickener in textile printing with degree of substitution of about 0.12 
%531 and Risica et al. synthesised and characterised methyl ether guar gum with DS value of 
around 0.3 to 1.6 %.377 
 
Table 2.4. Degree of substitution of butylglyceryl guar gum (GG-OX4) (n=3; ±SD). 
GG (sugar unit) : BGE molar ratio Degree of substitution (%) 
1 : 1 3.6 ± 2.4 
1 : 5 12.6 ± 2.1 
1 : 8 33.9 ± 3.3 
1 : 19 48.0 ± 3.0 
1 : 30 91.2 ± 5.7 
1 : 41 133.2 ± 5.1 
 
The linear relationship between the molar ratio and the degree of substitution was obtained by 
plotting linear regression of degree of substitution (%) versus molar ratio of chitosan sugar 
unit and BGE (y = 3.14x + 0.63, r2 = 0.98), as presented in Figure 2.11. Based on r2 value 
that is close to 1, the calculated degree of substitution was linearly proportional to the molar 
ratio, suggesting that the guar gum was probably capable of taking in higher molar ratio than 
were tested. 
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Figure 2.11. Linear regression of the molar ratio (GG sugar unit : BGE) effect on the degree 
of substitution of butylglyceryl guar gum (GG-OX4) (n=3; ±SD). 
 
To investigate the influence of the modifications on the molecular weight of the products, the 
novel butylglyceryl guar gum (GG-OX4) was analysed by GPC and compared to the 
molecular weight of the starting material (sourced commercially). The data presented in 
Table 2.5 suggested that the molecular weight increased with an increase in the degree of 
substitution. As the degree of substitution goes higher, the number of butylglyceryl-pendant 
chain attached to the polysaccharidic backbone of guar gum also increased, therefore 
contributing to the increase in molecular weight.514 An example of GPC chromatogram of 
GG-OX4 was shown in APPENDIX B. 
 
Table 2.5. Molecular weight of butylglyceryl-modified guar gum derivatives, as determined 
by GPC (n=3; ±SD). 
Compound Mn ± SD Mw ± SD PDI ± SD 
Guar gum (Sigma, Mw ~ 220 kDa) 215176 ± 109 285679 ± 311 1.33 ± 0.12 
GG-OX4 (DS 12.6 %) 268919 ± 268 291552 ± 178 1.08 ± 0.03 
GG-OX4 (DS 33.9 %) 289622 ± 199 299881 ± 273 1.04 ± 0.02 
GG-OX4 (DS 91.2 %) 295045 ± 288 331617 ± 309 1.12 ± 0.07 
 
Thermogravimetric analysis (Figure 2.12) and differential scanning calorimetry (Figure 2.13) 
of GG-OX4 demonstrates variations of decomposition process between unmodified guar gum 
and modified guar gum.  
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Figure 2.12. Thermogravimetric analysis curve of GG-OX4 (DS 12.6 %); DTG (first 
derivative) represented as dotted line. 
 
Table 2.6 illustrates the results of TGA analyses of unmodified guar gum and GG-OX4 
derivatives. Behari et al. reported that decomposition of guar gum will start after 200 oC.532 
As the degree of substitution goes higher, the decomposition process also started at higher 
temperature. The presence of butylglyceryl-pendant chain potentially increased the 
decomposition temperature. Unmodified guar gum contained the highest water content with 
value 9.50 % compared to modified guar gum. This is perhaps owing to the fact that the 
modification increased hydrophobicity, hence prevent the materials from absorbing and 
storing too much moisture. 
 
Table 2.6. Result of thermogravimetric analyses of butylglyceryl-modified guar gum 
derivatives (n=3; ± SD). 
Material Water evaporation Decomposition Residue (%)  
DTG Peak 
(oC)  
Mass loss  
(%)  
DTG Peak 
(oC)  
Mass loss  
(%)  
Unmodified guar gum 78.3 ± 8.9 9.50 ± 3.2 289.0 ± 5.6 64.30 ± 5.1 25.94 ± 5.2 
GG-OX4 (DS 12.6 %) 82.5 ± 4.2 6.73 ± 3.2 305.1 ± 4.8 68.14 ± 4.8 24.54 ± 4.3 
GG-OX4 (DS 33.9 %) 86.7 ± 5.1 5.12 ± 2.9 307.2 ± 7.1 77.63 ± 4.2 16.66 ± 4.4 
GG-OX4 (DS 91.2 %) 87.1 ± 4.4 4.41 ± 1.7 308.5 ± 6.6 76.79 ± 5.9 18.22 ± 3.2 
 
The chemical modification increased the Tg value, where the first derivative of the curve 
showed that the Tg of guar gum was shifted from approximately 21 oC to more than 24 oC 
after the chemical modification with n-butylglycidyl ether. An increase in Tg value perhaps is 
due to the addition of alkyl-pendant chain, leading to an increase in the bulkiness of the 
molecular structure and a decrease in mobility.15, 16 This is likely due to the presence of more 
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water in the unmodified guar gum, in which water can act as plasticiser that can lower the 
Tg.516-518 Detailed results are summarized in Table 2.7. 
 
 
Figure 2.13. DSC curve of GG-OX4 (DS 12.6 %); first run (top curve) and second run 
(bottom curve); first derivative represented as dotted line. 
 
The Tg measured in this study however is inconsistent with the ones reported in the literature; 
Banegas et al. reported Tg of guar gum to be around 12.5 oC in the investigation of the effect 
of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) cross-linking.533 
Guar gum that were cross-linked with 30 % EDC exhibited Tg of around 38 oC. Bhavya et al. 
in their study on the miscibility of guar gum/pullulan blend reported that guar gum alone has 
Tg of approximately at 55.5 oC.534 As the pullulan content increased, an increase in Tg was 
observed. This inconsistency perhaps due to the differences in solids composition that may 
come from the decomposition of the carbohydrate during processing and variations in the 
composition of raw materials that include molecular weight and water content. These will 
affect the Tg, where high molecular weight of carbohydrate will have higher Tg compared to 
the lesser ones and an increase in water content will decrease the Tg.520 
 
Table 2.7. DSC results of butylglyceryl-modified guar gum derivatives (n=3; ± SD). 
Material Glass transition, Tg (oC) Evaporation (oC) 
Unmodified guar gum 21.6 ± 1.7 96.3 ± 2.7 
GG-OX4 (DS 12.6 %) 24.4 ± 1.9 101.7 ± 3.1 
GG-OX4 (DS 33.9 %) 24.7 ± 1.2 101.8 ± 2.9 
GG-OX4 (DS 91.2 %) 25.3 ± 1.6 102.5 ± 2.9 
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Attempts to modify guar gum with n-butylglycidyl ether in aqueous acidic solution (HCl, pH 
1) using Zn(BF4)2 were performed, as described in the literature.
521, 522 Purified products 
recovered from lyophilisation were obtained as white and fluffy cotton-like compounds 
(yields 81–85 %) and analysed by 1H-NMR spectroscopy.  
 
2.3.3. Synthesis of butylglyceryl-modified pullulan derivatives 
The synthesis of butylglyceryl-modified pullulan (PUL-OX4) was achieved via a 
nucleophilic substitution reaction following a chemical reaction between pullulan and n-
butylglycidyl ether in DMSO, employing potassium tert-butoxide as a base, as well as a 
catalyst (chapter 2.2.3; Figure 2.14). The purified products of PUL-OX4, obtained as beige 
butylglyceryl pullulan (PUL-OX4) powder (yields 69–75 %) were analysed by FT-IR and 
NMR spectroscopy, therefore confirming the chemical modifications.  
 
route A
tBuOK
45 oC
route B
NaOH
45 oC
Butylglycidyl ether
R
 Figure 2.14. Synthesis of butylglyceryl-modified pullulan. 
 
According to Bataille et al., the reactivity of hydroxyl groups in pullulan follows this order; 
C2 > C4 > C6 > C3, therefore the substitution at C2 is expected to be dominant.535 The FT-IR 
spectra of unmodified pullulan and PUL-OX4 showed the main bands, which can be assigned 
as follows: 3345–3306 cm-1 (OH stretching) assigned to association due to -OH groups; 1152, 
1101, 1082 cm-1 assigned to C-O-C stretching from glycosidic linkages and O-H bending 
from alcohols.  
 
Comparison of IR spectra between unmodified pullulan, PUL-OX4 and a physical mixture of 
pullulan and BGE was presented in Figure 2.15. The bands of oxirane at 909 cm-1; assigned 
to the stretching of C-O of oxirane group, and 3050 cm-1; assigned to the stretching of C-H of 
the oxirane group,528 were recorded in the spectra of physical mixture of BGE and pullulan. 
However, the removal of these two bands in the spectra of modified pullulan indicates the 
opening of epoxy rings, thus confirming the modification. Modification of pullulan with 
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butylglyceryl chain appeared to increase the intensity in the ether band (1027 cm-1) and the 
appearance of new C-H band (attributed to asymmetric stretching vibration of -CH3 2931 cm
-
1). 
 
 
 
Figure 2.15. FT-IR spectra of; A) a physical mixture of pullulan and BGE with molar ratio of 
1 : 1 (PUL sugar unit : BGE); B) PUL-OX4 with degree of substitution 47.0 %; and C) 
unmodified pullulan. 
 
The 1H-NMR spectra of novel modified pullulan exhibited peaks at δ 0.9, δ 1.3 and δ 1.5 ppm 
which were indicative of the presence of the alkyl group (Figure 2.16). The spectra also 
showed the peaks of pullulan at δ 3.3–5.4 ppm. Examples of 13C- and 2D COSY 1H-NMR 
spectra of PUL-OX4 was shown in APPENDIX O. 
 
A) 
B) 
C) 
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Figure 2.16. 1H-NMR spectra of butylglyceryl pullulan (PUL-OX4) (synthesised in organic 
environment) in DSMO-d6 (5 mg/mL). Three sugar rings were assigned as A, B and C. 
 
The degree of substitution with butylglyceryl chain was determined based on the ratio of 
integral values of alkyl chain end CH3 group (0.9 ppm) to the sugar protons of the 
glucopyranosic ring (δ 3.3–4.0 ppm), revealed by the 1H-NMR spectra. The DS (expressed as 
the number of butylglyceryl chain attached to 100 sugar residues of pullulan (Figure 2.16); 
i.e. 100 % means only one OH group was substituted, with a maximum of 300 % when all the 
3 possible sites in each residue for the substitution were fully substituted) was calculated 
using the equation: 
 
𝐷𝑆 [%] =  
2𝐴 × 100
𝐵
         (Eq. 4) 
 
where; 
 
DS [%] Degree of substitution (the number of butylglyceryl chains attached to 100 
sugar residue of pullulan) 
A   Integral of the δ 0.9 ppm signal assigned to the alkyl chain end CH3  
group 
B   Integral of the δ 3.3–4.0 ppm signal assigned to sugar ring protons  
of the glucopyranosic ring 
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The excess of n-butylglycidyl ether (reagent) appeared to increase the degree of substitution 
of PUL-OX4 ranged from 47.0 to 77.3 %, depending on the amount of BGE reagent 
employed in the reaction (Figure 2.17). The linearity response between the degree of 
substitution and the BGE amount was obtained by plotting linear regression of degree of 
substitution (%) versus molar ratio of pullulan sugar unit and BGE (y = 4.25x + 41.1, r2 = 
0.95). Alkylation of pullulan with bromopropane and 1-bromobutane has been performed by 
Shibata et al., yielding propyl- and butyl-etherified pullulan derivatives with low degree of 
substitution ranged from 1 to 3 %.383 In another study, Souguir et al. prepared alkylated 
pullulan (with different degree of substitution ranging from 20 to 44 %) by reacting the 
polysaccharide with different alkyl bromides (C10, C12 and C16).
384  
 
  
Figure 2.17. Pullulan (sugar unit):BGE molar ratio influence on the degree of substitution 
(synthesised in organic environment) (n=3; ±SD). 
  
Analysis on the molecular weight of butylglyceryl pullulan (PUL-OX4) was performed by 
GPC and the example of GPC chromatogram was presented in APPENDIX C. Data presented 
in Table 2.8 suggested an increase in the molecular weight of PUL-OX4 when compared to 
unmodified pullulan (obtained commercially) perhaps due to the addition of the alkyl 
chain.514 As the degree of substitution increases, the molecular weight of modified pullulan 
also increased. 
 
 
 
47.0
58.5
77.3
0
10
20
30
40
50
60
70
80
90
1 : 1 1 : 5 1 : 8
D
eg
re
e 
o
f 
su
b
st
it
u
ti
o
n
 (
%
)
Pullulan (sugar unit) : BGE molar ratio
89 
 
Table 2.8. Molecular weight of butylglyceryl-modified pullulan derivatives, as determined by 
GPC (n=3; ±SD). 
Compound Mn ± SD Mw ± SD PDI ± SD 
Pullulan (Sigma, Mw ~ 100 kDa) 70321 ± 258 107174 ± 103 1.52 ± 0.13 
PUL-OX4 (DS 47.0 %) 89407 ± 222 117103 ± 259 1.31 ± 0.11 
PUL-OX4 (DS 58.5 %) 108830 ± 347 139746 ± 411 1.28 ± 0.11 
 
The decomposition curve of modified pullulan (synthesised via organic route) was presented 
in Figure 2.18. The decomposition of modified pullulan peaked at higher temperature 
compared to unmodified pullulan after the addition of butylglyceryl-pendant chain onto 
pullulan backbone. Thermal decomposition of unmodified pullulan was recorded at 288 oC, 
in a good agreement with the literature (250–295 oC).425, 536 The water content was detected 
the highest in unmodified pullulan due to its hydrophilic property as compared to PUL-OX4 
(Table 2.9). 
 
 
Figure 2.18. TGA curve of PUL-OX4 (via organic route; DS 47.0 %); DTG (first derivative) 
represented as dotted line. 
 
Table 2.9. Result of thermogravimetric analyses of butylglyceryl-modified pullulan 
derivatives (organic route) (n=3; ± SD). 
Material Water evaporation Decomposition Residue 
(%) DTG Peak 
(oC) 
Mass loss  
(%) 
DTG Peak 
(oC) 
Mass loss  
(%) 
Unmodified pullulan 80.9 ± 7.4 6.52 ± 1.6 288.5 ± 3.3 77.17 ± 6.2 16.03 ± 2.4 
PUL-OX4 (DS 47.0 %) 82.2 ± 6.9 5.65 ± 1.7 305.3 ± 2.9 71.70 ± 5.9 22.18 ± 3.1 
PUL-OX4 (DS 58.5 %) 85.6 ± 6.1 2.52 ± 1.2 343.0 ± 5.9 83.28 ± 8.1 13.85 ± 3.7 
PUL-OX4 (DS 77.3 %) 88.8 ± 7.4 1.22 ± 0.8 359.6 ± 7.2 87.18 ± 3.8 11.14 ± 2.0 
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Examples of PUL-OX4 DSC thermogram and detailed data are presented in Figure 2.19 and 
Table 2.10, respectively. Unmodified pullulan exhibited the lowest Tg as compared to PUL-
OX4 and as the DS of PUL-OX4 derivatives went higher, the Tg became lesser. The Tg of 
pullulan was shifted from ca. 21 (unmodified pullulan) to be as high as 28 oC (for the highest 
degree of substitution, 77.3 %). This is possibly due to a decrease in mobility of the PUL-
OX4 molecular structure after the attachment of alkyl-pendant chain.15, 16 In addition, 
moisture content of the materials, in which can act as plasticiser also perhaps may lower 
down the glass transition temperature (Tg).516-518 The higher the water content, the lesser the 
Tg value became.  
 
 
Figure 2.19. DSC thermogram of PUL-OX4 (via organic route; DS 47.0 %); first run (top 
curve) and second run (bottom curve); first derivative represented as dotted line. 
 
A number of literature reported different values for pullulan glass transition. Scandola et al. 
in their study investigated the Tg of several polysaccharides such as dextran, pullulan and 
amylose, where the results illustrated that no Tg was seen for either pullulan or amylose; only 
dextran showed Tg at 223 oC.537 A range of pullulan Tg was reported by Biliaderis et al. from 
-10 to 100 oC, depending on the moisture content ranged from 7.8 to 24.6 %.538 The higher 
the moisture content, the lower the Tg owing to water that acts as a plasticiser. This 
inconsistency perhaps due to the differences in solids composition that may come from the 
decomposition of the carbohydrate during processing and variations in the composition of 
raw materials that include molecular weight and water content, in which will affect the Tg of 
the carbohydrate 
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Table 2.10. DSC results of butylglyceryl-modified pullulan derivatives modified via organic 
route (n=3; ± SD). 
Material Glass transition, Tg (oC) Evaporation (oC) 
Unmodified pullulan 21.3 ± 1.1 81.0 ± 5.1 
PUL-OX4 (DS 47.0 %) 22.9 ± 1.9 85.8 ± 3.1 
PUL-OX4 (DS 58.5 %) 24.8 ± 1.0 86.2 ± 3.3 
PUL-OX4 (DS 77.3 %) 28.3 ± 1.3 85.8 ± 3.8 
 
Chemical modifications of pullulan with n-butylglycidyl ether were also performed in strong 
aqueous alkaline condition (NaOH, pH 14; Figure 2.14). The investigation was done owing 
to fact that native pullulan is soluble in both DMSO and aqueous solvents. The chemical 
modifications of PUL-OX4, obtained as white and fluffy cotton-like materials (yields 81–84 
%), were confirmed by 1H-NMR spectroscopy. 
 
In the 1H-NMR spectra of PUL-OX4, the signals of pullulan were recorded in the range δ 
3.3–5.4 ppm and peaks appeared at δ 0.9, δ 1.3 and δ 1.5 ppm were suggestive of the 
presence of the alkyl group (Figure 2.20). An example of 13C- NMR spectra of PUL-OX4 
was shown in APPENDIX O.  
 
 
 
 
Figure 2.20. 1H-NMR spectra of butylglyceryl pullulan (PUL-OX4) (synthesised in aqueous 
environment) in DMSO-d6 (5 mg/mL). Three sugar rings were assigned as A, B and C. 
 
The degree of substitution of PUL-OX4 synthesised via this aqueous route was determined 
using the same equation (Eq. 4) employed by the synthesis of PUL-OX4 in organic 
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environment. The influence of reagent (n-butylglycidyl ether) concentration on the degree of 
substitution was investigated. As evidenced by the results, the degree of substitution increases 
with the excess of n-butylglycidyl ether reagent (Figure 2.21).  
 
  
Figure 2.21. The influence of molar ratio pullulan : BGE on the degree of substitution 
(synthesised in aqueous environment) (n=3; ±SD). 
 
Linear regression was employed to investigate the linear relationship between the molar ratio 
(pullulan sugar unit : BGE) and the degree of substitution (%), as presented in Figure 2.22 (y 
= 1.98x + 7.80, r2 = 0.93). The calculated degree of substitution was found to be linearly 
proportional to the molar ratio, suggesting that the pullulan was probably capable of taking in 
higher molar ratio than were tested to produce PUL-OX4 with higher DS. 
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Figure 2.22. Linear regression of the influence of pullulan sugar unit : BGE molar ratio on 
the degree of substitution of butylglyceryl pullulan (PUL-OX4) (n=3; ±SD). 
 
The degree of substitution of PUL-OX4 synthesised via 2 different routes; organic and 
aqueous was compared and presented in Table 2.11. By comparing the two different 
environments, the modifications that were done in organic environment demonstrated higher 
degree of substitution. This is probably based on the strength of base employed in the 
reaction. Potassium tert-butoxide is a stronger base than NaOH, thus increase the reactivity of 
alcoholates to react with the opened-ring oxirane.539 Another possible explanation may lie in 
the presence of water that hindered the reaction between the butylglycerols and the polymer 
due to the property of water that could act as a nucleophile,540 thus making itself feasible to 
react with the polymer.  
 
Table 2.11. Degree of substitution of butylglyceryl pullulan derivatives synthesised in DMSO 
and aqueous environments (n=3; ±SD). 
PUL (sugar unit): BGE 
molar ratio 
Degree of substitution (%) 
In water In DMSO 
1 : 1  5.8 ± 3.4 47.0 ± 5.7 
1 : 5 12.6 ± 4.1 58.5 ± 5.5 
1 : 8 33.8 ± 4.8 77.3 ± 6.4 
 
Thermogravimetric study of PUL-OX4 synthesised via aqueous route presented in Figure 
2.23 showed that PUL-OX4 has higher decomposition temperature compared to unmodified 
pullulan and as the DS increased, the decomposition temperature also increased. The 
0
10
20
30
40
50
60
70
80
0 5 10 15 20 25 30 35
D
eg
re
e 
o
f 
su
b
st
it
u
ti
o
n
 (
%
)
Pullulan (sugar unit) : BGE molar ratio
94 
 
unmodified pullulan possessed higher water content, with value 7.88 %, compared to 
modified pullulan (Table 2.12).  
 
 
Figure 2.23. TGA curve of PUL-OX4 (via aqueous route; DS 33.8 %); DTG (first derivative) 
represented as dotted line. 
 
Table 2.12. Result of thermogravimetric analyses of butylglyceryl-modified pullulan 
derivatives (aqueous route) (n=3; ± SD). 
Material Water evaporation Decomposition Residue (%) 
Peak (oC) Mass loss (%) Peak (oC) Mass loss (%) 
Unmodified pullulan 80.9 ± 4.4 6.52 ± 1.9 288.5 ± 3.2 77.17 ± 6.8 16.03 ± 2.0 
PUL-OX4 (DS 5.8 %) 102.3 ± 4.8 5.32 ± 1.4 340.5 ± 4.9 78.02 ± 4.1 16.18 ± 2.1 
PUL-OX4 (DS 12.6 %) 104.5 ± 7.7 3.59 ± 0.9 349.2 ± 5.2 85.50 ± 5.9 10.55 ± 1.4 
PUL-OX4 (DS 33.8 %) 108.8 ± 5.1 2.93 ± 1.0 358.8 ± 3.6 88.67 ± 7.8 7.81 ± 1.7 
 
The Tg of PUL-OX4 was influenced by the degree of substitution, as presented in Figure 
2.24. The higher the DS of PUL-OX4, the higher the glass transition of the polymer. This 
could possibly be explained by the addition of alkyl-pendant chain that may increase 
molecular structure bulkiness, hence decrease its mobility.15, 16 The presence of moisture that 
can act as plasticiser also may reduce the Tg.516-518 The  unmodified pullulan possessed Tg 
around 21 oC, however the value increased up to ca. 30 oC for the highest DS of modified 
pullulan (DS 11.26 %). Detailed results are presented in Table 2.13. 
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Figure 2.24. DSC thermogram of PUL-OX4 (via aqueous route; DS 12.6 %); first derivative 
represented as dotted line. 
 
Table 2.13. DSC results of butylglyceryl-modified pullulan derivatives modified via aqueous 
route (n=3; ± SD). 
Material Glass transition, Tg (oC) Evaporation (oC) 
Unmodified pullulan 21.3 ± 0.8 81.0 ± 1.9 
PUL-OX4 (DS 5.8 %) 24.9 ± 0.7 83.7 ± 2.2 
PUL-OX4 (DS 12.6 %) 26.7 ± 1.1 93.7 ± 2.0 
PUL-OX4 (DS 33.8 %) 30.1 ± 1.2 94.8 ± 2.3 
 
As mentioned earlier, several literature reported Tg values that are different from what were 
measured in this study. Scandola et al.537 reported no Tg was found for pullulan while 
Biliaderis et al. in their study mentioned that the Tg for pullulan varies from -10 to 100 oC.538 
This is likely due to the differences in solids composition that may originate from the 
decomposition of the carbohydrate during processing and variations in the composition of 
raw materials that include molecular weight and water content, in which will affect the Tg of 
the carbohydrate.520 
 
2.3.4. Synthesis of butylglyceryl-modified chitosan derivatives 
Chemical modification of chitosan with n-butylglycidyl ether was done starting from the 
protection of free amino groups by phthaloyl groups followed by the attachment of 
butylglyceryl pendant chain to the available polysaccharidic hydroxyl groups prior to the 
deprotection of the amino groups by hydrazine (chapter 2.2.4). According to Cirillo et al., 
chitosan reactivity is based on three reactive groups; a free amino group at C2, primary OH at 
C6 and secondary OH at C3.541, 542 Majority of chemical reaction will proceed at amino group, 
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however it is possible to do modification involving hydroxyl groups and it was reported that 
hydroxyl groups at C6 is more reactive than at C3.543 
 
Step 1. Protection of amino groups by phthaloylation 
 
Phthalic anhydride
 DMF
136 oC
 
Figure 2.25. Synthesis of phthaloylated chitosan. 
 
The synthesis of butylglyceryl chitosan started with protecting the primary amino groups of 
chitosan by phthaloylation. Amino group is more reactive than hydroxyl group and is useful 
for the formulation of chitosan into nanoparticles with sodium tripolyphosphate.541, 544, 545 To 
prevent the amino group from reacting with n-butylglycidyl ether, protection by phthaloyl 
group was performed,546 which was done by the treatment of chitosan with phthalic 
anhydride in DMF (Figure 2.25). The solubility of the product in polar organic such as DMF 
and DMSO was improved. The 1H-NMR spectra of the product (Figure 2.26) showed the 
presence of chitosan pyranose signal (δ 3.0–5.1 ppm) and phthaloyl aromatic ring signal (δ 
7.4–7.9 ppm). The phthaloylated chitosan was obtained as beige compounds with yields of 
67–73 %. The synthesis protocol was adapted from the literature, in which the degree of 
phthaloylation was reported to be 100 %, therefore providing a full protection of the amine.546 
An example of 13C-NMR spectra of phthaloylated chitosan was shown in APPENDIX P. 
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Figure 2.26. 1H-NMR spectra of phthaloylated chitosan (PH-CS) in DMSO-d6 (5 mg/mL).  
 
Step 2. Addition of n-butylglycidyl ether 
 
R
ButylGlycidyl Ether
tBuOK
 DMF
 
Figure 2.27. Synthesis of butylglyceryl-modified phthaloylated chitosan (5 mg/mL). 
 
The attachment of butylglyceryl-pendant chain into the phthaloylated chitosan was achieved 
via a nucleophilic substitution reaction (Figure 2.27). The chemical modifications were 
confirmed by 1H-NMR (Figure 2.28). In addition to signals from hydrogens of the 
polysaccharidic units of chitosan (δ 2.8–4.3 ppm), the presence of alkyl hydrogen atoms 
signals at approximately δ 0.9, 1.3 and δ 1.5 ppm were also observed, therefore confirming 
the chemical modifications with n-butylglycidyl ether, yielding phthaloylated butylglyceryl-
modified chitosan. The products were obtained as light brown powders (yields 63–69 %). An 
example of 13C-NMR spectra of butylglyceryl-modified phthaloylated chitosan was shown in 
APPENDIX Q. 
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Figure 2.28. 1H-NMR spectra of phthaloylated butylglyceryl chitosan (PH-CS-OX4) in 
DMSO-d6 (5 mg/mL). 
 
Step 3. Deprotection of amino groups 
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Figure 2.29. Synthesis of butylglyceryl-modified chitosan (5 mg/mL). 
 
The final step of butylglyceryl chitosan (CS-OX4) synthesis involved the removal of the 
phthaloyl group from phthaloylated butylglyceryl-modified chitosan, achieved via chemical 
reaction with hydrazine monohydrate in water at 100 oC for 15 h (Figure 2.29). The removal 
of the phthaloyl group was confirmed by 1H-NMR, where the disappearance of the signals 
from phthalimido group (δ 7.1–7.9 ppm) was observed. The signals from alkyl chain (δ 0.9, δ 
1.3 and δ 1.5 ppm) and the aminoglycosidic ring (δ 2.8–4.3 ppm) were also confirmed and 
presented in the spectra (Figure 2.30). The final products that recovered from lyophilisation 
were obtained as white-off powders with yields of 58–65 %. Examples of 13C- and 2D COSY 
1H-NMR spectra of butylglyceryl-modified chitosan was shown in APPENDIX R. 
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Figure 2.30. 1H-NMR spectra of butylglyceryl chitosan (CS-OX4) in 2 % DCl in D2O (5 
mg/mL). 
 
In order to calculate the degree of substitution (DS) of chitosan, the degree of deacetylation 
(DDA) of chitosan was calculated. from 1H-NMR spectra based on the ratio of peak integrals 
using the signals correlated to CH1 (assigned as Hb; δ 4.9 ppm) and to terminal CH3 group of 
deacetylated chitosan (δ 2.1 ppm), using the equation: 
 
𝐷𝐷𝐴 (%) =  (
𝐻𝑏
𝐻𝑏+𝐻 𝐶𝐻3 3⁄
) × 100       (Eq. 5) 
 
The degree of substitution of chitosan with n-butylglycidyl ether then was worked out based 
on the DDA of chitosan, as well as the integral value of the signals from the terminal methyl 
group (CH3) of the alkyl chain (assigned as Hy; δ 0.9 ppm) and the methyl group (CH3) of the 
acetylated chitosan (δ 2.1 ppm), using the equation:  
 
𝐷𝑆 (%) =  (
3 𝐻𝑦 ×(100−𝐷𝐷𝐴)
𝐻 𝐶𝐻3
)        (Eq. 6) 
 
The results were presented in Figure 2.31, where the degree of substitution appeared to be 
influenced by the molar ratio between chitosan (CS) sugar unit and oxirane (OX4) in a 
directly proportional manner (y = 5.22x + 7.53, r2 = 0.97; obtained by linear regression of 
degree of substitution (%) versus molar ratio of chitosan sugar unit and BGE). Toman et al. 
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synthesised butylglyceryl-modified chitosan for brain delivery with degree of substitution of 
88 %,287 while Liu et al. in the study about the synthesis of N-octyl chitosan, yielded the 
product with the degree of substitution of 54.3 %.547   
 
Figure 2.31. The effect of chitosan : BGE molar ratio on the degree of substitution  
(n=3; ±SD). 
 
The FT-IR spectra of butylglyceryl chitosan (CS-OX4) recorded the presence of important 
signals corresponding to amino group band approximately around 1651 cm-1 and signals at 
1162 cm-1 for the anti-symmetric stretching of C-O-C. Comparison of FT-IR spectra between 
unmodified chitosan, butylglyceryl chitosan (CS-OX4) and a physical mixture of chitosan 
and n-butylglycidyl ether were presented in Figure 2.32. An increase in intensity in the ether 
band around 1068 cm-1 of CS-OX4 when compared to the unmodified chitosan was observed 
and the appearance of new C-H band around 2920 cm-1 was also recorded. The FT-IR spectra 
of a physical mixture between chitosan and n-butylglycidyl ether showed the presence of 
oxirane, which was recorded at 3050 cm-1 and 906 cm-1, as suggested in the literature.528 
These bands were not found in the spectra of CS-OX4, suggesting perhaps that all oxirane 
rings has been opened in order to react with chitosan and no excess of unreacted oxirane left 
in the CS-OX4.529 
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Figure 2.32. FT-IR spectra of; A) a physical mixture of chitosan and BGE; B) unmodified 
chitosan; and C) CS-OX4 with degree of substitution 14.1 %. 
 
Figure 2.33 presented the thermogravimetric curve of CS-OX4 (DS 14.1 %). Mass loss was 
determined by this technique, where it can be observed at 83.1 (evaporation) and 301.4 oC 
(decomposition), as shown clearly in the first derivative (dotted line) of the curve. Detailed 
results in Table 2.14 showed that unmodified chitosan possessed higher water content 
compared to modified chitosan, having the value of 9.60 %. This is in parallel to the effect of 
the chemical modification, where an increase in the hydrophobicity of the modified chitosan 
is expected. The decomposition temperature of unmodified chitosan was recorded lower than 
CS-OX4, approximately at 286 oC, in accordance with the literature (in the range of 230 to 
327 oC).548 
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Figure 2.33. TGA thermogram of CS-OX4 (DS 14.1 %); DTG (first derivative) represented as 
dotted line. 
 
Table 2.14. Result of thermogravimetric analyses of butylglyceryl-modified chitosan 
derivatives (n=3; ± SD). 
Material Water evaporation Decomposition Residue (%) 
DTG Peak 
(oC) 
Mass loss  
(%) 
DTG Peak 
(oC) 
Mass loss  
(%) 
Unmodified chitosan 80.2 ± 3.5 9.60 ± 2.4 286.6 ± 8.4 51.56 ± 6.6 38.43 ± 4.7 
CS-OX4 (DS 14.1 %) 83.1 ± 2.9 4.89 ± 1.7 301.4 ± 7.2 66.67 ± 5.0 28.04 ± 4.0 
CS-OX4 (DS 30.5 %) 85.7 ± 4.1 4.24 ± 1.3 314.6 ± 5.6 64.33 ± 4.2 30.78 ± 6.1 
 
The glass transition of CS-OX4 increased as the degree of substitution increased (presented 
in Figure 2.34), potentially owing to the addition of alkyl-pendant chain that may increase 
molecular structure bulkiness, therefore leading to a decrease in mobility.15, 16 Water content 
that presents in the materials may also act as plasticiser and decrease the Tg516-518; the higher 
the water content, the lower the Tg value. The unmodified chitosan recorded Tg around 24 
oC, while for the modified chitosan, the number recorded was more than 25 oC. Detailed 
results are presented in Table 2.15. 
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Figure 2.34. DSC curve of CS-OX4 (DS 14.1 %); first derivative represented as dotted line. 
 
Table 2.15. DSC results of butylglyceryl-modified chitosan derivatives (n=3; ± SD). 
Material Glass transition, Tg (oC) Evaporation (oC) 
Unmodified chitosan 24.3 ± 1.0 100.6 ± 2.4 
CS-OX4 (DS 14.1 %) 25.2 ± 0.7 94.4 ± 7.2 
CS-OX4 (DS 30.5 %) 25.8 ± 1.4 75.4 ± 4.9 
 
The Tg values reported in the literature is however different from the ones measured in this 
study, in which possibly due to variations in the compositions of carbohydrate raw materials 
that may originate from the production process.520 Mucha studied the thermal behaviour of 
chitosan and its blends with polyvinyl alcohol (PVAL) and hydroxypropylcellulose (HPC). 
The Tg values of pure chitosan were recorded in the range of 110–140 oC and increased to 
170–180 oC when chitosan is blended with PVAL and HPC.549 In another study, no Tg values 
for chitosan were reported in the investigation on the use of DSC to determine the degree of 
acetylation in chitosan, as mentioned by Guinesi et al.550  
 
2.4. Conclusions 
Possessing potential features such as biocompatibility, biodegradability, good drug carrier 
properties and ease of chemical modification, polysaccharides such as pectin, guar gum, 
pullulan and chitosan were selected as starting materials for the chemical modifications with 
short chain alkylglyceryl-like moieties (n-butylglycidyl ether). This particular chemical 
modification was rationalised by the hypothesis that short chain alkylglycerols could promote 
drug permeability towards the brain.64, 80, 89, 207, 359 Besides, the chemical modifications with 
alkylglycerols may enhance the lipophilicity of the polysaccharides, in which may increase 
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the possibility to enter the brain via passive transcellular pathway by lipid-mediated 
diffusion, as suggested by the literature.45, 47, 551 
 
Butylglyceryl-modified pectin derivatives were synthesised by reacting commercially 
available low esterified pectin with n-butylglycidyl ether in a strong aqueous alkaline (NaOH, 
pH 12) system. Several different molar ratios pectin : reagent were used to evaluate the effect 
towards the degree of substitution of the modified pectin (P-OX4). The resulting products 
were purified by DCM washing, dialysis and lyophilisation, yielding butyglyceryl pectin 
(yields 85–88 %), which were then confirmed by 1H-, 13C- and 2D COSY NMR, as well as 
FT-IR spectroscopy. 1H-NMR spectroscopy was employed to calculate the degree of 
substitution of P-OX4 derivatives, which was found to be in the range of 7.5–21.6 %. The 
modified pectin derivatives were also analysed for the changes in molecular weight by Gel 
Permeation Chromatography. The results indicated an increase in the molecular weight of P-
OX4 derivatives (MW 29.1 and 32.5 kDa for 7.5 % and 9.3 % degree of substitution, 
respectively) compared to the starting materials (MW 25.0 kDa), suggesting the successful 
attachment of butylglyceryl-pendant chain to pectin.  
 
Thermal analysis of the materials was done to determine the thermal stabilities. The 
decomposition temperature of the starting materials increased from 215.4 to 245.5 oC (P-OX4 
DS 9.3 %), as well as the glass transition temperature from 22.4 to 24.7 (P-OX4 DS 9.3 %) 
following the modification. Butylglyceryl pectin contained less water (10.72 %) compared to 
starting material (16.32 %) as a result of the chemical modification that is expected to 
increase the hydrophobicity of the materials, as suggested by the literature.552 An attempt to 
synthesise P-OX4 using Zn(BF4)2 as a catalyst in an aqueous acidic environment was also 
performed,522 however the reaction was unsuccessful to produce butylglyceryl-modified 
pectin as compared to using aqueous alkaline environment. 
 
Similar to modified pectin, butylglyceryl-modified guar gum derivatives were prepared by 
reacting commercially available guar gum with n-butylglycidyl ether under alkaline condition 
(NaOH, pH 12) in aqueous conditions. The products were purified by washing with DCM, 
followed by dialysis and freeze-drying, affording butyglyceryl guar gum (yields 86–88 %, 
relatively similar to P-OX4), which were then identified by FT-IR, 1H-, 13C- and 2D COSY 
NMR spectroscopy. The degree of substitution determined by 1H-NMR spectroscopy was 
found higher than P-OX4 (7.5 and 9.3 %), in the range of 3.6–133.2 %. Changes in molecular 
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weight of the starting material was determined by Gel Permeation Chromatography where an 
increase from 285.7 kDa (for unmodified guar gum) to 331.6 kDa (for GG-OX4 DS 91.2 %) 
was observed, suggesting the successful attachment of the butylglyceryl-pendant chain to the 
guar gum backbone.  
 
The products were also investigated for their thermal stabilities using TGA and DSC 
instruments. Identical to P-OX4, an increase in decomposition temperature was recorded for 
modified guar gum (308.5 oC for GG-OX4 DS 91.2 %) compared to unmodified guar gum 
(289.0 oC), as well as glass transition temperature (from 21.6 to 25.3 oC). As expected, GG-
OX4 derivatives recorded water content (ca. 4–6 %) lower than unmodified guar gum (ca. 
9.50 %) due to increase in hydrophobicity.552 Similar to the results obtained from pectin, 
employing a different system where Zn(BF4)2 was used as a catalyst in an aqueous acidic 
system, as suggested in the literature,522 was unsuccessful to afford butylglyceryl-modified 
guar gum. 
 
To synthesise butylglyceryl-modified pullulan derivatives, reaction between commercially 
available pullulan and n-butylglycidyl ether were performed in two approaches; either in the 
presence of a strong base (potassium tert-butoxide) in anhydrous DMSO or in alkaline 
aqueous system (employing NaOH, pH 12, as performed with pectin and guar gum). The 
products were purified by washing with diethyl ether, dialysis and freeze-drying, affording 
butyglyceryl pullulan (yields 69–84 %), which were identified by FT-IR, 1H-, 13C- and 2D 
COSY NMR spectroscopy. The degree of substitution varies depending on the chemical 
mechanism, where for organic route, 47.0–77.3 % DS was recorded while for aqueous route, 
the DS was lower, in the range of 5.8–64.4 %, as determined by 1H-NMR spectroscopy, 
which is likely due to stronger base of potassium tert-butoxide (in organic) as compared to 
NaOH (in aqueous), leading to higher reactivity of alcoholates towards the reaction with 
opened-ring oxirane.539 
 
Thermal stability was studied; an increase for decomposition from 288.5 to 359.6 oC and Tg 
from 21.3 to 28.3 oC was observed for PUL-OX4 DS 77.3 % (synthesised in organic). Similar 
trend was found for PUL-OX4 derivatives that were synthesised in aqueous route (DS 64.4 
%), where an increase in thermal decomposition from 288.5 to 358.8 oC and glass transition 
from 21.3 to 30.1 oC was observed. As expected, water content was found higher in 
unmodified pullulan (ca. 6 %) compared to modified pullulan (ca. 1 %). Similar to P-OX4 
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and GG-OX4, butylglyceryl pullulan derivatives showed an increase in the molecular weight 
from 107.2 kDa to 117.1 kDa (PUL-OX4 DS 47.0 %) and 139.7 kDa (PUL-OX4 DS 58.5 %). 
 
Butylglyceryl-modified chitosan derivatives were synthesised following a three-step reaction 
mechanism: protection of amino group by phthaloylation by the treatment of chitosan with 
phthalic anhydride yielding phthaloyl chitosan (which also increased the solubility in organic 
solvents), followed by treatment with n-butylglycidyl ether yielding butylglyceryl-phtaloyl 
chitosan, which was then eventually deprotected by removing the phthaloyl groups by 
treatment with hydrazine monohydrate. Amino groups possess higher reactivity when 
compared to hydroxyl groups, therefore to avoid the attachment of butylglyceryl-pendant 
chain to happen at amino site, protection by phthaloylation is needed.553 The CS-OX4 
resulted in lower yield (only 58–65 %) as compared to P-OX4 (85–88 %), GG-OX4 (86–88 
%) and PUL-OX4 (69–84 %). The final products (butylglyceryl chitosan, CS-OX4) were 
analysed by FT-IR spectroscopy, 1H-, 13C- and 2D COSY NMR spectroscopy. As determined 
by 1H-NMR spectroscopy, the degree of substitution was in the range 14.1-51.1 %. Thermal 
analysis was performed to investigate the thermal stabilities of the products, where an 
increase in decomposition temperature was recorded in the products (314.6 oC with DS 30.5 
%) compared to the starting material (286.6 oC). The glass transition also increased from 24.3 
oC (starting material) to 25.8 oC (DS 30.5 %). 
 
 
 
 
107 
 
3 
 
FORMULATION AND CHARACTERISATION OF NANOPARTICLES 
 
The formulation of nanoparticles from butylglyceryl-modified polysaccharides was carried 
out using a range of techniques including nanoprecipitation, ionotropic cross-linking, and 
reverse emulsification; the resulting nanoparticles were then characterised for their 
hydrodynamic size, zeta potential and stability at different pH conditions, and further 
investigated for their potential as drug carriers using model actives.  
 
3.1. Materials and instrumentation 
Sodium trimetaphosphate (STMP), sodium tripolyphosphate (TPP), sodium hydroxide 
(NaOH), sorbitan monooleate 80 (Span 80), glycerol (reagent grade ≥ 99.5 %), 
glutaraldehyde (25 % in H2O; cat. no. G6257), Rhodamine B base (Dye content 97 %; cat no. 
234141), and Angiotensin II human (HPLC grade ≥ 93 %; cat. no.A9525) were obtained 
from Sigma Aldrich, Gillingham, UK. Doxorubicin hydrochloride (cat. no. AD15377) was 
obtained from Carbosynth, Compton, UK. Texas Red-X succinimidyl ester (mixed isomers; 
cat. no. T6134) and Texas Red-X dichlorotriazine (cat. no. T30200) were sourced from 
Invitrogen, Life Technologies Ltd., Paisley, UK. Solvents such as acetone, acetic acid, 
DMSO, DCM, methanol and propanol were purchased from Fisher Scientific, Loughborough, 
UK and used without any further purification. 
 
An X3 ultracentrifuge (Beckman Coulter, High Wycombe, UK) equipped with a Ti 70.1 rotor 
was employed for the separation of nanoparticles, which was performed at 20 °C under 
vacuum (40,000 rpm; 164,391 g; 30 min, unless stated otherwise). A Jouan B4i centrifuge 
with S40 rotor and Eppendorf MiniSpin centrifuge with F-45-12-11 rotor were used for low 
speed centrifugation. A Grant ultrasonic bath XB3 (Grant Instruments, Cambridge, UK) was 
used for the redispersion of nanoparticles by sonication. Deionised water was sourced from 
PURELAB Optima lab system. Dialysis was carried out using Visking dialysis tubing 
(Medicell International Ltd., London, UK) with cut-off either 12–14 kDa or 3.5kDa. Aqueous 
samples were lyophilised using a VirTis SP Scientific Sentry 2.0 freeze drier (Genevac Ltd., 
Ipswich, UK) connected to an Oerlikon Leybold vacuum pump. Removal of volatile organic 
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solventswas performed under reduced pressure using a Büchi Rotavapor R-200 attached to a 
Sogevac Saskia PIZ 100 vacuum pump equipped with a liquid nitrogen cold trap. 0.2 and 
0.45 µm Nylon membrane filters and PTFE membrane filters were purchased from Pall Life 
Sciences, Poole, UK. 
 
The hydrodynamic diameter of nanoparticles was determined by dynamic light scattering 
(DLS) using a Malvern ZetasizerNano ZS instrument equipped with a 633 nm He-Ne laser; 
measurements were performed using a scattering angle of 173° (Malvern Instruments, 
Malvern, UK). Samples were analysed in triplicate at 25 °C and the results were expressed as 
Z-average mean (Z-av.) and polydispersity index (PDI). Electrophoretic mobility (EPM) 
measurements were conducted using the same instrument to determine the zeta potential (ZP) 
of nanoparticles. Automatic titrations with aqueous NaOH and HCl solutions were carried out 
in order to investigate the stability of the nanoparticles at varying pH values; experiments 
were performed in triplicate, employing an MPT-2 instrument (Multi Purpose Titrator-2, 
Malvern Instruments, Malvern, UK) equipped with a solvent degasser. In addition, the size of 
nanoparticles was also analysed by Nanoparticle Tracking Analysis (NTA) at 25 °C using a 
NanoSight LM-14 (Malvern Instruments, Malvern, UK) instrument equipped with a CCD 
Marlin camera unit and a 532 nm green laser.  
 
Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) were 
employed to investigate the morphology of nanoparticles. To prepare samples for SEM, dried 
nanoparticles were redispersed in ultrapure water and a droplet was deposited onto a metallic 
stub and dried prior to be coated with gold alloy in argon atmosphere using a Q150RES 
sputter coater equipment (Quorum Technologies Ltd., Ashford, UK). Samples were observed 
using a JEOL-JSM-6060LV SEM Microscope (JEOL, Tokyo, Japan). For TEM, a droplet of 
nanoparticles suspension was placed onto the surface of a TEM grid (copper grid, 3.0 mm, 
200 mesh, coated with Formvar film), stained with 2 % (w/v) uranyl acetate staining solution 
and allowed to dry at room temperature. The analysis of the stained grids was conducted with 
a JEOL JEM 2100 TEM Microscope equipped with AMT digital camera (JEOL, Tokyo, 
Japan). 
 
Drug release studies were performed using a linear shaking thermostatic bath Grant GLS 
Aqua 12 Plus (Grant Instruments, Cambridge, UK). UV/Vis spectroscopy measurements 
were performed employing a Lambda 650 Ultra Violet/Visible Spectrometer (Perkin Elmer, 
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Buckinghamshire, UK). High-performance liquid chromatography (HPLC) analysis was 
performed using an Agilent 1100 series HPLC system equipped with a G1311A quat pump, a 
G1313A ALS autosampler, a G1379A degasser and a photo diode array detector (280 nm). A 
C18 reversed phase column (250 mm x 4.6 mm, 5 µm particle size) was connected to a guard 
column (45 mm x 4.6 mm). The column temperature was set at 25 oC. The mobile phase 
consisted of a mixture of water (0.1 % v/v TFA) and acetonitrile (0.1 % v/v TFA), with 
gradient elution from 10 to 60 % acetonitrile over 16 min at a flow rate of 0.7 mL/min. The 
mobile phase was filtered through a 0.45 µm PTFE membrane and degassed by sonication 
prior to use.  
 
The statistical analysis was performed using IBM SPSS Statistics Version 22 software (SPSS 
Inc., Chicago, IL, USA). Results were expressed as mean ± standard deviation (SD) values; 
to determine statistical significance, p values were set at 0.05, unless stated otherwise. 
 
3.2. Methods 
3.2.1. Formulation of nanoparticles from butylglyceryl-modified guar gum derivatives 
A. Nanoprecipitation 
A solution of butylglyceryl-modified guar gum; GG-OX4 (various degree of substitution; 
concentration either 1, 4, 7 mg/mL;) in ultrapure water (2 mL) was filtered through a 0.2 µm 
nylon membrane Whatman syringe filter and added dropwise into either propanol or 
methanol (6 mL) under vigorous stirring. After addition, the mixture was stirred for another 
30 min, dialysed (MWCO 12 kDa) for 72 h against deionised water (10 L; exchanged 3 times 
per day) and finally lyophilised (flash freezing in liquid N2). The materials, obtained as a 
white and fluffy cotton-like compound (yields 75–80 %), were redispersed (0.5 mg/mL) in 
either ultrapure water or PBS (0.9 % NaCl; pH 7.4) and analysed. 
 
B. Covalent cross-linking with sodium trimetaphosphate (STMP) 
A solution of sodium trimetaphosphate (0.2, 1, 6 mg/mL; various degree of substitution) in 
deionized water (2 mL) was added dropwise (1 mL/min) into a butylglyceryl-modified guar 
gum; GG-OX4 solution (2.5 mg/mL) in deionised water (10 mL), which was made alkaline 
(pH 12) after the addition by means of NaOH (2M). Both solutions were previously filtered 
through a 0.2 µm nylon membrane Whatman syringe filter prior to use. The reaction mixture 
was stirred for 16 h, then it was neutralised with HCl (10 % v/v), centrifuged (Jouan B4i, 
4,000 rpm; 2,880 g; 5 min), and the supernatant was dialysed (MWCO 12 kDa) for 72 h 
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against deionised water (10 L; exchanged 3 times per day) and then lyophilised (flash 
freezing in liquid N2). The products, obtained as a white and fluffy cotton-like material 
(yields 74–83 %), were redispersed (0.5 mg/mL) in either ultrapure water or PBS (0.9 % 
NaCl; pH 7.4) for analysis as nanoformulation using dynamic light scattering (DLS), 
nanoparticle tracking analysis (NTA) and electrophoretic mobility (EPM). 
 
C. Reverse emulsification 
Guar gum nanoparticles were formulated using an oil-in-water emulsion method combined 
with in situ polymer cross-linking. Dropwise addition of Span 80 (0.4 g) under stirring into 
DCM (3.33 mL) formed the non-aqueous phase, which was introduced dropwise into a 
butylglyceryl-modified guar gum; GG-OX4 solution (10 mL) of concentration either 0.5, 1, 
or 2 % w/v (different degree of substitution, as specified) under constant magnetic stirring. 
Glycerol (1 mL) was added as stabiliser, followed by the addition of glutaraldehyde (1 mL; 3 
% v/v) under continuous stirring, to initiate the cross-linking process. The mixture was left 
stirring overnight for completion, then it was centrifuged (Beckman, 70.1 Ti rotor; 40,000 
rpm; 164,391 g; 30 min) and washed with deionised water three times. The resulting 
nanoparticles were freeze-dried (flash freezing in liquid N2) affording the nanoparticles as a 
white powder (yields 55–65 %), which was then redispersed (0.5 mg/mL) in either ultrapure 
water or PBS (0.9 % NaCl; pH 7.4) for characterisation. 
 
The stability of nanoparticles formulated from GG-OX4 was investigated at varying pH 
values, ranging from 3 to 8.5. The nanoparticles were redispersed in ultrapure water (0.5 
mg/mL) and the pH was adjusted to 8.5 with NaOH solution (0.005 M), then titrated 
automatically with HCl (0.05 M) from pH 8.5 to pH 3 using an MPT-2 Malvern instrument 
equipped with a solvent degasser; both diameter and zeta potential were measured at 0.5 pH 
increments). 
 
3.2.2. Formulation of nanoparticles from butylglyceryl-modified pullulan derivatives 
A. Nanoprecipitation 
Butylglyceryl-modified pullulan; PUL-OX4 was dissolved in DMSO (2 mL) at varying 
concentrations (1; 5; 10 mg/mL), the solution was filtered through a 0.2 µm nylon membrane 
Whatman syringe filter and then added to ultrapure water (8 mL) as dispersing phase by 
using a syringe, under vigorous magnetic stirring. The resulting nanoparticles were then 
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either centrifuged (Beckman, 70.1 Ti rotor; 40,000 rpm; 164,391 g; 30 min) or dialysed 
(MWCO 12 kDa) against deionised water (10 L; exchanged 3 times per day) for 72 h. After 
purification, the products were freeze dried. The nanoparticles, obtained as a beige powder 
(yields 42–81 %), were redispersed (0.5 mg/mL) in either ultrapure water or PBS (0.9 % 
NaCl; pH 7.4) for characterisation as nanoformulation using dynamic light scattering (DLS), 
nanoparticle tracking analysis (NTA) and electrophoretic mobility (EPM). 
 
PUL-OX4 nanoparticles were investigated for their stability in different pH conditions by 
titration with a MPT-2 Malvern instrument equipped with a solvent degasser. The 
nanoparticles redispersed (0.5 mg/mL) in ultrapure water; pH 8.5, as adjusted with NaOH 
(0.005 M) were titrated automatically with HCl (0.05 M) from pH 8.5 to pH 3 using an MPT-
2 Malvern instrument equipped with a solvent degasser (both diameter and zeta potential 
were measured at 0.5 pH increments). 
 
B. Reverse emulsification 
A solution of Span 80 (0.12 g/mL) in DCM (3.33 mL) was added dropwise to an aqueous 
solution of butylglyceryl-modified pullulan; PUL-OX4 (0.5 % w/v, 10 mL) with various 
degree of substitution under constant stirring. Stabiliser such as glycerol (1 mL) was added 
prior to the addition of glutaraldehyde (1 mL, 3 % v/v) and the mixture was left overnight 
under stirring to enable reaction completion. The resulting nanoparticles were isolated by 
centrifugation (Beckman, 70.1 Ti rotor; 40,000 rpm; 164,391 g; 30 min), washed with 
deionised water and freeze dried (flash freezing in liquid N2) yielding solid material as a 
white powder (yields 50–61 %), which were then redispersed (0.5 mg/mL) in either PBS (0.9 
% NaCl; pH 7.4) or ultrapure water for characterisation. 
 
3.2.3. Formulation of nanoparticles from butylglyceryl-modified chitosan derivatives 
A. Covalent cross-linking with sodium tripolyphosphate (TPP) 
A solution of sodium tripolyphosphate (0.1, 0.15, 0.2, 0.3 mg/mL) in ultrapure water (2 mL) 
was introduced dropwise (1 mL/min) under stirring to a solution of butylglyceryl-modified 
chitosan; CS-OX4 (1.07, 1.50, 2.0, 2.5 mg/mL; various degree of substitution) in aq. acetic 
acid (1 % v/v, 6 mL) and maintained under stirring for another 30 min after addition. Both 
solutions were filtered using a 0.2 µm nylon membrane Whatman syringe filter prior to use. 
The resulting suspension was analysed for diameter (dynamic light scattering, DLS and 
nanoparticle tracking analysis, NTA) and zeta potential (electrophoretic mobility, EPM) in 
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the preparative media (pH 3–4). To investigate the effect of pH towards the stability of 
nanoparticles, CS-OX4 nanoparticles suspension in acetic acid; pH 3, as adjusted with HCl 
(0.005 M), were titrated with NaOH (0.05 M) from pH 3 to pH 8.5 using an (both diameter 
and zeta potential were measured at 0.5 pH increments). The nanoparticles were then isolated 
by ultracentrifugation (Beckman, 70.1 Ti rotor; 40,000 rpm; 164,391 g; 30 min), followed by 
washing with deionised water (in triplicate) and lyophilisation (flash freezing in liquid N2), 
affording the final products, obtained as a beige powder (yields 16–45 %). 
 
B. Nanoprecipitation 
The butylglyceryl-modified chitosan; CS-OX4 was dissolved in acetic acid (1 % v/v, 2 mL) 
at varying concentration (0.2, 0.5, 1.0 mg/mL; various degree of substitution), filtered 
through a 0.2 µm nylon membrane Whatman syringe filter and then introduced dropwise to 
methanol (8 mL) under vigorous magnetic stirring. The resulting products were analysed for 
diameter (dynamic light scattering, DLS) and zeta potential (electrophoretic mobility, EPM) 
in the preparative media. Solvent removal was performed using rotary evaporator prior to 
centrifugation (Beckman, 70.1 Ti rotor; 40,000 rpm; 164,391 g; 30 min), dialysis (MWCO 12 
kDa) against deionised water (10 L; exchanged 3 times per day) for 72 h and lyophilisation 
(flash freezing in liquid N2) yielding the final products, obtained as a beige powder (yields 
65–72 %). 
 
3.2.4. Fluorescent labelling of butylglyceryl-modified polysaccharides nanoparticles 
Preparation of fluorescently-labelled nanoparticles was achieved by employing Texas Red as 
a fluorescent label; Texas Red-X dichlorotriazine for GG-OX4 and PUL-OX4, while Texas 
Red-X succinimidyl mixed ester for CS-OX4. The labelling process was performed onto the 
polysaccharides prior to the formulation into nanoparticles.  
 
A Texas Red-X dichlorotriazine solution (2 mg/mL) in DMSO (0.5 mL) was added dropwise 
to either GG-OX4 (10 mg/mL) in 0.1 M sodium bicarbonate buffer (10 mL) or PUL-OX4 (10 
mg/mL) solution in 70/30 DMSO/0.1 M sodium bicarbonate buffer (10 mL) under stirring. 
Labelling of CS-OX4 was performed employing Texas Red-X succinimidyl mixed ester (2 
mg/mL) in DMSO (0.5 mL), where it was added dropwise to the polymer that was dispersed 
(10 mg/mL) in 0.1 M sodium bicarbonate buffer (10 mL) under continuous stirring. The 
reaction was done at room temperature and maintained for 1 h. Labelled GG-OX4 and PUL-
OX4 was precipitated by the addition of DCM (10 mL). All product was centrifuged (Jouan 
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B4i, 4,000 rpm; 2,880 g; 30 min), purified by either washing three times with DMSO for 
labelled CS-OX4 or dialysis (MWCO 14 kDa) against deionised water (10 L; exchanged 3 
times per day) for labelled GG-OX4 and PUL-OX4 for 3 day and freeze dried, affording 
Texas Red-labelled polymer; GG-OX4 as a purple and fluffy cotton-like material (yields 78–
81 %), PUL-OX4 as a purple powder (yields 71–73 %) and CS-OX4 as a purple powder 
(yields 71–75 %). The product was then used for nanoparticles preparation, as described in 
chapter 4.2.1 and the resulting nanoparticles were characterised as nanoformulation. The 
experiment was performed in the dark and the materials were protected from light to avoid 
photo damage. For GG-OX4 and PUL-OX4, the degree of labelling was determined by 
weighing and dissolving the fluorescently-labelled polymer in DMSO before analysis by 
UV/Vis spectroscopy (589 nm) and subsequent plot against the calibration curve of Texas 
Red in DMSO (APPENDIX I). Meanwhile, for CS-OX4, the supernatant was analysed by the 
UV/Vis spectroscopy to determine the amount of unbound dyes based on calibration curve 
(APPENDIX I) of Texas Red prepared in DMSO:water (1:20, v/v), which was used to 
calculate the amount of bound Texas Red. The degree of labelling was calculated using Eq. 7 
below: 
 
𝐷𝐿 (%)  =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑇𝑒𝑥𝑎𝑠 𝑅𝑒𝑑
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 𝑥 100      (Eq. 7) 
 
3.2.5. Loading and release of model actives 
The loading capacity of nanoparticles for a number of model actives and/or fluorescent 
markers such as Doxorubicin, Rhodamine B and Angiotensin II was investigated following 
loading into nanoparticles via various techniques, dependent on the nature of the polymer, 
namely: nanoprecipitation for PUL-OX4, reverse emulsification for GG-OX4 and ionotropic 
gelation for CS-OX4, as described in chapters 3.2.1–3.2.3. Doxorubicin was purchased as 
hydrochloride salt and the removal of hydrochloride group was performed by treatment with 
triethylamine as described below. Triethylamine (0.1 mL) was added to an aqueous solution 
of Doxorubicin HCl (10 mL; 50 mg/mL). The mixture was then stirred for 1 h and washed 
with chloroform three times (approx. 150 mL). The combined organic layers were dried by 
stirring overnight with anhydrous magnesium sulphate to remove any trace of water, and the 
remaining organic solvent was removed by rotary evaporator, affording the free base of 
Doxorubicin as red powder (yield 71 – 80 %). 
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A solution of either Rhodamine B (0.5 mL, 0.037 mg/mL in DMSO), Doxorubicin (0.5 mL, 
0.4 mg/mL in DMSO) and Angiotensin II (1 mL, 0.1 mg/mL in deionised water) were mixed 
with polymer solution during nanoparticles preparation. The resulting nanoparticles were 
separated by ultracentrifugation (40,000 rpm; 164,391 g; 30 min, 20 °C, Beckman, rotor 70.1 
Ti); the pellets were lyophilised and weighted; the supernatant was measured to determine the 
amount of unbound model actives (which was used to calculate the amount of bound model 
actives) by UV/Vis (measuring at 544 nm for Rhodamine B; 486 nm for Doxorubicin) and 
the results were plotted against the calibration curves, as presented in APPENDICES E–H. 
For Angiotensin II, HPLC was used for the detection. The concentration of Angiotensin II in 
the supernatant was calculated based on the calibration curves presented in APPENDIX D, at 
retention time 8.32 min. The drug loading was calculated using the equation below: 
 
𝐷𝐿 (%)  =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
 𝑥 100      (Eq. 8) 
 
For the release of the model actives, nanoparticles were redispersed at a concentration of 1.5 
mg/mL in PBS (pH 7.4, saline 0.9 %), aliquots (1.5 mL) were taken and distributed into 
Eppendorf tubes, which were then placed in a thermostatic shaking water bath (37 °C). At 
varying time points, Eppendorf tubes were individually removed and an aliquot (0.7 µL) was 
removed from the supernatant and placed into another Eppendorf tube which was stored in 
freezer (-20 °C) until analysis. The tubes were then equilibrated at room temperature (25 °C) 
and the content was analysed using either HPLC or UV/Vis (based on calibration curves of 
the corresponding model actives dissolved in PBS presented in APPENDICES D, E and H), 
as described in chapter 3.1. 
 
3.3. Results and discussion 
The formulation of nanoparticles from butylglyceryl-modified polysaccharides (butylglyceryl 
guar gum, GG-OX4; butylglyceryl pullulan, PUL-OX4; and butylglyceryl chitosan, CS-OX4) 
was achieved using various methods such as nanoprecipitation,240, 554, 555 reverse 
emulsification556 or ionotropic cross-linking.255, 256, 287 Techniques to formulate nanoparticles 
were chosen depending on the nature of the polysaccharide (Table 3.1). The characterisation 
of nanoparticles was performed using a range of techniques including dynamic light 
scattering (DLS),278, 284 electrophoretic mobility (EPM),281, 282 nanoparticulate tracking 
analysis (NTA)279, 290 and electron microscopies (TEM and SEM).302, 303 Nanoparticles with 
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size approximately 100 nm or less were likely to reach the brain parenchyma.195-197 
Therefore, nanocarriers that possessed submicron diameter close to that range, with low 
polydispersity index (less than 0.5)557 and zeta potentials greater than +30mV or less than -
30mV 300, 301 in physiological media were investigated further for their loading and release 
properties using model actives; fluorescent labelling with Texas Red for potential imaging 
applications has also been investigated.   
 
Table 3.1. Nanoparticles formulation for butylglyceryl-modified polysaccharides. 
Material Technique investigated 
Butylglyceryl guar gum (GG-OX4) Nanoprecipitation 
Covalent cross-linking with STMP 
Reverse emulsification 
Butylglyceryl pullulan (PUL-OX4) Nanoprecipitation 
Reverse emulsification 
Butylglyceryl chitosan (CS-OX4) Ionotropic cross-linking with TPP 
Nanoprecipitation 
 
3.3.1. Formulation and characterisation of nanoparticles from butylglyceryl-modified guar gum 
derivatives 
A. Nanoprecipitation 
The formulation of nanoparticles from butylglyceryl guar gum (GG-OX4) using 
nanoprecipitation led to large particles size (micron range). The size of particles measured by 
NTA and DLS were found to be in micron range (approximately 1–3 µm) and are presented 
in Table 3.2. The particles exhibited negative zeta potential values ranging from -22 to -32 
mV, a high polydispersity index (PDI=1) and yields in the range 75–80 %. It was apparent 
that when methanol was used as a non-solvent, the size of particles was smaller.240 However, 
the size was still too large as the particles appeared in micron range; no general trend in size 
associated with varying the degree of substitution or the concentration of the polymers could 
be observed. 
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Table 3.2. Characteristics of nanoparticles prepared by nanoprecipitation of butylglyceryl-
modified guar gum (GG-OX4) with varying degrees of substitution (DS %), using either 
propanol or methanol as a non-solvent (n=3; ±SD). Yields were calculated after purification. 
Non-
solvent 
Polymer Concentration 
of polymers 
(mg/mL) 
Zeta potential 
(mV) ±SD 
Yield  
(% w) ±SD 
Propanol GG-OX4 (DS 
12.6 %) 
1 -26.9 ± 13.6 79 ± 5 
4 -31.1 ± 7.7 76 ± 6 
7 -22.3 ± 9.2 78 ± 3 
GG-OX4 (DS 
48.0 %) 
1 -23.4 ± 11.1 77 ± 5 
4 -28.8 ± 2.1 80 ± 3 
7 -24.6 ± 5.9 80 ± 9 
GG-OX4 (DS 
133.2 %) 
1 -28.1 ± 6.8 78 ± 6 
4 -30.1 ± 1.2 75 ± 4 
7 -24.1 ± 3.8 80 ± 3 
Methanol GG-OX4 (DS 
12.6 %) 
1 -22.2 ± 9.2 79 ± 5 
4 -27.8 ± 3.3 76 ± 4 
7 -25.5 ± 5.3 79 ± 5 
GG-OX4 (DS 
48.0 %) 
1 -28.9 ± 11.9 77 ± 5 
4 -27.1 ± 4.4 79 ± 3 
7 -30.1 ± 2.2 78 ± 5 
GG-OX4 (DS 
133.2 %) 
1 -26.2 ± 5.2 78 ± 6 
4 -30.2 ± 2.5 75 ± 5 
7 -30.4 ± 4.3 80 ± 5 
 
B. Covalent cross-linking with sodium trimetaphosphate (STMP) 
The formulation of nanoparticles from GG-OX4 by cross-linking with STMP was carried out 
following a method reported in the literature.558 The suggested mechanism of STMP cross-
linking was described by Anucha et al.559 and it involves two steps: 1) the STMP ring 
opening by guar gum in the presence of sodium hydroxide; and 2) the formation of new chain 
leading to the cross-linking of guar gum with pyrophosphate. The cross-linking step between 
guar gum and STMP is suggested in Figure 3.1. 
 
 
 
Figure 3.1. Schematic representation of the guar gum repeating unit (A) and the cross-
linking step between guar gum and STMP (B). Adapted from 558. 
STMP 
Guar gum 
backbone 
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However, the particles size obtained were in micron range (Table 3.3). Employing GG-OX4 
with various degrees of substitution and concentrations, the particles obtained were in micron 
range (approximately 1–2 µm) with high polydispersity index (PDI=1) and yields in the range 
74–83 %; though no trend in size related to a variety of degrees of substitution nor 
concentrations could be noticed. Zeta potential that was determined by electrophoretic 
measurements recorded values ranging from -22 to -33 mV.  
 
Table 3.3. Characteristics of nanoparticles prepared from GG-OX4 with varying degrees of 
substitution (DS %) using covalent cross-linking with sodium trimetaphosphate (STMP) 
(n=3). Yields were calculated following purification. 
Polymer Concentration 
of STMP 
(mg/mL) 
Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
GG-OX4  
(DS 12.6 %) 
0.2 -29.6 ± 5.5 79 ± 9 
1.0 -29.1± 6.7 74 ± 11 
6.0 -28.8 ± 2.9 75 ± 10 
GG-OX4  
(DS 48.0 %) 
0.2 -22.9 ± 4.1 76 ± 8 
1.0 -26.5 ± 4.0 81 ± 6 
6.0 -26.9 ± 2.1 78 ± 5 
GG-OX4  
(DS 133.2 %) 
0.2 -24.1 ± 6.2 74 ± 8 
1.0 -27.6 ± 3.3 83 ± 5 
6.0 -32.1 ± 1.9 80 ± 5 
 
C. Reverse emulsification 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic representation of the preparation of guar gum nanoparticles via 
reverse emulsification. 
Polymer in 
aqueous phase 
DCM (solvent) 
+ Span 80 
(emulsifier) 
Stirring 
w/o emulsion 
+ Glycerol (emulsion stabiliser) 
Nanoemulsion 
+ Glutaraldehyde (cross-linker) 
Cross-linked nanoparticles in media 
Centrifugation, wash, again centrifugation, freeze drying 
Dry nanoparticles 
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Reverse emulsification was employed to formulate nanoparticles from GG-OX4 by Sarmah 
et al.266; the technique (steps summarised in Figure 3.2) uses glutaraldehyde as a cross-linker. 
The glutaraldehyde cross-linking was achieved when aldehyde groups of glutaraldehyde 
reacted with hydroxyl groups of guar gum forming acetal bridges. The polymer chains then 
were linked together via the formation of an acetal structure between the aldehyde group and 
the hydroxyl groups of guar gum (Figure 3.3).560, 561 Using a constant concentration (0.5 % 
w/v), the influence of different degrees of substitution of GG-OX4 upon the nanoparticle 
characteristics was investigated; the results (Table 3.4) showed that GG-OX4 with lower DS 
values (DS 3.6, 12.6 and 33.9 %) produced nanoparticles with size in the range of 177 – 183 
nm, with good polydispersity index (PDI=0.2), negative zeta potential values (-25 to -33 
mV), and yields of 55–65 %. Several studies reported the formulation of cross-linked guar 
gum nanoparticles with the smallest size of about 200 nm and negative zeta potential.265, 374, 
562 Higher DS values (DS 48.0, 91.2 and 133.2 %) materials however resulted in polydisperse 
particles with size ranging from 1 to 3 micron. 
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Figure 3.3. Cross-linking reaction of GG-OX4 with glutaraldehyde.  
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Table 3.4. GG-OX4 nanoparticles of various degrees of substitution (DS %) formulated via 
reverse emulsification (n=3; ±SD). The concentration of GG-OX4 employed was 0.5 % w/v. 
Particles with size above 1µm are not shown in the table. Yields were calculated following 
purification. 
Degree of substitution of 
GG-OX4 (%) 
Diameter NTA 
(nm) ±SD 
Diameter DLS  
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
3.6 180 ± 18 177.6 ± 15.4 0.21 ± 0.03 -33.4 ± 8.2 59 ± 11 
12.6 179 ± 11 177.4 ± 6.2 0.23 ± 0.04 -28.3 ± 5.6 65 ± 8 
33.9 183 ± 21 178.3 ± 5.8 0.21 ± 0.07  -25.7 ± 4.9 56 ± 13 
48.0 - 614.6 ± 91.8 1.0   -25.9 ± 6.4 59 ± 11 
 91.2 -  -  1.0 -26.2 ± 13.9 55 ± 9 
 133.2 -  -  1.0 -28.6 ± 12.6 63 ± 7 
 
The influence of concentration upon the size of nanoparticles was studied employing GG-
OX4 (3.6, 12.6 and 33.9 % DS) with concentration in the range of 0.5–2 % w/v. The size of 
nanoparticles studied increased with the concentration due to the tendency of  highly 
concentrated solutions to aggregate, as also previously mentioned by Chen et al..392 All 
nanoparticles exhibited the size below 200 nm, good PDI (ca. 0.2), negative zeta potential 
values (-22 to -33 mV) and yields of 57–67 % (Table 3.5).  
 
Table 3.5. The influence of polymer concentration on GG-OX4 nanoparticles characteristics 
formulated by reverse emulsification (n=3; ±SD). Yields were calculated following 
purification. 
Polymer Concentration of 
polymers (% w/v) 
Diameter 
NTA (nm) 
±SD 
Diameter 
DLS 
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
GG-OX4  
(DS 3.6 %) 
0.5 145 ± 12 169.2 ± 9.4 0.22 ± 0.02 -32.7 ± 5.2 67 ± 5 
1.0 157 ± 15 172.3 ± 6.7 0.19 ± 0.02 -28.8 ± 2.9 57 ±15 
2.0 172 ± 16 199.8 ± 11.1 0.29 ± 0.03 -27.1 ± 7.0 58 ± 13 
GG-OX4  
(DS 12.6 %) 
0.5 166 ± 11 165.7 ± 3.2 0.21 ± 0.09 -29.9 ± 4.6 60 ± 10 
1.0 167 ± 13 169.5 ± 5.3 0.18 ± 0.06 -23.8 ± 1.9 58 ± 8 
2.0 178 ± 9 186.3 ± 7.8 0.15 ± 0.11 -22.1 ± 3.0 62 ± 9 
GG-OX4  
(DS 33.9 %) 
0.5 167 ± 11 166.9 ± 3.9 0.24 ± 0.04 -32.4 ± 6.2 61 ± 10 
1.0 176 ± 11 177.0 ± 10.9 0.20 ± 0.09 -25.5 ± 2.9 66 ± 11 
2.0 189 ± 17 191.7 ± 5.7 0.17 ± 0.10 -30.1 ± 5.7 59 ± 9 
 
GG-OX4 NPs were also studied for their stability in different pH conditions. Characteristics 
such as size and zeta potential were measured while varying the pH in the range of pH 3 to 9 
(Figure 3.4). GG-OX4 nanoparticles exhibited the size of around 170 nm with negative zeta 
potential values, however an increase in size and a decrease in zeta potential were noticed 
around pH 4, leading to agglomeration. At physiological pH (7.4), the nanoparticles showed 
promising properties, having the size below 200 nm. 
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Figure 3.4. The effect of pH on size (Z-average) and zeta potential of GG-OX4 nanoparticles 
(concentration 1 mg/mL) formulated via reverse emulsification (n=3, ±SD). 
 
 
Figure 3.5. SEM micrograph of lyophilised GG-OX4 nanoparticles (DS 12.6 %) cross-linked 
with glutaraldehyde via reverse emulsification (bar represents 5 µm). 
 
The morphology of the GG-OX4 nanoparticles, as analysed by scanning electron microscopy, 
can be observed in Figure 3.5; GG-OX4 nanoparticles tend to pack together likely following 
lyophilisation and centrifugation (during the purification process). 
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3.3.2. Formulation and characterisation of nanoparticles from butylglyceryl-modified pullulans 
A. Nanoprecipitation 
Nanoparticles from butylglyceryl pullulan (PUL-OX4) with different degrees of substitution 
and concentrations were prepared by nanoprecipitation. The results for the diameter of 
nanoparticles measured by NTA and DLS were consistent to each other, approximately 
ranging from 120 to 180 nm, with good polydispersity index (PDI=0.2) and negative zeta 
potential values (-23 to -30 mV) (Table 3.6). This is in agreement with nanoparticles from 
hydrophobised pullulan acetate prepared via nanoprecipitation reported by Ganeshkumar et 
al., having the size below 200 nm with negative zeta potential.563 Purification of the 
nanoparticles was performed either via dialysis or centrifugation, where the results suggested 
that higher yields were obtained via dialysis (76–81 %) rather than centrifugation (42–46 %) 
as not all fine particles can be recovered from centrifugation process. The yields were 
determined as a mass ratio between the starting material and the pellet recovered from freeze 
drying (expressed in percentage). The influence of polymer concentration was found to be 
directly proportional to the size of nanoparticles. 
 
Table 3.6. Characteristics of nanoparticles prepared from butylglyceryl-modified pullulan 
(PUL-OX4) with different degrees of substitution (DS %) by nanoprecipitation (n=3; ±SD). 
Yields were calculated following purification. 
Polymer Concentration 
of polymers 
(mg/mL) 
Diameter 
NTA 
(nm) ±SD 
Diameter 
DLS  
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
Dialysis Centrifugation 
PUL-OX4  
(DS 47.0 %)  
1 139 ± 22 142.8 ± 12.4 0.20 ± 0.10 -29.2 ± 2.8 79 ± 5 45 ± 8 
5 157 ± 20 155.3 ± 6.2 0.18 ± 0.07 -27.9 ± 1.7 80 ± 4 46 ± 10 
10 177 ± 17 181.6 ± 8.0 0.14 ± 0.06 -29.9 ± 1.4 81 ± 4 42 ± 9 
PUL-OX4  
(DS 58.5 %) 
1 133 ± 16 135.7 ± 14.9 0.21 ± 0.08 -23.4 ± 1.9 76 ± 5 44 ± 8 
5 141 ± 12 144.9 ± 9.4 0.19 ± 0.11 -28.2 ± 3.3 77 ± 7 45 ± 11 
10 158 ± 18 163.4 ± 7.7 0.17 ± 0.02 -30.1 ± 5.2 76 ± 9 47 ± 7 
PUL-OX4  
(DS 77.3 %) 
1 124 ± 23 124.7 ± 13.2 0.18 ± 0.12 -29.0 ± 4.3 82 ± 7 43 ± 10 
5 132 ± 19 142.2 ± 11.5 0.17 ± 0.09 -31.9 ± 5.1 83 ± 5 39 ± 8 
10 141 ± 20 178.2 ± 9.2 0.21 ± 0.05 -29.8 ± 2.9 79 ± 9 43 ± 7 
 
The nanoparticles prepared from PUL-OX4 were tested for their stability in different pH 
conditions by titration with aqueous NaOH and HCl, in ultrapure water. The diameter and 
zeta potential of the nanoparticles were measured while varying the pH (3–9) and the results 
were shown in Figure 3.7. As the pH increased, a slight increase in size accompanied by a 
decrease in zeta potential was observed. However, the nanoparticles diameter still remained 
below 200 nm over the whole range of pH.  
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Figure 3.7. The variation of size (Z-average) and zeta potential of PUL-OX4 nanoparticles 
with pH formulated via nanoprecipitation (concentration 1 mg/mL) (n=3, ±SD). 
 
Microscopy investigations (SEM and TEM; Figure 3.8 and 3.9, respectively) of nanoparticles 
prepared from PUL-OX4 via nanoprecipitation and separated by centrifugation demonstrated 
that the nanoparticles possessed micron/submicron diameter and the morphology close to 
spherical, in accordance with literature of hydrophobised pullulan nanoparticles.564, 565 
 
 
Figure 3.8. SEM micrograph of lyophilised PUL-OX4 (DS 47.0 %) nanoparticles prepared 
via nanoprecipitation (bar represents 1 µm). 
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Figure 3.9. TEM micrograph of nanoparticles from PUL-OX4 (DS 47.0 %) prepared via 
nanoprecipitation (bar represents 100 nm). 
 
B. Reverse emulsification 
Attempts to prepare nanoparticles from butylglyceryl pullulan (PUL-OX4) using reverse 
emulsification were performed. The influence of polymer degree of substitution (DS) upon 
the characteristics of the nanoparticles was investigated and the results were summarised in 
Table 3.7, where the diameter of the nanoparticles increased with the concentration. The 
PUL-OX4 NPs exhibited the size of between 450 and 640 nm, polydispersed, negative zeta 
potential values (-26 to -30 mV) and yields of 50–61 %. Though the particles obtained via 
this method were still in the nano range, they still require optimisation for brain delivery.195-
197  
 
Table 3.7. Nanoparticles from PUL-OX4 (different degrees of substitution, DS %) via 
reverse emulsification (n=3; ±SD). Yields were calculated following purification. 
Degree of 
substitution of PUL-
OX4 (%) 
Diameter 
NTA  
(nm) ±SD 
Diameter 
DLS  
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
5.8 452 ± 45 521.4 ± 20.9 0.86 ± 0.11 -29.9 ± 3.2 51 ± 5 
12.6 571 ± 63 512.7 ± 17.9 0.81 ± 0.19 -30.1 ± 3.3 50 ± 8 
33.8 603 ± 55 672.1 ± 22.1 1.0 -26.1 ± 0.9 61 ± 5 
47.4 611 ± 102 589.4 ± 25.2 1.0 -28.5 ± 2.6 60 ± 7 
64.4 638 ± 88 701.2 ± 72.8 0.74 ± 0.12 -27.8 ± 1.2 57 ± 7 
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3.3.3. Formulation and characterisation of nanoparticles from butylglyceryl-modified chitosan 
derivatives 
A. Ionotropic cross-linking with sodium tripolyphosphate (TPP) 
Nanoparticles from butylglyceryl chitosan (CS-OX4) were prepared by ionotropic gelation 
with TPP and the characterisation of the nanoparticles in terms of diameter and zeta potential 
was performed on freshly formed nanoparticles (pH 4; in 1 % v/v acetic acid). Using different 
concentrations, the influence of concentration upon the characteristics of the nanoparticles 
was studied, where the results (Table 3.8) suggested that 1.07 mg/mL was the optimum 
concentration, affording nanoparticles with size between 125 and 167 nm, with positive zeta 
potential values ranging from 31 to 36 mV, good polydispersity index (PDI=0.17), and yields 
of 29 %. Formulation of chitosan nanoparticles cross-linked with TPP has been presented in 
several studies, in which all of them reported particles with size varies from 100 to 300 nm 
and positive zeta potential.545, 566-568 Higher concentration of chitosan resulted in increased 
viscosity, therefore producing larger size of particles, as reported in the literature.569 
 
Table 3.8. Characteristics of nanoparticles from butylglyceryl-modified chitosan (CS-OX4; 
DS 14.1 %) cross-linked with TPP at varying polymer concentration. The concentration of 
tripolyphosphate used was 0.2 mg/mL (n=3; ±SD). 
Concentration of 
chitosan 
(mg/mL) 
Diameter NTA 
(nm) ±SD 
Diameter DLS 
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
1.07 151 ± 26 148.9 ± 17.2 0.17 ± 0.09 31.2 ± 1.7 29 ± 4 
1.50 167 ± 31 166.6 ± 15.6 0.31 ± 0.07 32.4 ± 2.0 28 ± 3 
2.00 218 ± 17 171.0 ± 15.4 0.35 ± 0.05 33.7 ± 1.8 34 ± 3 
2.50 324 ± 25 192.3 ± 17.2 0.27± 0.12 36.3 ± 1.3 36 ± 4 
 
Using a constant concentration of CS-OX4 (1.07 mg/mL), the influence of sodium 
tripolyphosphate (TPP) concentration on the characteristics of the nanoparticles was 
investigated. Results shown in Table 4.9 suggested that the nanoparticles diameter and yields 
increased with the concentration of TPP, as suggested by Asasutjarit et al..570 The optimum 
concentration of TPP was 0.2 mg/mL, yielding nanoparticles with the size between 147 
(measured by NTA) and 153 nm (measured by DLS), monodispersed (PDI=0.16), with 
positive zeta potential value (34.1 mV) and yields of 34 %. The zeta potential of the 
nanoparticles decreased with an increase in TPP concentration, owing to the fact that more 
negatively charged TPP is available for cross-linking with CS-OX4, therefore masking the 
positive surface charge of the CS-OX4 particles.570 
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Table 3.9. The influence of sodium tripolyphosphate (TPP) concentration on the 
characteristics of CS-OX4 nanoparticles (n=3; ±SD). The concentration of CS-OX4 (DS 14.1 
%) used was 1.07 mg/mL. 
 
To investigate if the degree of substitution of CS-OX4 can influence the nanoparticle 
properties, an experiment employing CS-OX4 with various degrees of substitution (DS 14.1, 
30.5 and 51.1 %) was performed. The concentrations of polymer and TPP were made 
constant (1.07 and 0.2 mg/mL, respectively). The results shown in Table 3.10 suggested that 
the degree of substitution influenced the diameter of nanoparticles, as the smallest 
nanoparticles were obtained from CS-OX4 with DS 14.1 %. 
 
Table 3.10. The influence of CS-OX4 degree of substitution on the characteristics of the 
nanoparticles prepared via TPP cross-linking. The concentration of chitosan and 
tripolyphosphate used was 1.07 mg/mL and 0.2 mg/mL, respectively (n=3; ±SD). 
 
The stability of CS-OX4 nanoparticles was investigated by measuring nanoparticle diameter 
and zeta potential over a range of pH values (3–9) (Figure 3.10). Nanoparticles obtained from 
CS-OX4 exhibited a stable diameter of about 140 nm and positive zeta potential values (ca. 
30 mV) in acidic conditions. However, as the pH increased above the pKa value of chitosan, 
ca. 6.3,571 a dramatic increase in diameter accompanied by a decrease of zeta potential was 
observed, thus leading to agglomeration. As a consequence, the diameter of CS-OX4 
nanoparticles at physiological pH (7.4) was found to be approximately more than 1 micron. 
 
Concentration of 
TPP (mg/mL) 
Diameter NTA 
(nm) ±SD 
Diameter DLS 
(nm) ±SD 
PDI (DLS) Zeta potential 
(mV) ±SD 
Yield  
(% w) ±SD 
0.10 153 ± 32 171.9 ± 18.2 0.33 ± 0.10 40.2 ± 1.7 16 ± 4 
0.15 156 ± 38 153.2 ± 17.0 0.36 ± 0.09 38.2 ± 1.4 22 ± 4 
0.20 147 ± 31 150.3 ± 16.6 0.16 ± 0.01 34.1 ± 3.2 34 ± 10 
0.30 289 ± 23  241.3 ± 13.9 0.31 ± 0.03 31.1 ± 1.4 45 ± 7 
Degree of substitution of 
CS-OX4 (%) 
Diameter NTA 
(nm) ±SD 
Diameter DLS 
(nm) ±SD 
PDI (DLS) Zeta potential 
(mV) ±SD 
Yield  
(% w) ±SD 
14.1 146 ± 34 145.8 ± 26.2 0.32 ± 0.07 32.1 ± 2.1 33 ± 4 
30.5 157 ± 28 148.3 ± 23.6 0.25 ± 0.02 35.8 ± 3.0 31 ± 4 
51.1 167 ± 32 156.3 ± 10.7 0.25 ± 0.01 31.9 ± 0.6 27 ± 3 
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Figure 3.10. The influence of pH on the size (Z-average) and zeta potential of CS-OX4 
nanoparticles (1 mg/mL) cross-linked with TPP (n=3, ±SD). 
 
SEM image of CS-OX4 (Figure 3.11) indicated that the nanoparticles were packed together 
after centrifugation and lyophilisation process which also affected the morphology. TEM 
image (Figure 3.12) showed better resolution where the spherical-like shape of nanoparticles 
were observed, as suggested by literature.572-574 
 
 
Figure 3.11. SEM micrograph representing lyophilised nanoparticles prepared from CS-OX4 
(DS 30.5 %) cross-linked with TPP (bar represents 5 µm). 
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Figure 3.12. TEM micrograph of nanoparticles prepared from CS-OX4 (DS 30.5 %) cross-
linked with TPP (bar represents 100 nm). 
 
B. Nanoprecipitation 
Other attempts to formulate nanoparticles from CS-OX4 were performed by 
nanoprecipitation, employing methanol as the non-solvent, where a solution of CS-OX4 in 
acetic acid (1 % v/v) was added into the non-solvent, yielding a homogenous dispersion 
system. The nanoparticles exhibited the size of below 500 nm, a good polydispersity index 
(below 0.5), positive zeta potential values ranging from 25 to 32 mV and yields going up to 
72 % (Table 3.11). The effect of the concentration and degree of substitution was found to be 
directly proportional to the diameter of the particles, as the smallest size of nanoparticles 
were obtained from CS-OX4 with DS 14.1 %, using 0.2 mg/mL concentration. 
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Table  3.11. Characteristics of nanoparticles prepared from CS-OX4 with varying degrees of 
substitution (DS %) via nanoprecipitation (n=3; ±SD). 
Polymer Concentration 
of polymers 
(mg/mL) 
Diameter 
DLS  
(nm) ±SD 
PDI (DLS) Zeta 
potential 
(mV) ±SD 
Yield  
(% w) ±SD 
CS-OX4  
(DS 14.1 %) 
0.2 359.6 ± 8.1 0.29 ± 0.14    25.1 ± 2.8 70 ± 6 
0.5 359.9 ± 16.7 0.32 ± 0.09 30.6 ± 3.0 68 ± 5 
1.0 373.7 ± 12.8 0.27 ± 0.21 27.7 ± 0.9 71 ± 6 
CS-OX4  
(DS 30.5 %) 
0.2 361.8 ± 13.2 0.30 ± 0.18 29.9 ± 1.1 65 ± 8 
0.5 388.1 ± 10.8 0.23 ± 0.20 30.4 ± 6.8 70 ± 4 
1.0 403.7 ±13.0 0.22 ± 0.20 27.2 ± 2.1 71 ± 6 
CS-OX4  
(DS 51.1 %)  
0.2 396.3 ± 12.4 0.19 ± 0.16 28.8 ± 2.1 72 ± 5 
0.5 418.4 ± 15.3 0.33 ± 0.09 31.4 ± 2.7 67 ± 9 
1.0 439.5 ± 11.9 0.37 ± 0.10 32.1 ± 5.6 68 ± 10 
 
3.3.4. Fluorescent labelling of butylglyceryl-modified polysaccharides nanoparticles 
Fluorescent labelling of nanoparticles with Texas Red was primarily performed for imaging 
purpose in order to follow the fate of nanoparticles in vitro and in vivo. Following procedures 
described in section 3.2.4 (adapted from 575, 576, butylglyceryl-modified polysaccharides 
(PUL-OX4 (DS 77.3 %), CS-OX4 (DS 30.5 %) and GG-OX4 (DS 12.6 %) were labelled 
with Texas Red prior to be formulated into nanoparticles. The degree of labelling was 
determined using calibration curves (APPENDIX I) and results were presented in Table 3.12. 
The comparison of nanoparticles formulated from Texas Red-labelled polysaccharides and 
unlabelled polysaccharides showed that both products exhibited almost similar particles 
diameter. CS-OX4 showed the lowest degree of labelling compared to GG-OX4 and PUL-
OX4. The possible explanation may lie in the solubility of the polymer in the reaction 
medium, in which heterogeneous reaction condition theoretically will produce lower degree 
of labelling.344 During the reaction, CS-OX4 was suspended in the medium while GG-OX4 
and PUL-OX4 were dissolved. 
 
Table 3.12. Characteristics of Texas Red-labelled CS-OX4, GG-OX4, PUL-OX4 
nanoparticles (formulation methods; CS-OX4 via TPP cross-linking; PUL-OX4 via 
nanoprecipitation; and GG-OX4 via reverse emulsification) (n=3; ±SD). 
Sample Degree of 
labelling  
(% w) 
Diameter of labelled 
nanoparticles  
(nm) ±SD by NTA  
Diameter of unlabelled 
nanoparticles  
(nm) ±SD by NTA  
CS-OX4 – Texas Red 1.84 ± 0.51 155 ± 16 142 ± 13 
PUL-OX4 – Texas Red 5.51 ± 1.29 145 ± 8 152 ± 8 
GG-OX4 – Texas Red 11.98 ± 2.56 178 ± 11 180 ± 9 
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3.3.5. Loading and release of model actives 
A number of model actives and/or fluorescent markers include Doxorubicin, Rhodamine B 
and Angiotensin II were employed as model actives to investigate drug loading and release 
profile of the nanoparticles. All model actives were loaded into nanoparticles via different 
methods depending on the polymers; nanoprecipitation for PUL-OX4 (DS 77.3 %), reverse 
emulsification for GG-OX4 (DS 12.6 %) and ionotropic gelation for CS-OX4 (DS 30.5 %), 
and the degree of loading was figured out using calibration curves, as described in section 
3.2.5.  
 
Loading comparison of salt form and free base of Rhodamine B and Doxorubicin was studied 
and compared (Table 3.13). In general, free base of Doxorubicin and Rhodamine B were 
loaded better compared to their salt form in all materials studied. The fact that the salt form 
(hydrophilic or water-liking) is more likely to stay in aqueous media (in dissolved state) and 
exhibits higher tendency to escape to aqueous media (or continuous phase) rather than being 
loaded into nanoparticles represent a likely explanation for the low loading degree. These 
results therefore encouraged the use of free base of Rhodamine B and Doxorubicin for later 
experiments. The results presented showed that GG-OX4 nanoparticles formulated via 
reverse emulsification exhibited the highest loading for Rhodamine B base (3.78 %) and 
Doxorubicin base (19.11 %) while Angiotensin II (8.46 %) was loaded the highest into PUL-
OX4.  
 
Table 3.13. Loading of butylglyceryl-modified polysaccharide nanoparticles using various 
methods; CS-OX4 via TPP cross-linking; PUL-OX4 via nanoprecipitation; and GG-OX4 via 
reverse emulsification) (n=4, ± SD). 
Loaded molecule Degree of loading (% w) 
CS-OX4 GG-OX4 PUL-OX4 
Rhodamine B salt 0.18 ± 0.15 0.88 ± 0.17 1.02 ± 0.26 
Rhodamine B base 1.38 ± 0.11 3.78 ± 0.58 2.11 ± 0.05 
Doxorubicin salt 0.13 ± 0.61 0.58 ± 0.18 0.42 ± 0.16 
Doxorubicin base 11.13 ± 1.60 19.11 ± 1.18 6.13 ± 0.82 
Angiotensin II 3.56 ± 0.71 6.11 ± 1.21 8.46 ± 0.98 
 
A similar release profile could be observed for all model actives considered (Figure 3.13), 
where an initial burst followed by a plateau release profile could be observed; this can be 
explained by the porous structure of nanoparticles resulted from the lyophilisation process.577 
However, Doxorubicin base showed a delay of about 1 h possibly due to poor solubility of 
the drug in the release medium. The initial burst release observed can be associated with the 
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rapid release of drugs adsorbed on the surface of the nanoparticles;578 while the burst effect 
may be preferable in some drug administration strategies such as for wound treatment, it 
requires more frequent dosing and can cause local or systemic toxicity.578 The excessive drug 
release in the burst phase may be harmful to brain tissues and lead to brain toxicities if the 
drugs concentration exceeds their therapeutic safety window. 
 
 
 
 
Figure 3.13. Release profiles of ; A) Rhodamine B base, B) Angiotensin II, C) Doxorubicin 
base from loaded butylglyceryl-modified nanoparticles (1 mg/ml) in PBS (pH 7.4; saline 0.9 
%) at 37 °C (n=3, ±SD). 
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To investigate the model active release process in more detail, the release data (3 h to 24 h) 
were fitted in a number of known kinetic models such as Higuchi, Hixon-Crowell and 
Korsmeyer-Peppas (Table 3.14).579-581  
 
Table 3.14. Kinetic models applied to the data release of model actives of butylglyceryl-
modified polysaccharide nanoparticles. 
Kinetic model Equation 
Higuchi 
𝐹 = 𝑘𝐻𝑡
1
2 
Hixon-Crowell 
1 − (1 − 𝐹)
1
3 = 𝑘1
3
𝑡 
Korsmeyer-Peppas 𝐹 = 𝑘𝐾𝑃𝑡
𝑛 
*F represents fraction of drug released at time t. kH is the Higuchi release rate constant, k1/3 is the Hixon-
Crowell release rate constant, kKP is the Korsmeyer-Peppas release rate constant and n is the release exponent. 
 
The quality of the fit was evaluated in each case using the squared correlation coefficient 
(R2), with results presented in Table 3.16. Overall, Korsmeyer-Peppas and Higuchi’s model 
appear to provide a reasonable fit for most nanoparticles considered, suggesting these models 
would be more suitable to explain the release of model actives from butylglyceryl-modified 
polysaccharide nanoparticles compared to Hixon-Crowell’s model (more suited to erosion-
dependent release systems582-584). 
 
Table 3.15. Kinetic model fit data for the drug release experiment; n is defined as release 
exponent.  
Kinetic model Model actives GG-OX4 CS-OX4 PUL-OX4 
R2 n R2 n R2 n 
Higuchi Rhodamine B base 0.9194 - 0.8685 - 0.7525 - 
Doxorubicin base 0.6406 - 0.7475 - 0.6777 - 
Angiotensin II 0.9448 - 0.9399 - 0.9024 - 
Hixon-Crowell Rhodamine B base 0.7871 - 0.6957 - 0.5542 - 
Doxorubicin base 0.4577 - 0.5636 - 0.5256 - 
Angiotensin II 0.8671 - 0.812 - 0.7437 - 
Korsmeyer-
Peppas 
Rhodamine B base 0.9366 0.2660 0.9282 0.5966 0.9840 1.2252 
Doxorubicin base 0.6819 0.2582 0.8263 0.4016 0.7929 0.3688 
Angiotensin II 0.9227 0.5775 0.9928 0.5776 0.8009 0.5946 
 
Higuchi’s mathematical model is generally used to describe drug release from a matrix 
system, based on Fick’s Law where the release occurs by drug diffusion.585 In this model, 
data obtained were plotted as cumulative percentage drug release versus squared root of time, 
where the best fitted release data was evaluated by correlation coefficient (R2), as shown in 
Table 3.15. The results indicate the release of Angiotensin II from GG-OX4 NPs and PUL-
OX4 NPs can be reasonably well described by the Higuchi’s model (with R2 values close to 
1), with the release controlled only by drug diffusion.  
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The Korsmeyer-Peppas kinetic equation is typically used to describe the drug release from a 
polymeric system by means of a release exponent, n (see Table 3.16),580,586 which is 
determined from the slope of the straight line of log cumulative percentage drug release 
versus log time.587 It is important to note that, when n is 0.5 or less, the Korsmeyer-Peppas 
model becomes identical with Higuchi’s.588 The Korsmeyer-Peppas model, normally limited 
to the first 60 % of drug release data,49 can be applied when the release mechanism is not 
well known or when multiple release phases take place (as suggested by Mathew et al587).  
 
Table 3.16. Diffusional release mechanism from polymeric dosage forms. 
Release exponent (n) Mechanism of drug transport Rate as a function of time 
n ≤ 0.5 Fickian diffusion t-0.5 
0.5 < n < 1 Non-Fickian transport tn-1 
n=1 Case II transport Zero order release 
n > 1 Super case II transport tn-1 
 
The R2 value obtained for the Korsmeyer-Peppas model for the release of Rhodamine B base 
from GG-OX4 NPs was the highest compared to other kinetic models and the n value was 
less than 0.5, suggesting that the release was controlled by Fickian diffusion (Table 3.16). It 
is therefore expected that the release of Rhodamine B base from GG-OX4 NPs is mainly a 
diffusion-driven process (as suggested in the literature for the release of propranolol 
hydrochloride from guar gum tablet589). Polymer hydrolysis and matrix erosion are expected 
to be minimal and considerably slower in this case.   
 
For CS-OX4 NPs, the release of Rhodamine B base and Angiotensin II appears to be 
controlled by non-Fickian transport (as suggested by n > 0.5, Table 3.16), indicating that the 
release mechanism involves multiple processes, possibly a combination of swelling- and 
diffusion-controlled release as previously suggested for unmodified chitosan 
nanoparticles.590, 591 In the case of PUL-OX4, the value of n > 1 for the Korsmeyer-Peppas 
model suggests that the release of Rhodamine B base from PUL-OX4 was controlled by 
super case II transport, which involves swelling of polymers.592 
 
As shown in Table 3.16, the release of Doxorubicin base from butylglyceryl-modified 
polysaccharide nanoparticles was reasonably well described by the Korsmeyer-Peppas model 
owing to averagely high R2 values, which suggests the process is controlled by Fickian 
diffusion (n < 0.5).  
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3.4. Conclusions 
Nanoparticles prepared from butylglyceryl-modified guar gum (GG-OX4, DS 3–34 %, conc. 
0.5 – 2.0 % w/v) via reverse emulsification presented an average hydrodynamic diameter of 
particles in the range of 145–200 nm, as measured by both DLS and NTA.  All particles had 
negative zeta potential (between -25 and -33 mV), and the particle size was found to be 
dependent mainly on the degree of substitution of the starting material (GG-OX4) but also on 
concentration. The effect of the degree of substitution was investigated (for 0.5 % w/v 
nanoparticle concentration) and a significant increase in size (up to 1000–2500 nm) was 
observed for higher degrees of substitution (48 % and above).Attempts to formulate 
nanoparticles from GG-OX4 using either nanoprecipitation or cross-linking with STMP only 
afforded particles in the micron size range (1000–3000 nm, as determined by NTA and DLS). 
The stability of the GG-OX4 nanoparticles prepared by reverse emulsification was tested in 
different pH environments and the results indicated that under physiologically relevant 
conditions (pH 7.4) particles exhibited size of around 170 nm with negative zeta potential. 
Agglomeration was however observed around the isoelectric point (zeta potential zero), with 
the size increasing up to 1100 nm for pH < 4.  
 
Nanoparticles from butylglyceryl-modified pullulan (PUL-OX4) were successfully 
formulated using nanoprecipitation, when the particle size was found to be in the range of 
120–180 nm (DLS and NTA), and had negative zeta potential (-23 to -30 mV). In contrast to 
the results obtained for guar gum, the size of pullulan-based nanoparticles remained 
considerably smaller (below 200 nm) over the whole range of pH studied (pH 3–8.5). In a 
similar manner, the particle size was found to be dependent on both the degree of substitution 
(DS 47–78 %) and concentration (1–10 mg/mL), where an increase will result in larger 
particle size. Dialysis and centrifugation were compared as alternative methods of 
purification, and results indicated that dialysis afforded higher yields (76–83 %) compared to 
centrifugation (39–47 %). An attempt to formulate PUL-OX4 nanoparticles using reverse 
emulsification led to particles with size between 450 and 750 nm (DLS and NTA) and -26 to 
-30 mV zeta potential; though still in the submicron range, this size range is however 
considered as too large and not suitable for IV delivery to the brain.197  
 
CS-OX4 (DS 14–51 %, conc. 1.07 mg/mL) was successfully formulated into nanoparticles 
with positive zeta potential and an average hydrodynamic diameter in the range 145–167 nm 
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(as measured by both DLS and NTA) by using ionotropic cross-linking with sodium 
tripolyphosphate (TPP) in an acidic environment. However, stability tests in different pH 
conditions indicated that the particle size increased dramatically above the pKa value of 
chitosan (pH ~ 6.3)40; it was found that at physiologically relevant pH (7.4), CS-OX4 
nanoparticles had the tendency of agglomerate into micron-sized particulates (up to 6 µm). 
Further studies revealed that the final particle size increased with the concentration of 
chitosan and TPP, as well as with an increase in the degree of substitution of CS-OX4. An 
attempt to formulate CS-OX4 nanoparticles (DS 14–51 %, conc. 0.2–1.0 mg/mL) using 
nanoprecipitation afforded submicron particles with positive zeta potential (25 to 32 mV) and 
hydrodynamic diameter above 350 nm. However, this was not further pursued owing to 
particle size that is not suitable for IV delivery to the brain, as reported in the literature.195, 196 
For all nanoparticles studied, SEM and TEM investigations indicated close to spherical 
particle morphology; particle sizes measured by SEM were generally larger compared to 
those determined by TEM, DLS or NTA (which were very close). 
 
Investigations on the fluorescent labelling of butylglyceryl-modified polysaccharides were 
performed in order to help with NP imaging in future in vitro/in vivo tests. The labelling was 
carried out by covalent conjugation to the polymers prior to their formulation into 
nanoparticles. GG-OX4 exhibited the highest labelling degree with Texas Red (ca. 12 % w) 
as compared to PUL-OX4 (ca. 6 % w) and CS-OX4 (ca. 2 % w). Size measurements (DTS 
and NTA) carried out on nanoparticles formulated from Texas Red-labelled GG-OX4 under 
similar conditions indicated that the hydrodynamic diameter was not affected by labelling. 
 
Doxorubicin, Rhodamine B and Angiotensin II were loaded into the nanoparticles and their 
loading and release properties were investigated. GG-OX4 nanoparticles had the highest 
loading capacity for Rhodamine B base (3.78 %) and Doxorubicin base (19.11 %), while the 
model peptide Angiotensin II was best loaded into PUL-OX4 nanoparticles (8.46 %). A 
similar release profile was observed in all cases, where a burst initial release followed by a 
constant release leading to a plateau were observed. Doxorubicin showed however a delay of 
about 1 h perhaps owing to poor solubility of the drug in the release medium. An 
investigation of the release of model actives from the nanoparticles using known kinetic 
models (Higuchi, Hixon-Crowell and Korsmeyer-Peppas) revealed that Korsmeyer-Peppas 
and Higuchi’s models fit best the experimental data, pointing to R2 values close to 1, which 
involves mainly swelling of polymers and drug diffusion. 
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4 
 
IN VITRO STUDIES 
 
In an attempt to investigate the influence of the butylglyceryl modification of selected 
polysaccharides on the cell-nanoparticle interactions, in vitro studies were performed using 
mouse brain endothelial cells (bEnd3). The cytotoxicity of nanoparticles was evaluated using 
MTT assays, and cell uptake studies employing nanoparticles that had been labelled with 
Texas Red as fluorescent marker were carried out by confocal microscopy and flow 
cytometry. The effect of the polysaccharide chemical modification on the permeability of 
bEnd3 cell monolayers was investigated using a Transwell permeability model. 
 
4.1. Materials and instrumentation 
Dulbecco’s Modified Eagle Medium (DMEM) media, Hoechst Blue 33342, NucGreen Dead 
488 and TrypLE Express were obtained from Invitrogen, Life technologies Ltd., Paisley, UK. 
Matrigel was obtained from BD Biosciences, Plymouth, UK. Hank’s Balanced Saline 
Solution (HBSS), Phosphate Buffered Saline (PBS) and distilled water (cell culture grade) 
were purchased from Gibco, Paisley, UK. Trypan blue, Triton X-100, Hydrocortisone (HPLC 
grade ≥ 98 %), Adenosine 3’,5’-cyclic monophosphate (HPLC grade ≥ 98.5 %) and 
Fluorescein Isothiocyanate (FITC) labelled dextran (MW 500 kDa) were sourced from Sigma 
Aldrich, Gillingham, UK. Forskolin and RO-20-1724 were obtained from Enzo Life 
Sciences, Exeter, UK. Sterile Nunc 96 well-plates were obtained from Fisher Scientific, 
Loughborough, UK. Sterile Transwell system (Millicell-24 Cell Culture Plate; polyethylene 
terephthalate membrane; 1.0 μm; 600 µL max volume; filtration surface 0.33 cm2; pore 
density 2x106 per cm2) was purchased from Millipore, Livingstone, UK.  
 
Mouse brain endothelial (bEnd3) cells (passage no. 20–27) were cultured in small T25 flasks 
(Fisher Scientific, Loughborough, UK), at 37o C with 5 % CO2 and under humidified 
atmosphere (in a Nuaire DH AUTOFLOW Air-Jacketed incubator). Cells were observed with 
an Olympus IX71 inverted phase microscope. LSM 510 META and 710 confocal 
microscopes (Carl Zeiss, Oberkochen, Germany) were used to obtain cells images. Low 
speed centrifugation (1,000 rpm; 115 g; 5 min) of trypsinised cell suspension was performed 
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employing a Beoco C28A centrifuge (Wolf Laboratories, Pocklington, UK) to isolate cells 
from media. Cell counting was performed using a c-chip disposable haemocytometer (Digital 
Bio, East Sussex, UK). For the fluorometric analysis of FITC-labelled dextran in 
permeability assay, a POLARStar OPTIMA (BMG Labtech, Aylesbury, UK; fluorescence 
recorded at 485 nm excitation and 520 nm emission) fluorimeter was employed. Flow 
cytometry was performed on a four-colour multi parameter BD FACSCalibur system 
equipped with a 488 nm argon gas laser and a 635 nm red-diode laser. Emission fluorescence 
of Doxorubicin was measured using a 530/30 nm filter and analysed by CellQuest Pro 
software. 
 
Butylglyceryl-modified polysaccharides (GG-OX4, PUL-OX4, and CS-OX4) were prepared 
as described in chapter 4.2. Nanoparticles from guar gum (GG) and butylglyceryl guar gum 
(GG-OX4) were obtained by reverse emulsification. Nanoparticles obtained from chitosan 
(CS) and butylglyceryl chitosan (CS-OX4) were formulated by ionotropic gelation. 
Nanoparticles from butylglyceryl pullulan (PUL-OX4) were prepared by solvent 
displacement. Chitosan, guar gum and pullulan were sourced from Sigma Aldrich, 
Gillingham, UK. 
 
4.2. Methods 
4.2.1. Cell cultures 
Mouse brain endothelial (bEnd3) cells were obtained from the European Collection of Cell 
Cultures (ECACC). The cells were cultured in a modified DMEM media that has been 
enriched with supplements (Table 4.1). The cells were grown at 37o C with 5 % CO2 under 
humidified atmosphere in an incubator (Nuaire DH AUTOFLOW). 
 
Table 4.1. Media compositions and conditions required for cell culturing. 
Cell type Mouse brain endothelial cells (bEnd3) 
Origin Health Protection Agency Culture Collections, UK 
Passage number 37–45 
Medium Dulbecco’s Modified Eagle’s Medium (DMEM) 
Culturing flask Corning T25 
Medium volume 6 mL 
Serum 10 % v/v FBS 
 
 
Supplement 
1 % v/v non-essential amino acids 
2 mM L-glutamine 
1 mM sodium pyruvate 
5 µM -mercapthoethanol 
100 U/mL penicillin 
0.1 mg/mL streptomycin 
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Cell passage 
All media and solutions required in cell passaging were equilibrated at 37o C in an incubator 
prior to use. The cells were washed twice with PBS. Trypsinisation was performed with 
TrypLE Express (1 mL per T25 flask) and flasks were equilibrated at 37 oC for 10–15 min to 
detach the cells (detachment monitored using a microscope). The cell suspension was then 
centrifuged (Beoco C28A, 1,000 rpm; 115 g; 5 min) and the supernatant was removed. The 
pellet was then re-suspended in fresh media and split in two: 1) to re-grow in a fresh culture 
flask; and 2) for cell counting using a haemocytometer. 
 
Cell counting 
The pellet recovered from centrifugation (described above) was re-suspended in media (1 
mL); an aliquot (10 μL) was taken and mixed thoroughly with a blue diazo dye trypan blue 
staining solution (90 μL). An aliquot (10 μL) of the  cell suspension was introduced onto the 
surface of the haemocytometer (Figure 4.1) and analysed by counting the living cells in 5 
counting square (4 corners and a central) under a microscope (in duplicate).  
.  
Figure. 4.1. Schematic view of a haemocytometer. 
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The number of cell per mL was calculated using the equation: 
𝑁𝑜. 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 10 (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑓𝑜𝑟 𝑡𝑟𝑦𝑝𝑎𝑛 𝑏𝑙𝑢𝑒) × 104 
 
Each large square of the haemocytometer represents a total volume of 0.1 mm3 or 10-4 and 1 
cm3 is thus equivalent to approximately 1 mL. Trypan blue is useful to distinguish between 
dead and living cells, as dead cells would appear as dark blue as a result of penetration of 
Trypan blue across cell membranes. 
 
4.2.2. Cytotoxicity assays 
An MTT assay was employed to investigate the toxicity of the nanoparticles (formulated 
from either unmodified or modified polysaccharides) against bEnd3 cells. Cells were grown 
(4.0 x 104 per well; incubated in 200 µL modified DMEM) in a 96-well plate and, after 
reaching confluence, the nanoparticles (50 µL, dispersed in modified DMEM at 
concentrations of either 1, 2, 4, 7, or 10 mg/mL) were added to each well and incubated for 
24 h at 37o C. Sterile PBS and Triton-X (0.1 % v/v in PBS) were used as negative and 
positive controls respectively. After incubation, media was removed from each well and cells 
were washed twice with PBS before replacing with MTT solution (100 µL, 1 mg/mL). The 
plate was wrapped in foil to exclude light and incubated for another 1 h 37o C. The MTT (3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) solution was prepared by 
diluting the stock solution (5 mg/mL in serum-free DMEM) in a serum-free DMEM media 
(1:4). Media/MTT was removed from each well and washed with PBS twice to remove 
residues of media as this may influence absorbance readings. DMSO (100 µL) was added to 
each well to facilitate solubilisation of formazan crystals and kept for 1 h incubation at room 
temperature. The plate was shaken horizontally for 30 s and inserted into a POLARstar 
OPTIMA (BMG Labtech, measuring absorbance at 570 nm) fluorescence plate reader for 
analysis. DMSO containing-wells were used as background signals and were subtracted from 
the values. The cells viability was expressed as percentage relative to the PBS control 
treatment. 
 
4.2.3. Confocal microscopy analysis 
Confocal laser microscopy was employed to investigate the interactions between bEnd3 cells 
and nanoparticles from butylglyceryl-modified polysaccharides that were previously labelled 
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with Texas Red. NucGreen Dead 488 and Hoechst 33342 were employed as nuclear counter-
stains to facilitate the visualisation. 
  
For the treatment with NucGreen Dead 488, bEnd3 cells were seeded directly in a petri dish 
(4.0 x 104 cells) and maintained at 37oC in incubator in modified DMEM (2 mL) until cell 
confluence (75–85 %) was reached. The media was replaced with the nanoparticle suspension 
in modified DMEM (2 mL, 0.5 mg/mL) and cells were incubated for another 3 h; cells 
without nanoparticles were used as a control. After incubation, the cells were washed three 
times with PBS, fixed for 10 min in paraformaldehyde (4 % w/v) at 4oC and permeabilised 
for 15 min with Tween 20 (0.1 % v/v) prior to incubation with a droplet of NucGreen Dead 
488 (for 15 min at room temperature). The cells were washed again with PBS and finally 
immersed in PBS (2 mL) before visualisation using a confocal microscope (LSM 510 META, 
ZEISS, 488 nm for NucGreen, 543 nm for Texas Red) with either 10 x Achroplan with 0.3 
NA or 40 x Achroplan with 0.8 NA water immersion objective. 
 
A slight adjustment was made for Hoechst 33342, in which the cells were grown onto glass 
cover slips in a petri dish. The cells were maintained and treated similar as above prior to 
incubation with Hoechst 33342 (5.0 µg/mL) for 60 min at room temperature. Visualisation 
using a confocal microscope (LSM 710, ZEISS, 405 nm for Hoechst, 543 nm for Texas Red) 
was performed using either a 63 x Plan Apochromatic NA1.4 differential interference 
contrast (DIC) oil objective or a 100 x Plan Apochromatic NA1.46 DIC oil objective, and a 
pin hole diameter of 1 Airy unit. All images were processed using Zen2009 Light Edition 
(ZEISS) software and exported into Adobe Photoshop. 
 
4.2.4. Flow cytometry analysis 
bEnd3 cells were seeded (4.0 x 104) in a petri dish until they reached confluence (75–80 %), 
then the media was replaced with Doxorubicin-loaded nanoparticles (2 mL, 0.5 mg/mL 
dispersed in modified DMEM). After 3 h of incubation, the cells were harvested by TrypLE 
Express and centrifuged (Beoco C28A, 1,000 rpm; 115 g; 5 min). The cells were then 
redispersed in PBS (400 µL) ready for the analysis. The measurement was done at two 
different time points (10 and 60 min respectively, after the cells were harvested). Cells treated 
with propidium iodide (1 % v/v; no nanoparticles) were used as control. 
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4.2.5. Studies of fluorescent marker translocation across bEnd3 cell monolayers 
To investigate the extent to which nanoparticles can modulate the permeability of bEnd3 cell 
monolayers, an assay using a Transwell-type BBB model (Figure 4.2) and FITC-DEX (MW 
500 kDa) as a fluorescent marker has been employed. The Transwell system comprised of a 
sterile 24-well plate Milipore Milicell that was washed twice with HBSS (500 µL) followed 
by distilled water; to enhance cell adhesion, Matrigel (150 µL, 1.5 mg/mL) was coated onto 
the filter membranes prior to incubation at 37 oC for 30 min, allowing Matrigel to solidify. 
The bEnd3cells were seeded (4 x 104 cells per well) and incubated at 37 oC in an appropriate 
media (Table 4.1) until confluent. Cells were also grown in parallel in a standard 24-well 
plate in order to monitor the cell growth until they reached confluence (as the Transwell filter 
prevented a direct observation during cell inspection). To promote the cell growth, a specific 
cocktail (consisting of cAMP (250 µM), RO-20-1724 (20 µM), Forskolin (50 µM) and 
hydrocortisone (550 µM)) was applied (as described by Toman et. al.209) after cells reached 
confluence, and incubation continued for another 24 h. Nanoparticles (2 mg/mL) and FITC-
DEX (100 µg/mL) dispersed in media were simultaneously applied to each well and the 
concentration of the FITC-DEX in the basolateral compartment was then monitored over time 
by fluorescence reading as further described. The experiment was run in triplicate and 
samples were collected every 30 min, up to 3 h. The volume removed from the basolateral 
compartment at each sampling (100 µL) was replaced with fresh media; samples were 
collected and placed into 96-well plates for analysis using a fluorescence plate reader 
POLARstar OPTIMA (excitation 485 nm; emission 520 nm) and the amount of FITC-DEX 
was calculated based on a calibration curve of FITC-DEX in cell media (APPENDIX K). 
 
Figure. 4.2. A schematic of the Transwell-type BBB model setup. 
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The apparent permeability coefficient (Papp) was calculated based on the formula suggested 
by Arthursson, as described below: 
 
𝑃𝑎𝑝𝑝 (𝑐𝑚. 𝑠−1) =  
𝑑𝑄
𝑑𝑡
 ×  
𝑉𝑅
𝐴 ×𝐶𝑜 ×60
       (Eq. 9) 
 
where; 
dQ/dt  the flux of FITC-DEX transported across the membrane (µg/sec) 
VR  the basolateral volume (600 µL) 
A  the surface area of the filter insert (0.33 cm2) 
Co  the initial mass concentration of FITC-DEX at the apical side (100 µg/mL) 
60  conversion factor (from minutes to seconds) 
 
4.2.6. Haemolysis study  
A male wistar rat, weighing 450 g was used in this experiment. After CO2 asphyxiation, 
blood was collected from the heart using a 21g needle and collected in a BD Vacutainer tube 
(lithium heparin) and was kept on ice. The RBC was separated by centrifugation of the blood 
(Heraeus Multifuge 3SR Plus; 2000 g; 10 min) at 4 oC, yielding a pellet containing RBC. 
Plasma fraction was removed prior to washing the RBC 3 times with PBS and centrifuged at 
2,000 rpm for 10 mins. The cells were then diluted with PBS (4 % w/v) to yield a cell 
suspension for further use. Controls were prepared either by adding PBS (10 µL; as a 
negative control) or Triton-X (1 % v/v in PBS; 10 µL; as a positive control) into cell 
suspension (190 µL). Each NPs concentration was added (10 µL) to cell suspension (190 µL) 
and was incubated for 1 h at 37 oC. After the incubation, the cells were centrifuged (Heraeus 
Multifuge 3SR Plus; 1200 g; 10 min) at 4 oC to sediment the RBC. The supernatant (150 µL) 
was transferred to a 96-well plate and the absorbance was measured at 570 nm using a 
Multiskan GO microplate reader (n, country). Percentage of haemolysis was calculated using 
the following equation: 
 
𝐻𝑎𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 (%) =
𝑆𝑎𝑚𝑝𝑙𝑒𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
   (Eq. 10) 
 
4.3. Results and discussion 
To assess the effect of butylglyceryl chemical modifications on the cell-nanoparticle 
interactions, a number of in vitro assays employing mouse brain endothelial cells (bEnd3) 
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were carried out. bEnd3 cells were selected as a model for the BBB as they are accessible to 
various molecular interventions and possess the ability to form functional barriers and 
maintain well their characteristics over a number of passages.593 Cytotoxicity, cell uptake and 
the potential for modulating the cell monolayer permeability were investigated. 
 
4.3.1. Cytotoxicity 
An MTT assay was employed to study the cytotoxicity of the nanoparticles prepared from 
butylglyceryl-modified polysaccharides. bEnd3 cells were incubated for 24 h with 
nanoparticles from butylglyceryl-modified polysaccharides (1–10 mg/mL) and the cell 
viability was determined using MTT and expressed as relative viability (PBS treatment with 
no nanoparticles as control; 100 % viability). Living cells react with MTT by reducing a 
yellow tetrazole (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple 
formazan crystals that accumulate inside the cells and that can be easily measured 
colorimetrically.438, 594  
 
Nanoparticles formulated from GG-OX4, PUL-OX4 and CS-OX4 were tested at various 
concentrations (range 1–10 mg/mL), with PBS and Triton-X (0.1 % v/v) being used as 
controls. Triton-X is a non-ionic surfactant widely used for the permeabilisation of 
membranes, leading to cell death by necrosis.595, 596 The results presented in Figure 4.3 show 
a consistent trend for all materials studied, where a certain degree of cytotoxicity appeared 
with an increase in NP concentration. However, for concentrations less than 2 mg/mL, 
toxicity was not significant when compared to the PBS control, where all nanoparticles 
showed 85 % cell viability (ANOVA, p < 0.05).  A significant cytotoxicity was observed 
however at concentrations of 4 mg/mL and higher, where the cell viability decreased below 
75 % (ANOVA, p < 0.05); this was similar to the cytotoxicity results reported by Toman et 
al. for nanoparticles prepared from dextran modified with alkylglycidyl ether.209  
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Figure 4.3. Relative cytotoxicity of nanoparticles formulated from butylglyceryl-modified 
polysaccharide derivative against bEnd3 cells: A) butylglyceryl pullulan (PUL-OX4; DS 77.3 
%); B) butylglyceryl chitosan (CS-OX4; DS 30.5 %); and C) butylglyceryl guar gum (GG-
OX4; DS 12.6 %); MTT assay; bEnd3 cells incubated with nanoparticles (1–10 mg/mL) for 
24 h; PBS and Triton-X (0.1 % v/v) as controls (n=36, ±SD). 
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The LC50 (lethal concentration 50; the concentration required to kill 50 % of the cell 
population) of the investigated nanoparticles was determined (Table 4.2), and it was found 
that PUL-OX4 exhibited the lowest toxicity (LC50 9.48 mg/mL), while CS-OX4 showed the 
highest (LC50 7.30 mg/mL) under the conditions studied.  
 
These values are usually useful to compare the efficacy of the nanocarriers, as well as in 
designing the dosage. LC50 of chitosan nanoparticles reported in the literature was found to 
be higher than what has been measured in this study, as reported Ali, where the toxicity of the 
unmodified chitosan nanoparticles against human cancerous cell lines (MCF7, HCT116, 
A549 and PC3) were evaluated using an MTT assay, giving values varied from 0.1 mg/mL to 
0.68 mg/mL.597 The concentration of nanoparticles used ranged from 0.05 to 2 mg/mL and 
the assay was performed for 48 h. 
 
Table 4.2. LC50 of nanoparticles prepared from different butylglyceryl-modified 
polysaccharides (n=3, ±SD). 
Nanoparticles LC 50 
(mg/mL) ± 
SD 
Butylglyceryl pullulan (PUL-OX4, DS 77.3 %) 9.48 ± 0.98 
Butylglyceryl guar gum (GG-OX4, DS 12.6 %) 8.84 ± 0.76 
Butylglyceryl chitosan (CS-OX4, DS 30.5 %) 7.30 ± 0.77 
 
Jiang et al. investigated the toxicity of cholesterol-modified pullulan nanoparticles against 
HepG2 by means of MTT assay, in which no toxicity was observed at concentration of 2 
mg/mL for 72 h, with 93 % cell viability recorded at the end of the assay.598 Soumya et al. in 
their study to assess the cytotoxicity of vanadium encapsulated guar gum nanoparticles by 
MTT assay have reported that the nanocarriers did not induce significant toxicity on H9c2 
cells after 24 h.599 
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4.3.2. Confocal microscopy investigations 
The interactions of nanoparticles with bEnd3 cells was investigated further using confocal 
microscopy. Cells previously incubated with nanoparticles for 3 h were then monitored under 
a confocal microscope in order to investigate the fate of the nanoparticles. For visualisation 
purposes, Texas Red-labelled nanoparticles (prepared as described in chapter 3.2.4) were 
employed. Results presented in Figure 4.4 suggest that nanoparticles were taken up by the 
cells and accumulated in the cell cytoplasm, as previously demonstrated by Lien et al. for 
butylglyceryl-modified chitosan nanoparticles.358 The nanoparticles possibly accumulated 
inside the vesicular structures such as endosomes or lysosomes, as suggested by the 
literature,600, 601 and apparently did not enter the nucleus. The cell uptake mechanism was not 
assessed in this study, however it has been suggested that particles with carbohydrates on the 
surface can trigger cellular uptake via caveolar / lipid-mediated endocytosis.601, 602  
                    
 
Figure 4.4. Confocal microscope images of bEnd3 cells following incubation for 3 h with 
Texas Red-labelled nanoparticles (laser 543 nm) from; a) butylglyceryl pullulan (PUL-OX4); 
b) butylglyceryl guar gum (GG-OX4); and c) butylglyceryl chitosan (CS-OX4) - bar 
represents 20 µm.  
a) b) c) 
20 µm 20 µm 
20 µm 
b)
) 
 a) 
c) 
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Cell internalisation of nanoparticles not only can be affected by their composition, but also by 
the size. As nanoparticles used in this study exhibited the size of 120–200 nm, it is expected 
that they will be internalised by the cells by endocytosis (either via caveolar / clathrin-
mediated or caveolar / clathrin-independent endocytosis).603 Aggregation of nanoparticles 
outside cells was also observed, especially for CS-OX4 likely owing to the fact that chitosan 
nanoparticles are not stable at pH 7.4.604 The accumulation of nanoparticles on cell 
membrane was observed possibly due to interaction with cells for the transport of 
nanoparticles across the membrane. 
 
                  
         
Figure 4.5. Confocal microscope images of bEnd3 cells treated with Texas Red-labelled 
nanoparticles (laser 543 nm) from a) butylglyceryl pullulan (PUL-OX4); b) butylglyceryl 
guar gum (GG-OX4); and c) butylglyceryl chitosan (CS-OX4), followed by NucGreen Dead 
488 counterstaining (laser 488 nm). bEnd3 cells treated with NucGreen Dead 488 only was 
used as a control (d) - bar represents 30 µm. Texas Red-labelled nanoparticles were pictured 
in red, while NucGreen-counterstained nuclei were in green. 
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To differentiate between the cell nuclei and the background signal, nucleus counterstain such 
as NucGreen Dead 488 was used.605, 606 Images presented in Figure 4.5 show a clear 
difference between the NucGreen-counterstained nuclei (green), nanoparticles (red) and the 
black background. 
 
       Hoechst                     Nanoparticles      Merge 
                          
                         
                          
Figure 4.5. Confocal microscope images of bEnd3 cells following incubation with Texas Red-
labelled nanoparticles (laser 543 nm) and Hoechst (laser 405 nm). From top, nanoparticles 
formulated from: 1) butylglyceryl guar gum (GG-OX4); 2) butylglyceryl chitosan (CS-OX4); 
and 3) butylglyceryl pullulan (PUL-OX4) - bar represents 20 µm. Nanoparticles are 
visualised in red, while Hoechst-counterstained nuclei appear in blue. 
 
Hoechst 33342607, 608 was also employed in this study as counterstain. The results obtained by 
staining with Hoechst (measured at 405 nm as it stains the nuclei blue) were slightly different 
compared to those obtained with NucGreen, where the intensity of red signal from Texas Red 
2b) 2c) 2a) 
1a) 1b) 2c) 
3b) 3a) 3c) 
20 µm 
20 µm 20 µm 20 µm 
20 µm 20 µm 20 µm 
20 µm 20 µm 
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was higher (Figure 4.5). A possible explanation may lie in the sample preparation (described 
in chapter 4.2.3), where the cells were grown on different surfaces (i.e. petri dish for 
NucGreen, and glass cover slips for Hoechst). These differences are not unusual, with 
Scholz609 reporting that the selection of growth substrates for cell culture influence the 
adhesion, growth, morphology and differentiation of cells, therefore affecting the appearance 
and observation of the cells under a confocal microscope. 
 
4.3.3. Flow cytometry investigations 
Quantification of the cellular uptake was performed by flow cytometry and the results were 
expressed as percentage of cell population that have taken up nanoparticles. For this purpose, 
bEnd3 cells were incubated for 3 h with Doxorubicin-loaded nanoparticles; measurements 
were carried out at 2 different time points, 10 and 60 min respectively (measured from the 
time point when the cells were harvested).  
 
                                   10 min    60 min 
 
 
a) 
b) 
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Figure 4.6. Comparison of dot plots following measurement at 10 min (left) and 60 min 
(right) after cells were harvested. Cells were incubated with Doxorubicin-loaded 
nanoparticles from butylglyceryl-modified polysaccharides: a) PUL-OX4; b) GG-OX4; and 
c) CS-OX4 for 3 h prior to analysis. As control (d), the cells were treated with 1 % v/v 
propidium iodide (no nanoparticles). 
  
The results were presented as dot plots in Figure 4.6, where the Y-axis represents the 
fluorescence intensity and X-axis the forward scatter (indicative of the surface area or size of 
the cells). As for the control, propidium iodide (PI) was employed to stain the cells in order to 
monitor the viability of cells throughout the experiment; dead cells lose their membrane 
integrity, hence become permeable to PI that binds to DNA of the dead cells,610 providing 
increased fluorescence to the dead cells that can be thus differentiated from live cells. 
 
The low fluorescence intensity of the control is due to the fact that the cells did not absorb 
propidium iodide, and indicates that the bEnd3 cells were alive and healthy at the time of the 
measurement. All nanoparticles showed an increase in fluorescence intensity compared to the 
PI control, indicating the uptake of Doxorubicin-loaded nanoparticles by the cells, in 
accordance to the results obtained from confocal microscopy presented in chapter 4.3.2. 
However, in all cases, some of the cells started to lose fluorescence after 60 min, possibly due 
to photo bleaching; another possible explanation may lie with the potential intracellular 
degradation that may happened after the nanoparticle internalisation (as described by 
c) 
d) 
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Sulheim611). According to literature,611 after internalisation, the nanoparticle-containing 
vesicles merge with hydrolase-containing vesicles from the Golgi body to form early 
endosomes; this is a rather fast process, occurring in about 10 min. The early endosomes will 
be transformed to become late endosome once the pH has dropped to become 5 and, after 
about 10–40 min, the latter will merge with lysosomes to start the degradation process. 
 
Table 4.3. Relative percentage of bEnd3 cellular uptake for PUL-OX4, GG-OX4 and CS-OX4 
nanoparticles. (n=3, ±SD). 
Measurement 
time (min) 
Gated area Percentage of cells 
PUL-OX4 GG-OX4 CS-OX4 Control 
10 R1 99.32 ± 3.57 95.25 ± 2.07 87.88 ± 3.76 10.99 ± 0.11 
R2 0.17 ± 0.07 3.33 ± 0.91 11.09 ± 1.03 85.03 ± 0.16 
60 R1 96.21 ± 1.23 93.84 ± 1.01 83.01 ± 2.07 7. 72 ± 0.67 
R2 2.70 ± 0.82 4.82 ± 1.11 9.02 ± 2.13 91.91 ± 0.86 
 
The results included in Table 4.3 represent the geo-means data obtained by gating (R1 and 
R2) the dot plots presented above. Gating was performed in order to remove debris signal and 
to allow quantitative analysis of the populations of interest only. The gated area was made 
constant throughout the analysis and only cells within this gated area were counted and 
expressed as %. At 10 min, a higher than 85 % cellular uptake was recorded over 3 h 
incubation for all materials studied, as the highest uptake was obtained from PUL-OX4 
nanoparticles and the lowest from the CS-OX4 with value ca. 99.32 % and 87.88 %, 
respectively (likely owing to the agglomeration or clustering of nanoparticles, evidenced by 
the stability results discussed in chapter 3.3.3 and confocal microscopy results presented in 
chapter 4.3.2); the percentage decreased to become approximately 83 % at 60 min. 
 
4.3.4. Investigations of the translocation of FITC fluorescent marker across a bEnd3 cell 
monolayer based BBB model 
The effect of nanoparticles formulated from butylglyceryl-modified polysaccharides on 
modulating the permeability of bEnd3 cells was investigated by using a Transwell-type BBB 
model and FITC as fluorescent marker, as described in section 4.2.5. The Transwell setup, 
comprising of a confluent monolayer of bEnd3 cells enriched with a barrier enhancing 
formula,358, 612 was previously employed as an in vitro model for studying permeability across 
the blood-brain barrier (BBB).613, 614 FITC-DEX 500 kDa is not normally expected to cross 
the barrier on its own, as the molecular weight of entities that can easily move across the 
barrier is lower than 150 Da for hydrophilic molecules and 400–600 Da for hydrophobic 
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ones.615 A cytotoxic agent such as Triton-X - widely used to lyse cells, therefore preventing 
the formation of any cell barriers - was used as a control.  
 
The basolateral compartment was measured using a fluorescence plate reader, and results are 
presented in Figure 4.7. The longer the incubation time, the more obvious the effect becomes, 
with CS-OX4 and PUL-OX4 showing a statistically significant effect after 3 h (ANOVA, p < 
0.05). In contrast, the effect produced by GG-OX4 nanoparticles was not significant 
(ANOVA, p < 0.05). The apparent permeability coefficient (Papp) which was defined as the 
rate of drug presence in the basolateral compartment (chapter 4.2.5), was calculated using the 
equation described by Arthursson;616 and is considered a representative for the translocating 
capacity of various treatments used on a specific cell monolayer (for a specific time point and 
surface area where the cells grow). 
 
The results presented in Table 4.4 indicate that the transport of 500 kDa FITC-dextran across 
the bEnd3 monolayer increased with the degree of substitution; PUL-OX4 (DS 77.3 %) 
appeared to have the highest effect in terms of increasing permeability (with a Papp value of 
5.64 x 10-5 at 3 h) compared to other butylglyceryl-modified polysaccharide nanoparticles 
(ANOVA, p < 0.05). This value is much higher than those previously reported by Toman et 
al.209, 287 for alkylglyceryl-modified dextran (DS 130–142 %) having the value between 1.5 
and 1.6 x 10-7 after 3 h incubation. As demonstrated by the results obtained from the 
cytotoxicity assay (presented in chapter 4.3.1), no significant toxicity was induced by 
nanoparticles at a concentration of 2 mg/mL (ANOVA, p < 0.05), therefore it was assumed 
that the translocation of FITC-DEX across the cell monolayer should not be associated with 
model membrane leaks associated with cell death.  
 
 
 
152 
 
 
 
 
Figure 4.7. Translocation of FITC-DEX through bEnd3 cell monolayers following treatment 
with nanoparticles (2 mg/mL, different degree of substitution) prepared from either native 
polysaccharides or butylglyceryl-modified polysaccharide derivatives nanoparticles; 1) 
butylglyceryl chitosan (CS-OX4); 2) butylglyceryl pullulan (PUL-OX4); and 3) butylglyceryl 
guar gum (GG-OX4). FITC-dextran and Triton-X (0.2 %) were employed as controls (n=5, 
±SD). 
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Table 4.4. Permeability coefficients (Papp) calculated from experiments using mouse bEnd3 
cells treated with butylglyceryl polysaccharide nanoparticles (2 mg/mL, different degree of 
substitution); unmodified chitosan (CS); unmodified guar gum (GG); butylglyceryl chitosan 
(CS-OX4); butylglyceryl pullulan (PUL-OX4); and butylglyceryl guar gum (GG-OX4) at 3 h 
incubation time. FITC-DEX and Triton-X as controls (n=5, ±SD). 
Material Degree of 
substitution (%) 
Concentration Papp  3 hours 
FITC-DEX - 100 µg/mL (3.28 ± 0.09) x 10-5 
CS 0 2.0 mg/mL (3.21 ± 0.04) x 10-5 
CSOX 
 
14.1 0.5 mg/mL (3.55 ± 0.14) x 10-5 
30.5 0.5 mg/mL (4.11 ± 0.25) x 10-5  
2.0 mg/mL (4.94 ± 0.28) x 10-5 
 
PULOX 
 
12.6 2.0 mg/mL (3.33 ± 0.11) x 10-5 
33.8 2.0 mg/mL (4.50 ± 0.20) x 10-5 
77.3 0.5 mg/mL (4.64 ± 0.13) x 10-5 
2.0 mg/mL (5.64 ± 0.09) x 10-5 
GG 0 2.0 mg/mL (3.38 ± 0.20) x 10-5 
GGOX 12.6 0.5 mg/mL (3.36 ± 0.23) x 10-5 
2.0 mg/mL (3.56 ± 0.18) x 10-5 
Triton-X - 0.2 % v/v (6.97 ± 0.33) x 10-5 
 
The effect of varying concentrations (0.5 and 2.0 mg/mL) was also studied and the results 
(presented in Table 4.4) showed a concentration-dependent effect for all materials; a 
significant difference between 0.5 mg/mL and 2.0 mg/mL was observed (ANOVA, p < 0.05). 
However, the trend was not consistent for GG-OX4, where an increase in concentration did 
not generate a significant difference (possibly owing to the low degree of substitution of GG-
OX4). 
 
4.3.5. Haemolysis study 
Haemolysis study was performed to investigate the toxicity of the nanoparticles prepared 
from the alkylglyceryl-modified polysaccharides (GG-OX4, PUL-OX4 and CS-OX4) in red 
blood cells. Rationalised by the fact that most of the future applications of therapeutic 
nanoparticles are based on intravenous applications, studies on their interaction with blood 
cells are essential. Red blood cells (RBC) collected from a male wistar rat were incubated for 
1 h with the nanoparticles of various concentration and the percentage of haemolysis was 
measured and is presented in Figure 4.8. 
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Figure 4.8. In vitro haemolysis test results exposed to alkylglyceryl-modified polysaccharides 
nanoparticles of various concentration after 1 h incubation at 37 oC. Red blood cells 
suspension mixed with PBS or Triton-X (1%) were used as controls (n=3; ±SD).  
 
The influence of nanoparticle concentration on the cell lysis was studied and compared to 
PBS and Triton-X controls. Nanoparticles did not show a significant toxicity at concentration 
less than 12 mg/mL when compared to the PBS control, where all nanoparticles showed less 
than 10 % haemolysis; however, they were found to induce a certain degree of haemolysis 
when the concentration increased. LC30 (lethal concentration 30; the concentration required to 
kill 30 % of the cell population) for the assay was calculated; CS-OX4 nanoparticles became 
the most toxic to RBC having the highest value of 13.95 mg/mL (ANOVA, p < 0.05). GG-
OX4 nanoparticles exhibited the value of around 18.01 mg/mL while the least toxic 
nanoparticles to RBC was demonstrated by PUL-OX4 nanoparticles with the value of 19.87 
% (ANOVA, p < 0.05). CS-OX4 nanoparticles were expected to induce higher haemolysis 
effect as a result of interaction between positively charged chitosan with negatively charged 
cell membrane.617 
 
4.4. Conclusions 
The nanoparticles prepared from chemically modified polymers (GG-OX4, PUL-OX4 and 
CS-OX4) were tested in the presence of mouse brain endothelial cells (bEnd3) to investigate 
the influence of the butylglyceryl modifications on the cell-nanoparticle interactions in terms 
of cytotoxicity, cell uptake and bEnd3 cell monolayer permeability. 
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The cytotoxicity of butylglyceryl-modified polysaccharides was studied on mouse brain 
endothelial cells (bEnd3) employing an MTT assay. The effect of nanoparticle concentration 
on the cell viability was studied and compared to PBS and Triton-X controls. Nanoparticles 
did not show a significant toxicity at concentration less than 2 mg/mL when compared to the 
PBS control, where all nanoparticles showed 85 % cell viability; however, they were found to 
induce a certain degree of cytotoxicity when the concentration increased (viability lower than 
75 % at 4 mg/mL and higher concentrations; ANOVA, p < 0.05). The LC50 (lethal 
concentration 50) of the investigated nanoparticles was determined, and it was found that 
PUL-OX4 exhibited the lowest toxicity (LC50 9.48 mg/mL), while CS-OX4 showed the 
highest (LC50 7.30 mg/mL) under the conditions studied.  
 
The effect of the interactions between butylglyceryl-modified polysaccharide nanoparticles 
and cultured mouse brain endothelial cells was investigated using confocal microscopy and 
nanoparticles labelled by chemical conjugation with Texas Red; cell nuclei were stained with 
either Hoechst Blue or NucGreen Dead 488. It was found that nanoparticles were taken up by 
the bEnd3 cells and were localised within the cytoplasm in the peri-nuclear region. 
Nanoparticle aggregation was also observed, in particular for CS-OX4 nanoparticles that 
demonstrated lower stability at physiological pH (7.4) compared to other modified 
polysaccharides considered in this study. Interestingly, and in agreement with Scholz’s 
observation,609 when comparing the cells grown on glass cover slips to those cultured in 
polystyrene plastic petri dishes, it was found that the nature of the growth substrate used for 
cell culture can affect the cell response.  
 
Flow cytometry investigations were carried out using Doxorubicin-loaded nanoparticles in 
order to quantify their cellular uptake by bEnd3 cells. Propidium iodide was employed as a 
control in order to monitor the cell viability during the assay, confirming that the bEnd3 cells 
were alive throughout the duration of the experiment. The increase in fluorescence intensity 
between the control (ca. 7–10 %) and cells incubated with nanoparticles (80–99 %) 
confirmed that the nanoparticles were taken up by the cells (as supported by the confocal 
microscopy results), likely through endocytosis. After 3 h incubation, a minimum of 85 % 
cellular uptake was recorded for all materials investigated; the highest cellular uptake was 
demonstrated by PUL-OX4 nanoparticles (99.3 %), and the lowest by CS-OX4 ones (87.9 
%). Cells were found to start diminishing their fluorescence after 60 min, likely due to photo 
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bleaching following internalisation of nanoparticles. Positively charged nanoparticles are 
reported to have higher cellular uptake due to stronger affinity for the negatively charged cell 
membrane,618 however perhaps due to aggregation, CS-OX4 nanoparticles could not easily 
cross the membrane to enter the cells. Gao et al. mentioned that larger particles have lower 
cellular uptake as they needed stronger driving force and additional energy in the cellular 
internalisation process.618 Therefore, PUL-OX4 nanoparticles which were the smallest, with 
size less than 145 nm, exhibited the highest cellular uptake compared to other materials 
studied. 
 
A Transwell-type BBB model comprising of confluent bEnd3 monolayers was employed to 
investigate the effect of the nanoparticles in terms of modulating the cell membrane 
permeability. This was achieved by assessing the transport of fluorescein labelled dextran 
(FITC-DEX; 150 kDa), and it was found that the translocation of FITC-DEX through the 
bEnd3 cell monolayer was enhanced by the presence of the nanoparticles when compared to 
the control. At 0.5 and 2 mg/mL concentrations, PUL-OX4 (DS 77.3 %) NPs were found to 
have the strongest flux-enhancing effect compared to CS-OX4 and GG-OX4 NPs. The 
influence of the degree of substitution and nanoparticle concentration was also studied and it 
was found that the effect increased in a concentration (0.5 and 2 mg/mL) and degree of 
substitution (0–78 %) dependent manner. GG-OX4 nanoparticles (12.6 %) did not increase 
the translocation of FITC-DEX significantly when compared to control (ANOVA, p < 0.05). 
 
In vitro haemolysis studies illustrated that after 1 h incubation at 37 oC at concentration less 
than 12 mg/mL, all nanoparticles studied did not induce haemolysis significantly when 
compared to PBS control. The haemolysis effect was found to be concentration-dependent, 
where an increase in the concentration induced a greater haemolysis effect. PUL-OX4 (DS 
(77.3 %) were found to be the least toxic with LC30 value of 19.87 mg/mL, with CS-OX4 (DS 
30.5 %) nanoparticles the most toxic with the highest LC30 having the value of 13.95 mg/mL 
(ANOVA, p > 0.05). These results were found to be in accordance to the cytotoxicity study 
by MTT assays, where CS-OX4 nanoparticles were found to be the most toxic having the 
lowest LC50 value of 7.30 mg/mL, while PUL-OX4 maintained to be the least toxic with LC50 
value of 9.48 mg/mL. 
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5 
GENERAL CONCLUSIONS 
 
The anticipated burden of cost and human suffering - as projected by the vast epidemiology 
of brain diseases combined with increasing life expectancy - has fuelled a considerable 
increase in recent research efforts dedicated to the development of effective drug delivery 
systems. The brain is well protected by the blood-brain barrier, which is responsible for 
maintaining the homeostasis and for restricting the access of potentially toxic compounds; as 
a consequence, delivering actives into the brain requires innovative transport strategies as the 
effectiveness of a vast majority of existing neuropharmaceuticals is severely limited by the 
presence of this barrier. Attempting to combine the advantages of polysaccharide-based 
nanoparticulate carriers with the capability of short chain alkylglycerols to increase BBB 
drug permeability, this project aimed to investigate the potential of alternative 
polysaccharides for chemical modification and subsequent formulation into nanoparticles that 
may have potential for applications related to drug delivery to the brain. 
 
Pectin, guar gum, pullulan, and chitosan were selected as starting materials due to a number 
of attractive features such as biocompatibility, biodegradability, non-toxicity, good carrier 
properties, and ease of chemical modification. Typical nucleophilic substitution reactions 
carried out using n-butylglycidyl ether (BGE) afforded amphiphilic butylglyceryl-modified 
polysaccharide derivatives of various degree of substitution, which were then characterised 
by FT-IR, 1H-, 13C- and 2D COSY NMR spectroscopy, TGA, DSC and GPC techniques that 
confirmed the successful chemical modification.  
 
The degree of substitution obtained (as determined using 1H-NMR) was found to vary widely 
with the nature of the polysaccharide and, to a certain extent, with the BGE molar excess 
ratio. While pectin demonstrated the lowest reactivity under the reaction conditions studied, 
having consequently been modified successfully only to a limited extent (DS 7.5–21.6 % for 
butylglyceryl pectin, P-OX4), guar gum and chitosan afforded materials with considerable 
higher degree of modification (DS; 3.6–133.2 % and 14.1–51.1 % for GG-OX4 and CS-OX4, 
respectively). The DS increased with the BGE / polysaccharide (sugar unit) molar ratio, as 
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expected, but only up to a ceiling value (above which, for the same reaction conditions, no 
further major increase was noted despite the huge excess of BGE reagent employed), likely 
due to a combination of steric hindrance, reduced reactivity of secondary OH groups, and 
competitive hydrolytic reactions. The extent of reaction was also found to be dependent on 
the nature of the catalyst employed; for PUL-OX4, higher DS values (47.0–77.3 %) were 
obtained using stronger bases such as potassium tert-butoxide compared to NaOH (DS 5.8–
64.4 %). Attempts to employ Lewis acids such as Zn(BF4)2 as catalyst for the modification 
reaction were unsuccessful. Thermal stability studies (TGA / DSC) of butylglyceryl 
polysaccharides indicated an increase of the thermal decomposition onset and glass transition 
temperature values compared to the original, unmodified polysaccharides, likely as a result of 
the molecular motion-limiting effect of the newly introduced pendant chains.  
 
The potential of selected butylglyceryl polysaccharides having high DS (GG-OX4, PUL-OX4 
and CS-OX4) to be easily formulated into nanoparticles was investigated using several 
techniques, and it was found that the degree of success varied with the nature of the 
polysaccharide. All nanoparticles had close-to-spherical morphology, as evidenced by TEM 
and SEM results.  
 
Nanoparticles with hydrodynamic diameter of around 145–200 nm and negative zeta 
potential (between -25 and -32 mV, as measured using DLS and NTA) could be easily 
obtained from GG-OX4 via reverse emulsification. It is interesting to note that an increase in 
size was observed for GG-OX4 as the DS of the modified polysaccharide increased. Attempts 
to formulate GG-OX4 nanoparticles via nanoprecipitation or cross-linking with STMP did 
afford only micron size particles (1–3 m). Stability studies in varying pH conditions using 
GG-OX4 NPs formulated via reverse emulsification indicated a significant increase in 
hydrodynamic diameter when the pH changed from 7.4 (around 170 nm) to acidic (>1 m at 
pH < 4). 
 
PUL-OX4 NPs (size 120–180 nm, as measured by DLS and NTA; zeta potential between -23 
and -30 mV) could be formulated by nanoprecipitation. Reverse emulsification led to 
particles with larger size, namely between 450 and 750 nm (DLS and NTA), but similar zeta 
potential values (-26 to -30 mV). PUL-OX4 nanoparticles prepared by nanoprecipitation were 
very stable over the whole range of pH investigated (pH 3 to 8.5). As with GG-OX4 NPs, the 
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size was found to be dependent (to a certain extent) on the DS and the concentration of the 
material (where an increase in any of these two parameters will result in a slight increase in 
particle size). A comparison of alternative purification techniques demonstrated that dialysis 
affords a significantly higher yield of nanoparticles (76–83 %) compared to centrifugation 
(39–47 %).  
 
CS-OX4 nanoparticles were found to be most conveniently formulated via typical ionotropic 
cross-linking with sodium tripolyphosphate (TPP), which yielded particles with size in the 
range 145–167 nm (DS 14.1–51.1 %) and with positive zeta potential (31 to 36 mV). The size 
of NPs was found to slightly increase with the DS of CS-OX4 and also with increasing in 
concentrations of TPP and/or chitosan. While the CS-OX4 NPs prepared in this way had very 
good size and stability in acidic environment, they were found to display some instability at 
physiological pH (pH 7.4), where agglomeration started to occur (gradually increasing the 
size to 6 m). Attempts to formulate CS-OX4 NPs via other methods such as 
nanoprecipitation yielded larger particles (size around 360–440 nm) with similar, positive 
zeta potential (25 to 32 mV). 
 
Investigations of model drug loading and release behaviour were performed on selected 
nanoparticles using model actives such as Doxorubicin, Rhodamine B and Angiotensin II. 
Among the materials considered in this study, GG-OX4 (DS 12.6 %) nanoparticles 
demonstrated the highest loading of Rhodamine B base (3.8 %) and of Doxorubicin base (9.1 
%), while PUL-OX4 (DS 77.3 %) loaded the highest amount of Angiotensin II (8.5 %). The 
release profiles of all model actives showed an initial burst discharged followed by a constant 
release, with Doxorubicin evidencing a delayed release of up to 1 h. Attempts to fit the 
experimental data to suitable kinetic models indicated that the drug release can be best 
described by either Korsmeyer-Peppas’ or Higuchi’s equations.  
 
Selected NPs were also labelled with Texas Red to facilitate in vitro cell uptake studies and to 
investigate thus their potential for imaging applications. GG-OX4 NPs exhibited the highest 
degree of Texas Red labelling (around 12 % w/w).  
 
In vitro MTT assays using mouse brain endothelial cells (bEnd3) revealed that all tested 
nanoparticles showed no cytotoxic effect at concentrations below 2 mg/mL (around 85 % cell 
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viability or above), although cell viability was found to decrease (below 75 %) at 
nanoparticle concentrations above 4 mg/mL. PUL-OX4 nanoparticles were found to be the 
least toxic, having the lowest LC50 value (9.48 mg/mL; for comparison, CS-OX4 has 7.30 
mg/mL). Confocal microscopy investigations employing Texas Red-labelled nanoparticles 
indicated that all NPs tested were taken up by bEnd3 cells within 3 h; some agglomeration 
could be visualised for CS-OX4 nanoparticles in the culture media, confirming the result of 
the stability studies that pointed to the instability of CS-OX4 NPs at physiological pH. 
Quantification of the cellular uptake was performed using flow cytometry measurements; it 
was found that, after 3 h, about 80–99 % of the cells did take up the selected nanoparticles 
with which they were incubated. A comparison of the materials tested based on the nature of 
the polysaccharide indicated that PUL-OX4 NPs had the highest uptake (99.3 %). 
 
In vitro haemolysis assay illustrated that all nanoparticles formulated from butylglyceryl-
modified polysaccharides did not induce a significant haemolysis effect at concentration 
below 12 mg/mL after 1 h incubation at 37 oC. However, a consistent trend for all materials 
studied was observed, where a certain degree of cytotoxicity appeared with an increase in NP 
concentration. PUL-OX4 (DS (77.3 %) were found to be the least toxic, having the highest 
LC30 value of 19.87 mg/mL, while CS-OX4 (DS 30.5 %) nanoparticles became the most 
toxic, having the highest LC30 value of 13.95 mg/mL. 
 
Permeability studies using a Transwell BBB model setup employing mouse brain endothelial 
cells (bEnd3) indicated that the presence of all butylglyceryl-modified polysaccharide 
nanoparticles enhanced the transport of FITC-DEX across the model membrane. Results 
showed that, for concentration around 0.5 to 2 mg/mL, PUL-OX4 (DS 77.3 %) nanoparticles 
showed the highest permeability enhancing effect compared to GG-OX4 (DS 12.6 %) and 
CS-OX4 (DS 30.5 %); moreover, the effect was found to be dependent on both the DS of the 
butylglyceryl polysaccharide and on the concentration of nanoparticles. As such, the effect 
exhibited by GG-OX4 (DS 12.6 %) nanoparticles was not statistically significant when 
compared to the control, likely due to the relatively low degree of substitution of the 
butylglyceryl guar gum employed. 
 
Overall, nanoparticles formulated from PUL-OX4 appear to have most promising 
characteristics and would warrant further development for potential use in brain drug delivery 
applications. PUL-OX4 nanoparticles were found to have a hydrodynamic diameter below 
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200 nm, were stable at physiological pH and relatively non-toxic when tested against mouse 
brain endothelial cells (bEnd3); PUL-OX4 NPs were found to have the highest effect in terms 
of enhancing the FITC-DEX permeation through the model bEnd3 cells monolayer, when 
compared to CS-OX4 and GG-OX4 NPs. In addition, the process of formulating PUL-OX4 is 
simple and does not involve any additional reagents (such as TPP or glutaraldehyde, for CS-
OX4 or GG-OX4 NPs respectively) that may impart additional toxicity risks. Under the 
conditions tested, the CS-OX4 NPs investigated in this study did not appear suitable for 
intravenous delivery due to their noticeable aggregation potential at physiologically relevant, 
neutral pH.  
 
Further relevant in vitro assays (that would investigate the nanoparticle binding interactions 
with plasma proteins and their influence upon the transendothelial resistance (TEER) of 
confluent cells) would be necessary in order to gain a deeper insight into the potential of 
PUL-OX4 NPs as drug carriers that can transport therapeutic drugs across the BBB. Positive 
results would then warrant an in vivo investigation of the biodistribution of PUL-OX4 
nanoparticles. At that stage, a systematic DOE study might also be beneficial for further 
optimization of the formulation process.  
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APPENDICES 
 
APPENDIX A – GPC results of butylglyceryl-modified pectin (P-OX4) 
 
 
 
 
GPC data of butylglyceryl-modified pectin (P-OX4); A) unmodified pectin; B) P-OX4 with 
DS 7.5%; and C) P-OX4 with DS 9.3 %. 
A) 
B) 
C) 
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APPENDIX B – GPC results of butylglyceryl-modified guar gum (GG-OX4) 
 
 
 
 
 
GPC data of butylglyceryl-modified guar gum (GG-OX4); A) unmodified guar gum; B) GG-
OX4 with DS 12.6 %; C) GG-OX4 with DS 33.9 %; and D) GG-OX4 with DS 91.2 %. 
A) 
B) 
C) 
D) 
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APPENDIX C – GPC results  of butylglyceryl-modified pullulan (PUL-OX4)  
 
 
 
 
GPC data of butylglyceryl pullulan (PUL-OX4); A) unmodified pullulan; B) PUL-OX4 with 
DS 47.0 %; and C) PUL-OX4 with DS 58.5 %. 
A) 
B) 
C) 
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APPENDIX D - Calibration curves of Angiotensin II, at retention time 8.32 min 
 
 
HPLC calibration curve of Angiotensin II in acetic acid (1% v/v) for CS-OX4 NPs drug 
loading determination. 
 
 
 
 
 
HPLC calibration curve of Angiotensin II in dmso:water (1:5, v/v) for PUL-OX4 NPs drug 
loading determination. 
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HPLC calibration curve of Angiotensin II in DCM/water (1:3, v/v) for GG-OX4 NPs drug 
loading determination. 
 
 
 
 
 
 
 
HPLC calibration curve of Angiotensin II in PBS for release studies of butylglyceryl-modified 
polysaccharide nanoparticles. 
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APPENDIX E - Calibration curves of Rhodamine B free base 
 
 
UV-Vis calibration curve of Rhodamine B base in acetic acid (1% v/v) for CS-OX4 NPs drug 
loading determination. 
 
 
 
 
UV-Vis calibration curve of Rhodamine B base in water:dmso (5:1, v/v) for PUL-OX4 NPs 
drug loading determination. 
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UV-Vis calibration curve of Rhodamine B base in DCM/water (1:3, v/v) for GG-OX4 NPs 
drug loading determination. 
 
 
 
 
 
 
UV-Vis calibration curve of Rhodamine B base in PBS for release studies of butylglyceryl-
modified polysaccharide nanoparticles. 
y = 0.2551x - 0.0061
R² = 0.997
0 1 2 3 4 5 6
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Concentration (µg/mL)
A
b
so
rb
a
n
ce
 a
t 
5
4
4
 n
m
y = 0.2259x + 0.0028
R² = 0.9999
0 1 2 3 4 5 6
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Concentration (µg/mL)
A
b
so
rb
a
n
ce
 a
t 
5
4
4
 n
m
198 
 
APPENDIX F – Calibration curves of Rhodamine B salt  
 
 
 
UV-Vis calibration curve of Rhodamine B salt in acetic acid (1% v/v) for CS-OX4 NPs drug 
loading determination. 
 
 
 
APPENDIX G – Calibration curves of Doxorubicin HCl 
 
 
UV-Vis calibration curve of Doxorubicin HCl in acetic acid (1% v/v) for CS-OX4 NPs drug 
loading determination. 
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APPENDIX H – Calibration curves of Doxorubicin free base  
 
 
UV-Vis calibration curve of Doxorubicin base in DMSO/DCM/water (1:7:20 v/v/v) for GG-
OX4 NPs drug loading determination. 
 
 
 
 
 
 
UV-Vis calibration curve of Doxorubicin base in DMSO/1 % v/v acetic acid (1:16, v/v) for 
CS-OX4 NPs drug loading determination. 
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UV-Vis calibration curve of Doxorubicin base in water:dmso (5:1, v/v) for PUL-OX4 NPs 
drug loading determination. 
 
 
 
 
 
 
 
 
 
UV-Vis calibration curve of Doxorubicin base in PBS (with 2 % SLS surfactant) for release 
studies of butylglyceryl-modified polysaccharide nanoparticles. 
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APPENDIX I – Calibration curves of Texas Red  
 
 
UV-Vis calibration curve of Texas Red in DMSO for determination of labelling degree of 
PUL-OX4 and GG-OX4 – Texas Red NPs. 
 
 
 
 
 
 
UV-Vis calibration curve of Texas Red in DMSO:water (1:20, v/v) for determination of 
labelling degree of CS-OX4 – Texas Red NPs. 
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APPENDIX J – Calibration of bend3 cell seeding density  
 
 
 
Calibration of bEnd3, intensity vs seeding numbers of cells, MTT assay. 
 
 
 
APPENDIX K – Calibration of FITC-labelled dextran  
 
 
 
Fluorescence calibration curve of FITC-DEX in EGM-2 media (excitation/emission 485/520 
nm, respectively). 
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APPENDIX L – 13C- and 2D COSY 1H-NMR spectra of n-butylglycidyl ether (BGE) 
 
13C-NMR spectra of n-butylglycidyl ether (BGE) in CD3OD (5 mg/mL). 
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2D COSY 1H-NMR spectra of n-butylglycidyl ether (BGE) in CD3OD (5 mg/mL). 
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APPENDIX M – 13C and 2D COSY 1H-NMR spectra of butylglyceryl-modified pectin 
(P-OX4) 
 
13C-NMR spectra of butylglyceryl-modified pectin (P-OX4) in D2O (5 mg/mL). 
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2D COSY 1H-NMR spectra of butylglyceryl-modified pectin (P-OX4) in D2O (5 mg/mL). 
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APPENDIX N – 13C and 2D COSY 1H-NMR spectra of butylglyceryl-modified guar 
gum (GG-OX4) 
 
13C-NMR spectra of butylglyceryl-modified guar gum (GG-OX4) in D2O (5 mg/mL). 
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2D COSY 1H-NMR spectra of butylglyceryl-modified guar gum (GG-OX4) in DMSO-d6 (5 
mg/mL). 
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APPENDIX O – 13C and 2D COSY 1H-NMR spectra of butylglyceryl-modified pullulan 
(PUL-OX4) 
 
13C-NMR spectra of butylglyceryl-modified pullulan (PUL-OX4) in DMSO-d6 (5 mg/mL). 
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2D COSY 1H-NMR spectra of butylglyceryl-modified pullulan (PUL-OX4) in DMSO-d6 (5 
mg/mL). 
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APPENDIX P – 13C-NMR of phthaloylated chitosan (PH-CS) 
 
13C-NMR of phthaloylated chitosan (PH-CS) in DMSO-d6 (5 mg/mL). 
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APPENDIX Q – 13C-NMR spectra of phthaloylated butylglyceryl chitosan (PH-CS-
OX4) 
 
13C-NMR spectra of phthaloylated butylglyceryl chitosan (PH-CS-OX4) in DMSO-d6 (5 
mg/mL). 
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APPENDIX R – 13C and 2D COSY 1H-NMR spectra of butylglyceryl-modified chitosan 
(CS-OX4) 
 
13C-NMR spectra of butylglyceryl-modified chitosan (CS-OX4) in 2 % DCl in D2O (5 
mg/mL).  
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2D COSY 1H-NMR spectra of butylglyceryl chitosan (CS-OX4) in 2 % DCl in D2O (5 
mg/mL). 
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